Author Index For Volume 29

Abarzua M (abst) 296, 352
Abboud H (abst) 345
Abboud HE (abst) 263, 291
Abdelhamid S (abst) 1259
Abe E *See* Nagakura K et al 834
Abe K (abst) 258, 260
Abella M (abst) 105
Abraham J (abst) 234
Abraham PA (abst) 175
Abramson RG (abst) 105, 402, 411, 412, 422
Abrashkin S (abst) 302
Abrass CK (abst) 263
Abreo K (abst) 176
Absy MM (abst) 426
Abu-Hamdan DK (abst) 154, 234
Abuelo JG (abst) 176, 197, 211, 224
Ackrill P, Ralston AJ, Day JP: Role of desferrioxamine in the treatment of dialysis encephalopathy S-104
Adafer D *See* Boucher A et al 1043
Adafer E (abst) 266
Adami S (abst) 609
Adamson JW *See* Delwiche F et al 641
Adler AJ (abst) 154, 174
Adler RA (abst) 157
Adler S (abst) 181, 187, 237, 231, 287, 361, 362
Adler SG (abst) 183
Adrogue HJ (abst) 362
Agnes E (abst) 777
Agodoa L (abst) 264
Agrawal M (abst) 238, 263
Agrawal R (abst) 177
Aguilar F (abst) 172
Agus D, Mann R, Clayman M, Kelly C, Michaud L, Cohn D, Neilson EG: The effects of daily cyclophosphamide administration on the development and extent of primary experimental interstitial nephritis in rats 635
Ahmad S (abst) 223, 240
Ahmed Z (abst) 176, 209
Ahn YS (abst) 181
Ainis H (abst) 179
Ainsworth SK (abst) 270
Aizawa S *See* Kawaguchi Y et al S-49
Akiba T (abst) 362
Akikusa B *See* Ueda S et al 539
Al-Awqati Q (abst) 378, 400
Al-Bander H (abst) 350
Al-Bander HA (abst) 296
Al-Khader AA (abst) 426
Al-Kudsi RR (abst) 200
Alatorre C (abst) 342
Albini B (abst) 264
Albus U (abst) 1254
Alderman FR *See* Gitelman HJ et al S-28
Aldins Z (abst) 313
Alexander EA (abst) 363, 376
Alexander F (abst) 205
Alexander RW *See* Herrera GA et al 725
Alfrey AC (abst) 209, 313, 1261
Alfrey AC *See* Coburn JW et al S-1
Alfrey AC *See* Lumlertgul D et al 658
Alfrey AC *See* Nebeker HG et al S-96
Alfrey AC: Aluminum metabolism S-8
Alfrey AC: Dialysis encephalopathy S-53
Alfrey P (abst) 209
Ali ACY (abst) 264
Allegri L (abst) 269, 608
Allen D (abst) 379
Allen JC (abst) 248
Allen ML (abst) 424
Allen WR (abst) 264
Allenberg J (abst) 191
Alliapolous JC (abst) 238
Allison N (abst) 313
Allison NL (abst) 205
Almany SL (abst) 426
Alon U (abst) 328
Alpern RJ (abst) 362
Alpert H (abst) 297
Alpert HC (abst) 363, 374
Alphone JC (abst) 778
Alvis R (abst) 210, 218
Ambrus K (abst) 266
Amiel C (abst) 413, 413
Amore A (abst) 608
Amoroso A (abst) 612
Amundsen E *See* Berg KJ et al 1180
Anagnostopoulos T (abst) 158, 375
Anderson CF (abst) 429, 436
Anderson K (abst) 317
Anderson RJ (abst) 253, 328, 415, 426
Anderson RJ: Hospital-associated hyponatremia (Nephrology Forum) 1237
Anderson S (abst) 314, 328
Anderson SA (abst) 180
Andrassy K (abst) 1256
André C (abst) 776
Andres G (abst) 268
Andress DL (abst) 176, 199, 218
Andress DL *See* Nebeker HG et al S-96
Andress DL *See* Ott SM et al S-108
Andress DL, Endres DB, Ott SM, Sherrard DJ: Parathyroid hormone in aluminum bone disease: A comparison of parathyroid hormone assays S-87
Andrews PM (abst) 234, 297
Ang KS (abst) 225, 777
Anger M (abst) 198, 425
Angles-Cano E (abst) 344
Aperia A (abst) 390
Appel G (abst) 437
Appel GB (abst) 427
Appel RG (abst) 379
Araujo A (abst) 246
Arbeit L (abst) 304
Arbeit LA (abst) 210, 224, 333, 431
Ardaillou N (abst) 331

Ardaillou R (abst) ... 331, 346
Ardila M (abst) ... 173
Ardito T (abst) ... 353
Areas J (abst) ... 353, 356
Argy WP (abst) ... 234
Arias R (abst) ... 210, 217, 224
Arieff AI (abst) ... 158, 177, 181, 204
Arisz L (abst) ... 941
Armbrecht HJ (abst) ... 171, 175
Armstrong MA (abst) ... 221
Arnaout M (abst) ... 394
Arnold WC (abst) ... 177, 241
Aronoff GR (abst) ... 177, 341
Aronson PS (abst) ... 367, 369, 407
Arriba G (abst) ... 344
Arruda JAL (abst) ... 377, 425
Arsz J (abst) ... 942
Arthus MF (abst) ... 412
Arze RS *See* Kerr DNS et al ... S-58
Asano Y (abst) ... 173, 336
Asano Y *See* Takeda K et al ... 863
Ash SR *See* Larson EA et al ... 1131
Assadi FK (abst) ... 177
Assan R (abst) ... 413
Atik A *See* Fournier A et al ... S-114
Atkins C (abst) ... 437
Atlas S (abst) ... 395
Attie M (abst) ... 159
Atuk NO (abst) ... 298
Aubry M (abst) ... 231
Aucoutrier P (abst) ... 287
Audet P (abst) ... 237, 239
Aune TM (abst) ... 290
Aurell M (abst) ... 241, 251
Ausiello D (abst) ... 413
Ausiello DA (abst) ... 331, 424
Auzan C *See* Michel J-B et al ... 1011
Avasthi PS (abst) ... 379
Aversano R (abst) ... 301
Avison MJ (abst) ... 396
Aviv A (abst) ... 338
Avner ED (abst) ... 314, 352
Avram MM (abst) ... 210, 218, 231
Awazu M (abst) ... 390
Axelrod M (abst) ... 325
Ayiomamitis A (abst) ... 231
Aynedjian HS (abst) ... 314
Ayon MA (abst) ... 307
Azar S (abst) ... 241
Bönner G (abst) ... 1254
Büchsler U (abst) ... 1254
Bürrig KF (abst) ... 1262
Bachmann C (abst) ... 348
Bachmann F (abst) ... 213
Backer A (abst) ... 401
Baczyński R (abst) ... 1260
Badie-Dezfooiy B (abst) ... 318
Badr KF (abst) ... 328
Baehler RW (abst) ... 209
Bagchus WM (abst) ... 945
Bagdasarova I (abst) ... 269
Baggio B (abst) ... 609
Bagnasco S (abst) ... 412
Baguet JC (abst) ... 778
Bahlmann J (abst) ... 182, 1258
Bailly C (abst) ... 413
Baines AD (abst) ... 264, 349
Baines AD *See* Sole MJ et al ... 689
Bairnsfather L (abst) ... 267
Baker BJ (abst) ... 287
Baker WB (abst) ... 198, 226
Bakir AA (abst) ... 178, 179
Bakker RJ (abst) ... 309
Bakker WW (abst) ... 945
Balaban CD (abst) ... 246
Balaban R (abst) ... 412
Balaban RS (abst) ... 370
Baldamus CA (abst) ... 1260
Baldwin DW (abst) ... 187, 322, 324
Balfe JW *See* Rush PJ et al ... 1066
Balghiti D (abst) ... 776
Ballerman BJ (abst) ... 329
Balow JE (abst) ... 178, 278
Balson S *See* Cournot-Witmer G et al ... S-37
Baltopoulos G (abst) ... 296
Baluarte HJ (abst) ... 233
Bancale E (abst) ... 608
Banfi G (abst) ... 612
Bank N (abst) ... 314
Banks RO (abst) ... 248, 380, 398
Barajas L, Powers K, Carretero O, Scicli AG, Inagami T: Immunocytochemical localization of renin and kallikrein in the rat renal cortex ... 965
Baranowski R (abst) ... 192, 297, 330
Baranowski RL (abst) ... 385, 389
Barbaric Z (abst) ... 434
Barber JD (abst) ... 329
Barcelli U (abst) ... 329, 336
Bardin T (abst) ... 229
Bargman JM (abst) ... 265
Baricos WH (abst) ... 291
Bariéty J (abst) ... 775, 776, 777
Barini G (abst) ... 609
Barjon JN (abst) ... 178, 193
Barnes JL (abst) ... 265
Barr W (abst) ... 194
Barratt TM (abst) ... 202
Barre P (abst) ... 232
Barre PE (abst) ... 173
Barrett PQ (abst) ... 329
Barry JM (abst) ... 179
Barth H (abst) ... 266
Barth RH (abst) ... 214
Basci A (abst) ... 291, 349
Bashour BN (abst) ... 178
Basolo B (abst) ... 608
Bastani B (abst) ... 228, 229, 298
Bastl CP (abst) ... 330
Bataille P (abst) ... 775, 777, 778
Bates SB (abst) ... 234, 297
Batlle DC (abst) ... 426
Batsford S (abst) ... 1249
Batsford SR (abst) ... 1248
Bauer J (abst) ... 1255
Bauer JH (abst) ... 256, 259
Baum H-P (abst) ... 1259
Baum M (abst) ... 390
Baumal R *See* Rush PJ et al ... 1066
Bauman JW Jr (abst) ... 391
Baverel G (abst) ... 350

Baylis C (abst) 380, 386
Bazilinski N (abst) 178, 179
Bazzato G (abst) 173
Beach RE (abst) 391, 394
Beal A (abst) 218
Bear R (abst) 178, 182
Beauchamp D (abst) 311
Beaumont W (abst) 426
Beck F (abst) 1251
Beck F (abst) 1252
Beck FX (abst) 391
Beck JC (abst) 412
Beck T (abst) 313
Becker B (abst) 355
Becker GJ *See* Ihle BB et al S-80
Beckman BB (abst) 229
Beckwith D (abst) 354
Bedetti CB (abst) 284
Bedogna V (abst) 609
Bedoya LA (abst) 287
Beeuwkes R (abst) 174
Beierwaltes WH (abst) 408
Beijer WEP (abst) 942
Beischel L *See* Waldo FB et al 1229
Belghiti D (abst) 776
Beliveau R (abst) 155
Belknap S (abst) 349
Belli LS (abst) 613
Bello-Reuss E (abst) 381
Belo D (abst) 368
Ben-Ari J (abst) 252
Benabe JE (abst) 330
Bender W (abst) 230
Benedetti RG (abst) 173
Bengele HH (abst) 363, 376
Benigni A (abst) 343
Bennett W (abst) 185, 188
Bennett WM (abst) 179, 313
Bennett WM (abst) 324
Bens M (abst) 346
Benson B (abst) 339
Bentley F (abst) 435
Bentley MD (abst) 380
Bentzel CJ (abst) 422
Benvenisty AI (abst) 427
Berant M (abst) 328
Berardinelli L (abst) 612
Berden JHM (abst) 943
Berecek K (abst) 256
Beretta-Piccoli C *See* Bianchetti MG et al 882
Berg KJ *See* Talseth T et al 1072
Berg KJ, Førre Ø, Bjerkhoel F, Amundsen E, Djøseland O, Rugstad HE, Westre B: Side effects of cyclosporin A treatment in patients with rheumatoid arthritis 1180
Berger ME (abst) 251
Berger P (abst) 325
Bergfeld M (abst) 208
Berglund G (abst) 251
Berkseth R (abst) 205
Berl T (abst) 425
Berlin A (abst) 201
Berlin A (abst) 610
Berlyne GM (abst) 154, 174, 223
Berman E (abst) 178
Bernard A *See* Foidart JM et al 1050
Bernardini J (abst) 227
Bernasconi P (abst) 608
Berndt TJ (abst) 155
Bernholc AS (abst) 225
Bernick C (abst) 195
Bernstein J (abst) 280
Beroniade V (abst) 179
Berry CA (abst) 412
Berry PL (abst) 179, 204
Bersin R (abst) 180
Berstein K (abst) 283
Bertani T (abst) 282
Bertolatus JA (abst) 265
Bertorello A (abst) 390
Besarab A (abst) 427
Besozzi M (abst) 434
Bettcher KB (abst) 230
Better OS (abst) 328, 384
Better OS: Renal and cardiovascular dysfunction in liver disease (Nephrology Forum) 598
Betzelos SJ (abst) 195
Beukers JJB (abst) 265
Beukers JJB *See* Weening JJ et al 789
Beukhof JR, Kardaun O, Schaafsma W, Poortema K, Donker AJM, Hoedemaeker PJ, van der Hem GK: Toward individual prognosis of IgA nephropathy ... 549
Beyenbach KW (abst) 393
Bia M (abst) 210
Bialy G (abst) 257
Bialy GB (abst) 210, 225
Bianchetti MG, Beretta-Piccoli C, Weidmann P, Ferrier C: Blood pressure control in normotensive members of hypertensive families 882
Bianchi G (abst) 281
Biber J (abst) 167, 373
Bichara M (abst) 363
Bichet D (abst) 178, 193, 317, 412
Bichet DG, Kortas C, Mettauer B, Manzini C, Marc-Aurele J, Rouleau J-L, Schrier RW: Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure 1188
Bidani A (abst) 299, 305, 308, 314
Bies C (abst) 251
Bingel M (abst) 219
Birch F (abst) 330
Birchall I *See* Walker RG et al 875
Birembaut P (abst) 777
Birenboim N (abst) 315
Birkenhäger WM (abst) 944
Birmingham DJ (abst) 271
Birnbaumer J (abst) 333
Bisceglia J (abst) 211
Bisceglia J (abst) 610
Bishop GA, Hall BM, Duggin GG, Horvath JS, Sheil AGR, Tiller DJ: Immunopathology of renal allograft rejection analyzed with monoclonal antibodies to mononuclear cell markers 708
Biwer E (abst) 1250
Bjerkhoel F *See* Berg KJ et al 1180
Blæhr H *See* Jensen PK et al 490
Blake S (abst) 344
Blanchart A (abst) 281, 343, 381, 385
Blanchet F (abst) 413
Blantz RC (abst) 380, 383

Blecher SR (abst) 271
Bloch KD (abst) 329
Block T (abst) 1262
Blonsky SL (abst) 211, 330
Blumenthal NC *See* Posner AS et al S-17
Blumenthal S (abst) 363
Bobadilla NA (abst) 260
Bockhorn H (abst) 1262
Bockhorn H (abst) 1263
Bockhorn H (abst) 1263
Bodvarsson M (abst) 232
Boer P (abst) 1251
Boer WH (abst) 193, 392, 420
Boeri R (abst) 608
Boeschoten EW (abst) 941
Boesken WH (abst) 1258
Bognetti E (abst) 289
Bogusky RT (abst) 350
Bohle A (abst) 1249
Bohle A (abst) 1250
Bohle JA (abst) 286
Bohon J (abst) 211
Boineau FG (abst) 331
Boles MA (abst) 261
Bolla G (abst) 610
Bolton WK (abst) 180, 266, 269, 298
Bommer J (abst) 266
Bomsztyk K (abst) 364
Bond GC (abst) 346
Bonduris DN (abst) 365
Bonitati J (abst) 242
Bonjour JP *See* Jobin JR et al 1124
Bonn F (abst) 225
Bonomini V (abst) 611
Bonomini V (abst) 613
Bonsib SM (abst) 276
Bonventre JV (abst) 305, 347
Bonventre JV *See* Diamond JR et al 478
Booker BB (abst) 411
Booker BB *See* Galla JH 997
Border WA (abst) 176
Bordet S (abst) 412
Borelli I (abst) 612
Borgnino LC (abst) 611
Borkan S (abst) 364
Borle AB (abst) 157
Boron WF (abst) 371, 373, 376
Borsatti A (abst) 609
Bosch JP (abst) 196
Boskey AL *See* Posner AS et al S-17
Bosly A (abst) 776
Boucher A (abst) 266
Boucher A, Droz D, Adafer D, Nöel LH:
Characterization of mononuclear cell subsets in renal cellular interstitial infiltrates 1043
Boucher LD (abst) 255
Boughter M (abst) 177
Bouillon R (abst) 166
Boulanger Y (abst) 392
Boulpaep EL (abst) 403
Bourdeau A *See* Cournot-Witmer G et al S-37
Bourdeau AM, Bourdon R, Kindermans C, Sachs C:
Effects of aluminum addition on parathyroid tissue incubation medium composition (Technical Note) ... 924
Bourdeau JE (abst) 155
Bourdon R *See* Bourdeau AM et al 924
Bourgoignie JJ (abst) 181, 288, 306, 392
Bourke E (abst) 185
Bouvier M (abst) 178
Bovee KC (abst) 242
Bovee KC *See* Robertson JL et al 511
Bower J (abst) 236
Bower JD (abst) 337
Bowman C (abst) 200, 266
Bowring MA (abst) 350
Boylan JW (abst) 242, 245
Braden G (abst) 180, 188
Brady R (abst) 161
Bragantini L *See* Ronco C et al 908
Brancaccio D (abst) 211
Brancaccio D (abst) 610
Brandina L (abst) 430
Brandis A (abst) 281
Brando B (abst) 613
Branellec A (abst) 776
Braquet P (abst) 342
Brater DC (abst) 180, 414
Brater DC *See* Henrich WL et al 484
Braun WE (abst) 427
Brautbar N (abst) 317
Brax C (abst) 235
Brazy PC (abst) 242, 391
Breckon R (abst) 415
Breidenbach Th (abst) 1261
Brem AS (abst) 242
Bremner W (abst) 225
Brendolan A *See* Ronco C et al 908
Brennan S (abst) 413
Brenner BM (abst) 289, 314, 320, 328, 329, 340, 360, 382, 397, 401, 402, 406
Brenner BM *See* Shemesh O et al 916
Brentjens J (abst) 268
Brentjens JR *See* Noble B et al 841
Breton S (abst) 392
Breuning MH (abst) 181
Brewer E (abst) 277
Brewer ED (abst) 230
Breyer J (abst) 364
Brezis M (abst) 310, 360
Brezis M *See* Shanley PF et al 1021
Brezis M *See* Shanley PF et al 1033
Brezis ML (abst) 298
Brianti E (abst) 269
Brianti E (abst) 608
Bricker NS (abst) 339
Brickman AS *See* Corry DB et al 1197
Briefel G (abst) 321, 326
Brier R (abst) 177
Briggs J (abst) 259, 414
Briggs JP (abst) 387
Briggs JP *See* Schnermann J et al 520
Brighenti G (abst) 610
Brill J (abst) 236, 270
Brinck-Johnsen T (abst) 382
Brinker K (abst) 437
Brodkin M (abst) 267
Brodsky WA (abst) 365
Brodwall EK *See* Talseth T et al 1072
Brokl OH (abst) 414
Brooke AMC (abst) 205

Brookins J (abst) 167
Brooks CS (abst) 201
Brothis J (abst) 321
Brown D (abst) 413
Brown RC (abst) 155, 165
Brown ST (abst) 177
Brown ST III (abst) 185, 212
Brown T (abst) 157
Brown-Cartwright D (abst) 180
Bruijn JA (abst) 1256
Brukman J (abst) 295
Brukman J *See* Wiggins RC et al 591
Brummett R (abst) 313
Brunati C (abst) 610
Brunati C (abst) 613
Bruneau C (abst) 776
Brunisholz M, Geniteau-Legendre M, Ronco PM, Moullier P, Pontillon F, Richet G, Verroust P: Production of monoclonal antibodies specific for human Tamm-Horsfall protein 971
Brunk B (abst) 1259
Brunkhorst R (abst) 1258
Brunkhorst R (abst) 181
Brunner G (abst) 1258
Brunori G (abst) 612
Bruns FJ (abst) 181, 187, 237
Brutuco LH (abst) 211
Bruwier M *See* Foidart JM et al 1050
Bryce GF *See* Smothers RL et al 578
Buchet JP (abst) 221
Buckalew VM (abst) 404
Buddington B (abst) 1261
Bugiani O (abst) 211
Bugiani O (abst) 610
Buja M (abst) 291
Bukoski RD (abst) 243
Bulger RE (abst) 300, 301
Bulger RE *See* Saubermann AJ et al 675
Bull JM (abst) 300
Buller HR (abst) 217
Bunke M (abst) 298
Burchette J (abst) 432
Burckhardt *See* Jaeger et al 563
Burette A (abst) 185
Burg M (abst) 412
Burg MB (abst) 366
Burger HR (abst) 1260
Burk RF (abst) 307
Burkart J (abst) 211
Burke C (abst) 415
Burke T (abst) 299
Burke TJ (abst) 298, 313, 319
Burke TJ *See* Lumlertgul D et al 658
Burnet D (abst) 234
Burnett JC (abst) 384, 389, 393
Burnett JC Jr (abst) 245, 384, 406, 407
Burnier M (abst) 298, 299
Burno D (abst) 317
Burns G (abst) 289
Burns V (abst) 230
Bursten S (abst) 243
Bushinsky DA (abst) 156, 164, 186, 315
Busnach G (abst) 613
Buszta C (abst) 427
Butt K (abst) 206
Butt KMH (abst) 429
Buxbaum J (abst) 187
Bygren P (abst) 282
Byrum GV (abst) 364
Cabrini G (abst) 393
Cadnapaphornchai P (abst) 216
Caflisch C (abst) 366
Cain JR (abst) 181, 206
Calalb MB (abst) 364
Calamia J (abst) 362, 395
Caldwell J (abst) 366
Calleja C (abst) 260
Cam G (abst) 225
Cam G (abst) 777
Camargo MJF (abst) 395
Cameron JS (abst) 1202 267
Cameron JS *See* Nolasco F et al 1215
Camilleri JP (abst) 775
Camilleri JP (abst) 775
Campbell RA (abst) 267
Campbell WB *See* Henrich WL et al 484
Campbell WG (abst) 185
Campese VM (abst) 248, 317
Camussi G (abst) 268, 292
Camussi G (abst) 609
Camussi G: Potential role of platelet-activating factor in renal pathophysiology (Editorial Review) 469
Canaud B (abst) 778
Cance W (abst) 156
Candiano G (abst) 189
Canizaro P (abst) 301
Cannon JK (abst) 293
Cantiello H (abst) 331
Cantin M (abst) 340
Cantley L (abst) 352
Capasso G (abst) 265
Capasso G (abst) 611
Capdevila J (abst) 254
Capozi A (abst) 610
Caramelo C (abst) 382, 384
Cardamone I (abst) 611
Cardinal J (abst) 393
Carey RM (abst) 382
Carey SW (abst) 268
Carlier MB (abst) 311
Carlson J (abst) 206
Carmines PK (abst) 282, 382
Carnazzola AE (abst) 252
Caro J (abst) 427
Carone FA (abst) 268, 323
Carozzi S (abst) 610
Carpenter BJ (abst) 187
Carpenter C (abst) 289
Carpenter CB (abst) 428, 432
Carr M (abst) 185
Carretero O *See* Barajas L et al 965
Carretero OA (abst) 348, 408
Carroll FX (abst) 373
Carroll HJ (abst) 373, 377
Cartier P (abst) 317
Caruana RJ (abst) 221, 232
Carvounis C (abst) 421
Carvounis CP (abst) 331
Carvounis G (abst) 421
Casas E (abst) 293

Cashman S (abst) 212
Castiglione A (abst) 608
Cataldo T (abst) 240
Cattell V *See* Macdougal DF et al 1144
Cattran D (abst) 210
Cattran DC (abst) 182
Cavallo T (abst) 264, 268, 276
Cavallo-Perin P (abst) 262
Cecchin E (abst) 609
Cederholm B (abst) 252
Celio MR: Renin-containing cells in kidney transplants into the anterior eye chamber (Technical Note) 1234
Cermeno J (abst) 260
Chagnac A (abst) 156
Chaimovitz C (abst) 315
Chakrabarti E (abst) 232
Challoner-Hue L (abst) 259
Chan JCM (abst) 160
Chan JCM (abst) 212
Chan L (abst) 310, 336, 433, 438
Chandan R (abst) 336, 382
Chander PE (abst) 272
Chandra M (abst) 269
Chang A (abst) 152
Chang H (abst) 393
Chang WC (abst) 170
Chansel D (abst) 331
Charlier L (abst) 185
Chatelet F (abst) 269
Chatelet F (abst) 608
Chatterjee K (abst) 180
Chaudhari A (abst) 339
Chavers B (abst) 273
Chazan JA (abst) 221
Chebotareva V (abst) 269
Check IJ (abst) 294
Cheema-Dhadli S (abst) 351, 367
Chekal MA (abst) 368, 400
Chen CB (abst) 218, 351, 367
Chen TC (abst) 156
Cheng J (abst) 243
Chenoweth DE (abst) 282
Chenoweth DE *See* Cheung AK et al 799
Chesney R (abst) 413
Cheung AK (abst) 227, 269
Cheung AK, LeWinter M, Chenoweth DE, Lew WYW, Henderson LW: Cardiopulmonary effects of cuprophane-activated plasma in the swine 799
Cheung C (abst) 313
Cheung HS *See* Lemann Jr J et al 743
Cheung L (abst) 321
Chevalier RL (abst) 382
Chiaramonte S *See* Ronco C et al 908
Childress D (abst) 365
Chiron B (abst) 415
Chmielewski D (abst) 342
Cho SYT (abst) 427
Chou SY (abst) 383
Choudat L *See* Michel J-B et al 1011
Christensen EI *See* Hellfritzsch M et al 983
Christensen J (abst) 1250
Christensen R (abst) 183
Christiansen JS *See* Jensen PK et al 490
Christine C (abst) 394
Chrysant SG (abst) 243
Chu MH (abst) 261
Chuba JV (abst) 274
Churchill D (abst) 236
Churchill P (abst) 299, 305, 308
Chusid P (abst) 182, 194
Ciavarella A (abst) 611
Cicerello E (abst) 609
Cinotti GA (abst) 610
Citron B (abst) 778
Civati G (abst) 610
Civati G (abst) 613
Clark HS (abst) 189
Clark WF (abst) 182
Clarke HS (abst) 254
Clarke MC (abst) 270
Clarkson AR *See* Hale GM et al 718
Clarkson T (abst) 199
Clavel A (abst) 263
Clayberger C (abst) 281
Clayberger CG (abst) 270
Clayman M *See* Agus D et al 635
Clayman MD (abst) 239, 270, 286
Clayman P (abst) 424
Cluzel P (abst) 778
Coburn JW (abst) 151, 176, 199, 215, 236
Coburn JW *See* Milliner DS et al S-100
Coburn JW *See* Nebeker HG et al S-96
Coburn JW *See* Ott SM et al S-108
Coburn JW *See* Smothers RL et al 578
Coburn JW, Alfrey AC: Introduction S-1
Cockerill C (abst) 177
Codd T (abst) 183
Codina J (abst) 333
Coe F (abst) 194
Coe FL (abst) 150, 155, 156, 158, 161, 295, 315
Coe FL *See* Lopez M et al 829
Coevet B (abst) 777
Coffman TM (abst) 332
Cogan MG (abst) 332, 384
Coggi G (abst) 288
Cohen A (abst) 382, 434, 438
Cohen AH (abst) 183
Cohen AS (abst) 213
Cohen D (abst) 437
Cohen DJ (abst) 427
Cohen JJ (abst) 364
Cohen L (abst) 429
Cohn D *See* Agus D et al 635
Colasanti JG (abst) 608
Cole EH (abst) 270
Coleman MD *See* Llach F et al S-74
Coleman RA (abst) 417
Colen D (abst) 239
Coles GA *See* Lucas PA et al 995
Coli U (abst) 241
Collart F (abst) 185, 211
Collaud J (abst) 213
Collier F (abst) 200
Collins A (abst) 214, 215, 217
Colman J (abst) 190
Comoy E (abst) 777
Condro P (abst) 355
Conger JD (abst) 299, 318
Connor BJ (abst) 183
Conrad KP (abst) 382

Constantini E (abst) 214, 217
Constantini S (abst) 211
Convery ME (abst) 303
Cook, T *See* Macdougal DF 1144
Cooley CF *See* Herrera GA et al 725
Cooper K (abst) 210, 299, 300, 315
Copley JB (abst) 183, 184, 205
Coppo R (abst) 608
Cordy PE (abst) 190
Corman B (abst) 386, 414
Corry DB (abst) 172, 316
Corry DB, Tuck ML, Brickman AS, Yanagawa N, Lee DBN: Sodium transport in red blood cells from dialyzed uremic patients 1197
Cortas N (abst) 394
Cortell S (abst) 230
Cortes P (abst) 195
Corvol P *See* Michel J-B et al 1011
Corwin HL (abst) 184
Cosby R (abst) 184, 203, 438
Cosio FB (abst) 271, 273, 277, 431
Costantini C (abst) 610
Costanzo LS (abst) 157
Costello J (abst) 316, 321
Costerton JW (abst) 230
Coulson R (abst) 332
Cournot-Witmer G *See* Drüeke TB et al S-45
Cournot-Witmer G *See* Karsenty G et al 1058
Cournot-Witmer G, Placot JJ, Bourdeau A, Lieberherr M, Jorgetti V, Mendes V, Halpern S, Hemmerle J, Drüeke T, Balson S: Effect of aluminum on bone and cell localization S-37
Couser WG (abst) 271, 278, 287
Cowan RS (abst) 289
Cowgill LD (abst) 157
Cowie JF *See* Winney RJ et al S-91
Cowley Jr AW *See* Merrill DC et al 1152
Cox M (abst) 351, 408
Crage MA (abst) 428
Cragoe E Jr (abst) 363, 400
Cragoe EJ Jr (abst) 405
Craven PA (abst) 332
Craven PA, Verbalis JG, DeRubertis FR: Increased urinary excretion of PGE_2 during inappropriate antidiuresis induced by DDAVP 1110
Crine P (abst) 271
Cristinelli L (abst) 612
Crocker JFS (abst) 271
Croker B (abst) 429
Cronin R (abst) 300
Crooks PW (abst) 157, 199
Cruet P (abst) 775
Cubela R (abst) 320
Cullen P (abst) 281
Culpepper M (abst) 333
Cumming AD (abst) 300, 305
Cummings R (abst) 228
Cupples WA (abst) 394, 407
Curtin JP (abst) 333
Curtis JJ (abst) 428
Curtis JJ *See* Herrera GA et al 725
Curtis WS (abst) 337
Curtoni ES (abst) 612
Cushley P (abst) 331
Cushner HM (abst) 184
Cybulsky AV (abst) 272
Cybulsky AV *See* Feintzeig ID et al 649
Dabbs DJ (abst) 272
D'Agati V (abst) 272
Dagher F (abst) 435
D'Agrosa MC (abst) 778
Daigneault B (abst) 317
Dall'Aglio PP (abst) 608
D'Amico G (abst) 608
Daniel F (abst) 776
Daniel TO (abst) 272
Daniels BS (abst) 244
Daniels F (abst) 230
Daniels FX (abst) 316, 324
Danovitch G (abst) 428
Danovitch GM (abst) 434
Dantzler WH (abst) 414
Darai G (abst) 1256
Darsinos J (abst) 212
Das C (abst) 311
Dasguta MK (abst) 230
Dass PD (abst) 361
D'Atena T (abst) 611
Daugaard H (abst) 162, 351
Daugirdas JT (abst) ... 195, 200, 212, 215, 218, 220, 231, 369
Davenport M (abst) 221
Davidai G (abst) 328
Davidson R (abst) 243
Davie J (abst) 156
Davis BB (abst) 175, 347, 360, 361
Davis CL (abst) 414
Davis JA (abst) 352, 356
Davis JM (abst) 1253
Davis JO (abst) 409
Davis JW (abst) 243
Davis L (abst) 291
Davis R (abst) 187
Davis TA (abst) 316
Day JP *See* Ackrill P et al S-104
De Alba JA (abst) 302
De Broe ME (abst) 312
De Frémont F (abst) 777
De Frémont JF (abst) 777
de Jong PE (abst) 945
De Jong PE (abst) 178, 254
De La Rosa J (abst) 176
De La Rosa JP (abst) 209
De Marchi S (abst) 609
De Rycker C *See* Foidart JM et al 1050
De Santo NG (abst) 611
De Vecchi A (abst) 612
De Vecchi A (abst) 612
De Vries PMJM (abst) 162
De Zeeuw D (abst) 254, 314
DeRubertis FR *See* Craven PA et al 1110
Debrevi L (abst) 320
Deen W (abst) 323
Deen WM (abst) 390
Deen WM *See* Shemesh O et al 916
Defregger M (abst) 1251
Deftos L (abst) 359
Del'Orto P (abst) 288
Delaney VB (abst) 185
Delarge J (abst) 1255
Delarue F (abst) 339, 344

Delea CS (abst) 316
de Leeuw PW (abst) 944
Delfino G (abst) 189
Delgado FA (abst) 208
Delin K (abst) 241
Dell'Aquila R *See* Ronco C et al 908
Delmez J (abst) 226, 231
Delmore T (abst) 200
Delong E (abst) 259
Deltenre M (abst) 185
Delwiche F, Segal GM, Eschbach JW, Adamson JW: Hematopoietic inhibitors in chronic renal failure: Lack of in vitro specificity 641
Demisch K (abst) 1255
de Moor EAM (abst) 942
Dendle T (abst) 431
Denis G (abst) 317
Dennis MB Jr (abst) 240
Dennis VM (abst) 179, 391, 394
Depner T (abst) 317
de Rouffignac C *See* Elalouf JM et al 807
Derubertis FR Jr (abst) 332
Deteix P (abst) 778
Detjen G (abst) 1255
Detjen G (abst) 400
Devarajan P (abst) 304
Devault GA (abst) 261
Devault GA Jr (abst) 185, 212
de Vries PMJM (abst) 943
Dewar J *See* Kerr DNS et al S-58
de Zeeuw D (abst) 945
Deziel C (abst) 317
DiBona GV (abst) 244, 249
DiFelice A (abst) 613
Diamantstein T (abst) 432
Diamond JR (abst) 273
Diamond JR, Bonventre JV, Karnovsky MJ: A role for oxygen free radicals in aminonucleoside nephrosis .. 478
Diamond S (abst) 212
Diaz-Diaz FD (abst) 352
Dicorleto P (abst) 263
Diefendorf AS (abst) 232
Diehl S (abst) 224
Dieplinger H (abst) 224
Diethelm AG (abst) 428
Dietl P (abst) 1251
Dietl P (abst) 404
Dietrich R (abst) 196
Dietrich RL (abst) 350
Digenis GE (abst) 231
Dillingham MA (abst) 328, 415, 426
Dinarello CA (abst) 219
Dinh N (abst) 212
Dipette D (abst) 346
Dirks JH (abst) 175, 306
Dirusso SC (abst) 294
Distler A (abst) 1258
Dittmer JE *See* Feintzeig ID et al 649
Dixon BS (abst) 415, 426
Dixon T (abst) 366
Djøseland O *See* Talseth T et al 1072
Djøseland O *See* Berg KJ et al 1180
Dkhissi H *See* Fournier A et al S-114
Dobyan DC (abst) 300
Dobyan DC *See* Saubermann AJ et al 675
Dobyan DD (abst) 301
D'Occhio MA (abst) 245
Dodds R (abst) 389
Dolbashian J (abst) 289
Dombros N (abst) 231
Dominguez JH (abst) 157
Donadio JV (abst) 182, 429, 436
Donhowe J (abst) 217
Donker A (abst) 325
Donker AJM (abst) 162, 254
Donker AJM (abst) 942
Donker AJM (abst) 943
Donker AJM (abst) 944
Donker AJM (abst) 945
Donker AJM *See* Beukhof JR et al 549
Donker AJM *See* ter Wee PM et al 870
Donnelly R (abst) 209
Donoso V (abst) 315
Dorge A (abst) 391
Dörge A (abst) 1251
Dorhout EJ (abst) 182, 184, 392
Dorhout Mees EJ (abst) 187, 188
Dorhout Mees EJ (abst) 1251
Dorval BL (abst) 273
Dosa S (abst) 323
Dossetor J (abst) 182
Dossetor JB (abst) 230, 432
Dougan S (abst) 231
Doughtery K (abst) 182
Dousa TP (abst) 158, 161, 166, 168, 335, 352, 361, 425
Dowling JP *See* Walker RG et al 875
Drüeke T *See* Cournot-Witmer G et al S-37
Drüeke T *See* Karsenty G et al 1058
Drüeke TB, Lacour B, Touam M, Jucquel JP, Placot JJ, Cournot-Witmer G, Galle P: Effect of aluminum on hematopoiesis S-45
Drangova R (abst) 349
Drannik G (abst) 269
Draper R (abst) 377
Dratwa M (abst) 185, 211
Dreyer I (abst) 1262
Dreyer JL (abst) 222
Drezner MK (abst) 163
Droz D (abst) 223, 266, 287
Droz D *See* Boucher A et al 1043
Drueke T (abst) 159, 213, 223, 252
Druet Ph (abst) 776
Dubach UC (abst) 1253
Dubb J (abst) 313
Dubb JW (abst) 205
Dubczak J (abst) 211
Dubose TD Jr (abst) 352
Dubovsky EV (abst) 428
Dufour F (abst) 777
Duggin GG *See* Bishop GA et al 708
Dulawa J (abst) 1257
Dumler F (abst) 195
Dunbar K (abst) 429
Dunea G (abst) 178, 179
Dunn BR (abst) 328, 340, 382
Dunn M (abst) 340
Dunn MJ (abst) 343, 379, 401
Dunn S (abst) 317
Dunstan CR, Evans RA: Aluminum and renal bone disease in Australia S-65

Dupuy MC (abst) 776
Durasin I (abst) 1253
Durham J (abst) 365
Durozard D (abst) 350
Durrington PN *See* Short CD et al 1224
Dusing R (abst) 341, 400, 401
Düsing R (abst) 1255
Dussaule J-C *See* Michel J-B et al 1011
Dworkin LD (abst) 244
Dytko G (abst) 418
Dzielak DJ (abst) 253
Eaton D (abst) 397
Eberle P (abst) 1257
Eby B (abst) 157, 244
Edelman A (abst) 158, 375
Edelman IS (abst) 394
Edwards BS (abst) 245, 407
Edwards L (abst) 438
Edwards RM (abst) 333
Egfjord M (abst) 162, 351
Eggena P (abst) 415
Eggensperger D (abst) 429
Egidi F (abst) 612
Egidi F (abst) 612
Ehrich JHH (abst) 1256
Ehrlich R (abst) 208
Eichin S (abst) 1258
Eiff AWV (abst) 258
Eigenbrodt E (abst) 273
Eisele S (abst) 1252
Eisenbach G (abst) 181
Eiser AR (abst) 223
Eisinger RP (abst) 210, 225
Eisner CM (abst) 333, 385
Eknoyan JG (abst) 301
El-Belbessi S (abst) 317
Elalouf JM, Roinel N, de Rouffignac C, Malorey P, Philippe P, Soyeux N, Zimmerman A: Effects of glucagon and PTH on the loop of Henle of rat juxtamedullary nephrons 807
Elema JD (abst) 945
Elema JD *See* Weening JJ et al 789
Elliot DL (abst) 223
Elliott WC (abst) 301, 303
Ellis D (abst) 314, 352
Ellis EN (abst) 373, 384
Ellis EN, Steffes MW, Goetz FC, Sutherland DER, Mauer SM: Glomerular filtration surface in type I diabetes mellitus 889
Ellis HA *See* Kerr DNS et al S-58
Ellison A (abst) 210
Ellison DH (abst) 395
Elmquist W (abst) 214
Eloy L (abst) 246
Elzinga L (abst) 185
Emancipator SN (abst) 268, 274, 343
Emmett M (abst) 212, 213
Endo Y, Hara M: Glomerular IgA deposition in pulmonary diseases 557
Endres DB *See* Andress DL et al S-87
Engen DE (abst) 1264
Epstein FH (abst) 298, 310, 360, 361
Epstein FH *See* Shanley PF et al 1021
Epstein FH *See* Shanley PF et al 1033
Epstein M (abst) 386, 395
Erdos EG (abst) 348
Ernst W (abst) 1260
Erslev A (abst) 427
Eschbach JW *See* Delwiche F et al 641
Escott M *See* Walker RG et al 875
Eskridge SL (abst) 246
Estafanous EF (abst) 427
Etheredge SB (abst) 357
Ettenger RB (abst) 427
Evan AP (abst) 320, 323, 375
Evan AP *See* Gardner Jr KD et al 1116
Evans DJ (abst) 202
Evans RA *See* Dunstan CR et al S-65
Eveloff J (abst) 362, 395
Fabris A (abst) 609
Fabris A *See* Ronco C et al 908
Facchini MG (abst) 613
Fajman WA (abst) 261
Falk RJ (abst) 274, 275
Falk SA (abst) 318
Falkner B (abst) 251
Fallon M (abst) 159, 237, 239
Familiar R (abst) 313
Familiar RG (abst) 205
Fanti P (abst) 165, 186
Farge D (abst) 415
Farnsworth PN (abst) 391
Farrow GM (abst) 276
Fasel J (abst) 1261
Fauchald P *See* Talseth T et al 1072
Fauchald P: Transcapillary colloid osmotic gradient and body fluid volumes in renal failure 895
Fauchet M *See* Karsenty G et al 1058
Faugere MC (abst) 165, 213
Faugere MC *See* Malluche HH et al S-70
Faustino EF (abst) 186
Favre H (abst) 222
Favret M (abst) 612
Favus MJ (abst) 161, 162
Feig PU (abst) 245
Feigal DW (abst) 204
Fein P (abst) 210, 231
Feiner H (abst) 324
Feiner HD (abst) 244, 274
Feintzeig ID (abst) 272
Feintzeig ID, Dittmer JE, Cybulsky AV, Salant DJ: Antibody, antigen, and glomerular capillary wall charge interactions: Influence of antigen location on in situ immune complex formation 649
Felder CC (abst) 186, 385
Felder RA (abst) 245, 385
Fellner SK (abst) 186
Felsenfeld A (abst) 158, 164, 168, 170, 322
Felsenfeld AJ *See* Llach F et al S-74
Felts J (abst) 193
Fenves JAJZ (abst) 213
Feola M (abst) 301
Ferder LF (abst) 245
Ferguson RM (abst) 431
Feriani M *See* Ronco C et al 908
Fernandez S (abst) 221
Fernandez-Cruz A (abst) 383
Fernandez-Repollet E (abst) 383
Ferrari C (abst) 608
Ferrario F (abst) 608

Ferrier C *See* Bianchetti MG et al 882
Fetterman G (abst) 314
Fettman MJ (abst) 327
Feussner JR (abst) 259
Field JB (abst) 423
Fielding CJ (abst) 224
Fields PA (abst) 234
Fiessenger JN (abst) 777
Fievet P (abst) 775
Fievet P (abst) 777
Fievet P (abst) 777
Fievet P (abst) 778
Fiksen-Olsen MJ (abst) 380
Filburn CR (abst) 334, 353
Filsinger S (abst) 277
Finch J (abst) 226
Fine A (abst) 353
Fine LG (abst) 318
Fine LG: Pathological specimens of the kidney examined by Richard Bright (Historical Archives) 779
Fine LG: The biology of renal hypertrophy (Editorial Review) 619
Fine RN (abst) 196, 208, 236, 238, 427
Finet M (abst) 775
Finet M (abst) 778
Fischl M (abst) 288
Fish A (abst) 279
Fish AJ (abst) 274
Fisher JW (abst) 167, 229
Fisher P (abst) 304
Fitzgibbons J (abst) 180, 188
Flanigan MJ (abst) 322
Flatmark A *See* Talseth T et al 1072
Fleuren GJ (abst) 1256
Flombaum CD (abst) 187, 191
Florence-Green D (abst) 187
Foellmer HG (abst) 275
Foidart JM, Hunt J, Lapiere CM, Nusgens B, De Rycker C, Bruwier M, Lambotte R, Bernard A, Mahieu P: Antibodies to laminin in preeclampsia 1050
Foley J (abst) 234
Foley JA (abst) 194
Fong J (abst) 395
Forbes C (abst) 282
Foreman JW (abst) 350
Forman SJ (abst) 206
Fornasieri A (abst) 608
Fornell L (abst) 177
Førre Ø *See* Berg KJ et al 1180
Forrest JN Jr (abst) 337
Fortin S (abst) 271
Fosburg M (abst) 226
Foulkes EC (abst) 416
Fournier A (abst) 775
Fournier A (abst) 777
Fournier A (abst) 777
Fournier A (abst) 778
Fournier A, Moriniere P, Sebert J L, Dkhissi H, Atik A, Leflon P, Renaud H, Gueris J, Gregoire I, Idrissi A, Garabedian M: Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia. S-114
Fowler B (abst) 346
Frömter E (abst) 1252
Fracasso A (abst) 241, 301
Fracasso AR (abst) 290
Fraley DS (abst) 181, 187, 237
Franco M (abst) 260
Frangione B (abst) 288
Franson R (abst) 316
Franzone A (abst) 263
Frascà GM (abst) 613
Fraser CL (abst) 158
Fraser W (abst) 349
Freeman H (abst) 423
Freeman RH (abst) 409
Freeman RM (abst) 323
Freer KE (abst) 229
Frei U (abst) 1262
Freiberg M (abst) 353
Frick A (abst) 1253
Friedland E (abst) 395
Friedlander G (abst) 413, 416
Friedlander MA (abst) 158
Friedler RM (abst) 165, 213
Friedler RM *See* Malluche HH et al S-70
Friedman A (abst) 318
Friedman EA (abst) 201, 429
Friedman PA (abst) 159
Friedrich RA (abst) 213
Frigon RP (abst) 234, 236
Frindt G (abst) 404
Fritschka E (abst) 1258
Froehlich J (abst) 374
Frohnert PP (abst) 1264
Frohnert PP (abst) 429, 436
Fromter E (abst) 393, 396
Frymoyer PA (abst) 183
Fuhro R (abst) 351
Fujii DK (abst) 272
Fujimaki H *See* Kawaguchi Y et al S-49
Fujimi S *See* Okuda S et al 502
Fujishima M *See* Okuda S et al 502
Fuld R (abst) 301, 311
Fulde JR (abst) 1262
Fuller PJ, Funder JW: The cellular physiology of glandular kallikrein (Editorial Review) 953
Funder JW *See* Fuller PJ et al 953
Fürstenberger G (abst) 1256
Fusi M (abst) 206
Gabbai F (abst) 260, 380, 383
Gafter U (abst) 159
Gaga A (abst) 1259
Gagnon RF (abst) 232, 318
Galceran T (abst) 319
Gale DA (abst) 202
Galicka-Piskorska G (abst) 232
Galla JH, Booker BB, Luke RG: Role of the loop segment in the urinary concentrating defect of hypercalcemia 977
Galla JH (abst) 309, 364, 365, 411
Galle P *See* Drüeke TB et al S-45
Gallieni M (abst) 211
Gallieni M (abst) 610
Gallimore B (abst) 232, 318
Gallo G (abst) 288
Gallo GR (abst) 187, 274
Gallon L (abst) 329, 336
Gambardella S (abst) 611
Gambaro G (abst) 609

Gambertoglio J (abst) 191
Gambertoglio J *See* Kaysen GA et al 572
Gamero D (abst) 335
Gammaro L (abst) 609
Gan A (abst) 210
Ganapathy V (abst) 1252
Gandhi VC (abst) 200, 212, 231
Gannari FJ (abst) 372
Ganousis L (abst) 243
Ganten D (abst) 1252
Ganten D (abst) 1254
Ganten D (abst) 259, 334, 340
Ganten D *See* Luft FC et al 1004
Ganten U (abst) 252
Gao CY (abst) 353
Gao Y (abst) 259, 334
Gao Y *See* Luft FC et al 1004
Gapstur S (abst) 167
Gapstur SM (abst) 352, 361, 425
Garabedian M *See* Fournier A et al S-114
Garcia JC (abst) 330
Garcia Prugue N (abst) 207
Garcia-Maldonado M (abst) 317
Garcia-Robles R (abst) 257
Garcia-Sainz JA (abst) 342, 426
Gardenswartz MH (abst) 238
Gardin JP (abst) 199
Gardner Jr KD, Evan AP, Reed WP: Accelerated renal cyst development in deconditioned germ-free rats .. 1116
Gardner KD (abst) 324
Gardner PW (abst) 227
Garella S (abst) 364
Garetto G (abst) 608
Garg LC (abst) 395
Garland DS (abst) 245
Garovoy MR (abst) 275
Garvin JL (abst) 366, 370
Gattone VH (abst) 246, 321, 375
Gau GT (abst) 1264
Gaudio K (abst) 299, 300, 315
Gaudio KM (abst) 353
Gaudry C (abst) 776
Gaulton G (abst) 280
Gauthier B (abst) 430
Gavellas G (abst) 392
Gavin JR III (abst) 354
Gazinski B (abst) 225
Gearing B (abst) 231
Gebhardt M (abst) 1249
Gebhardt M (abst) 286
Geers AB (abst) 188, 194
Gehr M, MacCarthy EP, Goldberg M: Guanabenz: A centrally acting, natriuretic antihypertensive drug .. 1203
Gehrig JJ Jr (abst) 319
Gelder FB (abst) 267
Gellai M (abst) 379, 395
Gemsa D (abst) 282
Geniteau-Legendre M (abst) 360
Geniteau-Legendre M *See* Brunisholz M et al 971
Gentile DE (abst) 235
Gentric D (abst) 775
Gephardt GN (abst) 275
Gerald S (abst) 230
Geratz JD (abst) 275
Gerber JG (abst) 388
Gerhardt DH (abst) 188
Gerlag PGG (abst) 943
Germain M (abst) 180, 188
German P (abst) 347
Gerok W (abst) 1257
Gerozissis K (abst) 424
Gersh A (abst) 219
Gerzer R (abst) 1253
Gerzi K (abst) 199
Ghiggeri GM (abst) 189
Giacchino F (abst) 608
Giansiracusa R (abst) 196
Gibbons JT (abst) 281, 283
Gibbons N (abst) 425
Gibbs VC (abst) 275
Gibbs VG (abst) 272
Giebisch G (abst) . 365, 371, 391, 396, 398, 399, 403, 406, 407
Gilbert DN (abst) 313
Gillespie C (abst) 295
Gillespie GY (abst) 275
Gillum DM *See* Lumlertgul D et al 658
Gimenez L (abst) 312
Ginalski JM *See* Jaeger P et al 563
Ginevri F (abst) 189
Ginkinger K (abst) 361
Giordano C (abst) 611
Giordano R (abst) 610
Giraudo G (abst) 608
Gitelman HJ (abst) 169
Gitelman HJ, Alderman FR: Electrothermal determination of aluminum in biologic samples by atomic absorption spectroscopy S-28
Gitter A (abst) 393
Givens G (abst) 365
Givner ML (abst) 271
Glas-Greenwalt P (abst) 279
Glass M (abst) 273
Glass N (abst) 434
Glassock R (abst) 293, 438
Glassock RJ (abst) 190
Glatfelter A *See* Wiggins RC et al 591
Gleim GW (abst) 238, 263
Glenni JL (abst) 430
Glicklich D (abst) 214
Gloor F (abst) 1263
Gloria DS (abst) 334
Glotz D (abst) 776
Gluck S (abst) 366, 369, 398
Gluck Z (abst) 233
Glurich I (abst) 264
Gnadinger MP (abst) 348, 388
Go IH (abst) 943
Gockerman JP *See* Herrera GA et al 725
Godet A (abst) 334
Goetz FC *See* Ellis EN et al 889
Goetz R (abst) 159
Gokel M *See* Schnermann J et al 520
Goldberg L (abst) 223
Goldberg M *See* Gehr M et al 1203
Goldfarb D (abst) 396, 397, 403
Goldfarb S (abst) 159
Goldring RM (abst) 223
Goldschmidt M *See* Robertson JL et al 511
Goldstein M (abst) 192
Goldstein MB (abst) 188

Goldstein SJ (abst) 222
Golfarb S (abst) 174
Goligorsky MS (abst) 160
Golper TA (abst) 214, 324
Golub MS (abst) 251
Gondi B (abst) 217
Gonzalez H (abst) 301
Good D (abst) 397
Good DW (abst) 366
Good JT Jr (abst) 196
Goodman AI (abst) 252
Goodman WG (abst) 236
Goodman WG: Experimental aluminum-induced bone disease: Studies in vivo S-32
Gordon JA (abst) 335
Gorsline J (abst) 253
Gotch F (abst) 217
Gougoux A (abst) 227, 340, 354
Gouvea W (abst) 297
Gröger U (abst) 1258
Gröne E (abst) 1248
Gröne H-J (abst) 1248
Grabensee B (abst) 1262
Graber M (abst) 374
Graber ML (abst) 366
Graham S (abst) 383
Granger JP (abst) 358, 384, 390, 393, 406
Granholm NA (abst) 268, 276
Grant D (abst) 198
Grantham J (abst) 315, 419
Grantham JJ (abst) 323, 371
Grassi G (abst) 610
Grassl SM (abst) 367
Graves K (abst) 264, 268, 276
Gray RW (abst) 162
Gray RW *See* Lemann Jr J et al 743
Green N (abst) 396
Greenberg A (abst) 188
Greene ER (abst) 379
Greger B (abst) 1263
Greger B (abst) 1263
Greger R (abst) 1255
Greger R (abst) 409
Gregoire I *See* Fournier A et al S-114
Gregoire JR (abst) 276
Gregory M (abst) 224, 277
Grekas D *See* Kerr DNS et al S-58
Gretz N (abst) 325
Griffiths S (abst) 220
Groger U (abst) 181
Groggel GC (abst) 276
Grond AJK (abst) 944
Grond J (abst) 945
Grond J *See* Weening JJ et al 789
Grone HJ (abst) 246
Grosman M (abst) 245
Gross ML (abst) 189, 254
Gross P (abst) 1252
Gross P (abst) 1259
Gross P (abst) 393, 396
Gruber KA (abst) 246
Gruenberg J (abst) 420
Grunfeld JP (abst) 246
Gruskin A (abst) 235
Gstraunthaler G (abst) 354
Guastoni C (abst) 610
Guckian W (abst) 365
Guder WG (abst) 1252
Gueris J *See* Fournier A et al S-114
Guettier C (abst) 775
Guettier C (abst) 775
Guggino WB (abst) 396
Guggion SE (abst) 396
Gullans S (abst) 353
Gullans S (abst) 611
Gullans SR (abst) 396
Gung A (abst) 385
Gunther J (abst) 277
Gupta B (abst) 254
Gupta RK (abst) 356
Gupta RK *See* Kumar AM et al 747
Gurich RW (abst) 367
Gushwa LC (abst) 383
Gusmano R (abst) 189
Gusowski N (abst) 413
Guthrie GP Jr (abst) 410
Gutierrez J (abst) 354
Gutjahr E (abst) 357
Gutterman C (abst) 426
Guttmann RD (abst) 220
Guttmann W (abst) 1261
Guyton AC (abst) 253
Haag K (abst) 1257
Haag M (abst) 1257
Haberle DA (abst) 1253
Hackenthal E (abst) 1259
Haddad J (abst) 160
Hadjat N (abst) 251
Hafezi A (abst) 397
Hagler H (abst) 291
Hahn T (abst) 175
Hahn TJ (abst) 157
Hain H (abst) 233
Hakim R (abst) 226
Hakim RM (abst) 213, 214, 221
Hale GM, McIntosh SL, Hiki Y, Clarkson AR, Woodroffe AJ: Evidence for IgA-specific B cell hyperactivity in patients with IgA nephropathy 718
Hall BM *See* Bishop GA et al 708
Hall JE (abst) 253, 389
Hall JW (abst) 198, 227
Hall M (abst) 200, 430
Hall PW (abst) 354
Hall TL (abst) 238
Hall-Craggs M (abst) 301
Haller H (abst) 1258
Halloran BP (abst) 169
Halloran P (abst) 182, 264
Halloran PF (abst) 276
Halloran PR (abst) 294
Halperin ML (abst) 188, 208, 351, 367
Halpern S *See* Cournot-Witmer G et al S-37
Halstenson CE (abst) 175
Hamet P (abst) 1253
Hamet P (abst) 340
Hamilton K (abst) 397
Hamm L (abst) 367, 413
Hammerman MR (abst) 354, 372
Hammond E (abst) 277
Hammond T (abst) 257

Hammond TG (abst) 319, 383
Hammond WS (abst) 319
Hammond WS *See* Lumlertgul D et al 658
Hanai H (abst) 174
Handler JS (abst) 354, 411, 416
Hano J (abst) 194
Hansch GM (abst) 277
Hansen T (abst) 243
Hanson P (abst) 434
Hara M *See* Endo Y et al 557
Haramati A (abst) 160, 384, 389
Hardy M (abst) 437
Hardy MA (abst) 427
Harnell M (abst) 377
Harnett JD (abst) 220
Harnik M (abst) 242, 253
Harpold GJ (abst) 262
Harrelson JM (abst) 169
Harrington R (abst) 374
Harris DC *See* Lumlertgul D et al 658
Harris DCH (abst) 303, 319
Harris HW Jr (abst) 416
Harris LS (abst) 272
Harris RA (abst) 403
Harris RC (abst) 397, 401, 402, 406
Harrison P (abst) 202
Harrison S (abst) 353
Hart D (abst) 416
Hartford M (abst) 251
Hartig F (abst) 1257
Hartley B (abst) 202, 267, 295
Hartmann A *See* Langberg H et al 820
Hartupee D (abst) 335
Hartwig J (abst) 413
Harwig S (abst) 1258
Hasbargen J (abst) 203
Haskell L (abst) 368
Hasler L (abst) 348, 388
Hassid A (abst) 335
Hasslacher C (abst) 189
Hasslacher Ch (abst) 1250
Hassoun A (abst) 211
Hathiwala SC (abst) 178
Hatton D (abst) 254
Hatton DC (abst) 247
Hatzigeorgiou G (abst) 296
Haughey D (abst) 217
Haughey DB (abst) 214
Haverty T (abst) 160
Hawkins EP (abst) 437
Hawkins R (abst) 428
Hayakawa M *See* Nagakura K et al 834
Hayashi M (abst) 368, 400
Hayhurst RA (abst) 397
Hays RM (abst) 345
Hays SR (abst) 368
Hebbel RP (abst) 308
Hebel R (abst) 328
Hebert LA (abst) 271
Hebert LA (abst) 273, 277
Hebert RL (abst) 342
Hebert SC (abst) 320, 398
Heckmann M (abst) 1255
Heidbreder E (abst) 159
Heidland A (abst) 1257
Heidland A (abst) 159, 309
Heilman RL (abst) 189
Heilo A *See* Talseth T et al 1072
Helderman JH (abst) 430
Hellfritzsch M, Christensen EI, Sonne O: Luminal uptake and intracellular transport of insulin in renal proximal tubules 983
Hellmuller B (abst) 348
Helmchen U (abst) 1248
Helmchen U (abst) 1250
Helmchen U (abst) 246, 281
Helmstadter KA (abst) 320
Hem JD: Geochemistry and aqueous chemistry of aluminum S-3
Hem SL *See* Larson EA et al 1131
Hemmerle J *See* Cournot-Witmer G et al S-37
Henderson A (abst) 190
Henderson LW (abst) 234, 236
Henderson LW *See* Cheung AK et al 799
Henderson LW: Heterogeneity of the cardiovascular response to hemofiltration 901
Henderson R *See* Holloway JC et al 989
Hendler E (abst) 210
Hendrix P (abst) 312
Hene RJ (abst) 190
Hené RJ (abst) 1251
Henny FC (abst) 944
Henrich W (abst) 212
Henrich WL, Brater DC, Campbell WB: Renal hemodynamic effects of therapeutic plasma levels of sulindac sulfide during hemorrhage 484
Henry HL (abst) 162
Hensel A (abst) 199
Hensley G (abst) 288
Heptinstall RH *See* Olson JL et al 849
Hercz G (abst) 199, 215
Hercz G *See* Milliner DS et al S-100
Herlitz H (abst) 241, 277
Hermann J (abst) 183
Hernandez JA (abst) 430
Hernandez L (abst) 221
Hernandez R (abst) 190
Hernando L (abst) 281, 343, 381, 385
Herrera CY (abst) 178
Herrera GA (abst) 288
Herrera GA, Alexander RW, Cooley CF, Luke RG, Kelly DR, Curtis JJ, Gockerman JP: Cytomegalovirus glomerulopathy: A controversial lesion 725
Herrera-Acosta J (abst) 260
Herrero-Bervera B (abst) 302
Herrman J (abst) 355
Heublein DM (abst) 245, 407
Heuck CC (abst) 1257
Heywood EF *See* Nolasco F et al 1215
Hicks J *See* Nolasco F et al 1215
Hierholzer K (abst) 358
Higgins JT (abst) 254
Hiki Y *See* Hale GM et al 718
Hildebrandt DA (abst) 398
Hilden SA (abst) 368
Hill DE (abst) 177
Hill G (abst) 326
Hill GS *See* Robertson JL et al 511
Hill KE (abst) 307

Hinglais M (abst) 775
Hino T (abst) 247
Hipp CG (abst) 278
Hiramatsu M (abst) 278
Hirayama P (abst) 359
Hirlte RW (abst) 417
Hirsch DJ (abst) 417
Hirsch F (abst) 775
Hirsch S (abst) 369
Hirschberg R (abst) 190
Hirszel P (abst) 232
Hirtle RW (abst) 417
Hirzel B (abst) 1254
Hise M (abst) 355, 378, 406
Hjelle T (abst) 359
Ho C (abst) 362
Ho P (abst) 349
Hoch BS (abst) 417
Hodsman A (abst) 190
Hodsman AB (abst) 173
Hoechst AG (abst) 1254
Hoedemaeker PJ (abst) 265
Hoedemaeker PJ *See* Beukhof JR et al 549
Hoedemaeker PhJ (abst) 945
Hoeldtke R (abst) 194
Hoette M (abst) 430
Hoffman A (abst) 389
Hoffman EA (abst) 380
Hoffman W (abst) 231
Hofmann E (abst) 1263
Hogewind B (abst) 181
Hogg R (abst) 207, 284, 287
Hogg RJ (abst) 179, 191, 204
Hoilien C (abst) 403
Hoitsma AJ (abst) 941
Hoitsma AJ (abst) 942
Holden MC (abst) 302, 307
Holland I (abst) 302
Holley J (abst) 398
Holley KE (abst) 182
Holley KE (abst) 189, 276, 429
Hollomby D (abst) 190
Holloway JC, Phifer T, Henderson R, Welbourne TC: Renal acid-base metabolism after ischemia 989
Holmes N (abst) 270
Holmes S (abst) 230
Holohan P (abst) 301
Homma S (abst) 167, 335, 425
Honma S (abst) 173
Honsage L (abst) 187
Hood S (abst) 209
Hopfner C (abst) 777
Hopp L (abst) 338
Hopt U (abst) 1262
Hopt UT (abst) 1263
Hopt UT (abst) 1263
Horisberger JD (abst) 398, 399
Horizonte B (abst) 430
Hörl WH (abst) 1257
Horl WH (abst) 309
Horner C (abst) 423
Hornych A (abst) 777
Horster MF (abst) 1252
Horton C (abst) 386
Horvath JS *See* Bishop GA et al 708
Hosoda S (abst) 173
Hosser H (abst) 1248
Hostetter MK (abst) 293
Hostetter TH (abst) 244, 293, 325, 341, 384
Houghton D (abst) 313
Houser MT (abst) 191
Housset E (abst) 777
Hovingh P (abst) 276
Howell KE (abst) 420
Hruby Z (abst) 282
Hrushesky W (abst) 241
Hruska KA (abst) 160, 162, 174, 344, 421
Hryhorczuk DO (abst) 178
Hsieh H (abst) 436
Hsu C (abst) 262
Hsu CH (abst) 247
Hsueh W (abst) 323
Huang CL (abst) 384
Hudson C (abst) 202
Hudson SL (abst) 428
Hueber P (abst) 303, 331
Huffman W (abst) 418
Hugel U (abst) 170
Hügel U (abst) 1256
Hughes H (abst) 175
Hughes ML, Ichikawa I: Interglomerular heterogeneity of filtration fraction among superficial nephrons 814
Huie P (abst) 254
Huie PE (abst) 247
Hull A (abst) 437
Humes HD (abst) 302, 303, 307, 312
Humphreys MH (abst) 357
Hunt DA (abst) 302, 307, 312
Hunt J (abst) 295
Hunt J *See* Foidart JM et al 1050
Hunt LP *See* Short CD et al 1224
Hunter M (abst) 398, 399
Huntsberger T (abst) 201
Hupp TH (abst) 191
Hura CE (abst) 385
Hursh J (abst) 199
Hurtado H (abst) 231
Huseman R (abst) 315
Huskey M (abst) 174
Husted RF (abst) 399
Hutchinson FN *See* Kaysen GA et al 572
Hutchinson TA (abst) 173
Hutchison FN (abst) 193, 320, 321, 344
Hütteroth T (abst) 1258
Hütteroth T *See* Kurz P et al 1209
Huysmans FThM (abst) 941
Hwang KH (abst) 306, 392
Hwang SD (abst) 195, 232
Iaina A (abst) 302
Ianhez E (abst) 430
Iannelli S (abst) 611
Ibarra-Rubio ME (abst) 302
Ibnoul-Khatib H (abst) 155
Ibrahim S (abst) 311
Icardi A (abst) 610
Ichikawa I (abst) 328
Ichikawa I (abst) 382, 390
Ichikawa I *See* Hughes ML et al 814
Idrissi A *See* Fournier A et al S-114
Iesato K *See* Ueda S et al 539

Igarashi P (abst) 369
Ihle BB, Becker GJ, Kincaid-Smith PS: Clinical and biochemical features of aluminum-related bone disease S-80
Iida-Klein A (abst) 157, 175
Iino Y (abst) 369, 375
Ilstrup K (abst) 215, 217
Imai H (abst) 278
Imai M *See* Takeda K et al 863
Imamura N *See* Kawaguchi Y et al S-49
Inagami T *See* Barajas L et al 965
Ing TS (abst) 200, 212, 220, 231, 369
Innes JT (abst) 431
Inscho EW (abst) 248
Intrator L (abst) 776
Irmler HY (abst) 357
Isaacs M (abst) 187, 191
Iseki K (abst) 248
Ishibashi K (abst) 369
Ishida M (abst) 171
Ishola M *See* Short CD et al 1224
Isordia J (abst) 172
Issa A (abst) 197
Itabashi A (abst) 310, 336
Ito K (abst) 247, 258
Ito Y (abst) 329, 336
Ittel TH (abst) 1261
Ituarte HG (abst) 157
Ives HE (abst) 370, 378, 384
Jackson A (abst) 222
Jackson B (abst) 320
Jackson K (abst) 201
Jackson NM (abst) 303, 307
Jacob M (abst) 160
Jacobs WR (abst) 399
Jacobson H (abst) 209, 356
Jacobson HR (abst) 368, 414
Jacobson HR *See* Levine DZ et al 1099
Jacoby M (abst) 419
Jacquet A-F *See* Jaeger P et al 563
Jadot JP (abst) 776
Jaeger P, Portmann L, Ginalski J-M, Jacquet A-F, Temler E, Burckhardt: Tubulopathy in nephrolithiasis: Consequence rather than cause 563
Jaeger P (abst) 192, 365
Jaffe D (abst) 288
Jahan S (abst) 385, 389
Jain S (abst) 215
Jameson D (abst) 163
Jamison RL (abst) 319, 337, 418
Janis R (abst) 325
Jann K (abst) 1257
Janssen F (abst) 200, 367
Jao S (abst) 368
Jao W (abst) 161
Jarrard E (abst) 317
Jarrell B (abst) 427
Jeanmonod R (abst) 222
Jeekel J (abst) 944
Jenkins PG (abst) 215, 222
Jennette JC (abst) 274, 275, 278
Jennings AE (abst) 232
Jennings ML (abst) 376
Jensen PK, Steven K, Blæhr H, Christiansen JS, Parving HH: Effects of indomethacin on glomerular hemodynamics in experimental diabetes 490
Jerome E (abst) 216
Jimenez I *See* Kaysen GA et al 572
Jindal K (abst) 192
Jo OD (abst) 161
Jobin JR, Bonjour JP: Compensatory renal growth: Modulation by calcium PTH and 1,25-$(OH)_2D_3$ 1124
John EG (abst) 177
John HD (abst) 1259
Johnson CA (abst) 437
Johnson J (abst) 317
Johnson MA (abst) 250
Johnson RJ (abst) 271, 278, 287
Johnson WJ (abst) 165
Johnston CI (abst) 320
Johnston JR (abst) 320
Jones DB (abst) 301, 303
Jones ER (abst) 355
Jones H *See* Kaysen GA et al 572
Jones P (abst) 428
Jones Q (abst) 236
Jones RL (abst) 170
Jones S (abst) 249
Jorden A (abst) 231
Jorgetti V *See* Cournot-Witmer G et al S-37
Jorgetti V *See* Karsenty G et al 1058
Jose PA (abst) 186, 245, 333, 385
Josepovitz C (abst) 303
Joshi SK (abst) 370
Josselson J (abst) 216, 228
Jucquel JP *See* Drüeke TB et al S-45
Julian BA (abst) 209
Julian TB (abst) 237
Jungas RL (abst) 367
Köhler H (abst) 1248
Köhler H (abst) 1258
Könler H (abst) 1259
Köhler H *See* Kurz P et al 1209
Kühn K (abst) 1258
Kablitz C (abst) 192, 389
Kachadorian WA (abst) 417
Kachny WD (abst) 209
Kahn AM (abst) 248
Kaiser B (abst) 233, 235
Kaiser DL (abst) 381
Kaissling B (abst) 1261
Kaku T (abst) 334
Kaloyanides GJ (abst) 303, 308
Kanalas J (abst) 279, 284
Kanazi G (abst) 436
Kang CW (abst) 326
Kangarloo H (abst) 196, 208
Kant KS (abst) 279
Kanwar YS (abst) 268, 279, 281, 283
Kaplan AA (abst) 214, 216
Kaplan AP (abst) 210
Kaplan F (abst) 237, 239
Kapoor V (abst) 330
Kapp Ch (abst) 1254
Kaptein EM (abst) 192
Karakpanos G (abst) 306
Karanja N (abst) 166, 173, 248
Karasek M (abst) 281
Kardaun O *See* Beukhof JR et al 549
Karl IE (abst) 316

Karli J (abst) 212
Karniski LP (abst) 407
Karnovsky MJ (abst) 273
Karnovsky MJ *See* Diamond JR et al 478
Karow AM (abst) 431
Karsenty G, Vigneron N, Jorgetti V, Fauchet M, Zingraff J, Drüeke T, Cournot-Witmer G: Value of the 99mTc-methylene diphosphonate bone scan in renal osteodystrophy 1058
Kashgarian M (abst) 275, 300, 353
Kashtan C (abst) 279
Kasinath BS (abst) 279
Kasiske BL (abst) 316, 324, 336, 381
Kaskel F (abst) 304
Kathpalia SC (abst) 159, 161
Katoh T (abst) 336
Katz A (abst) 200
Katz AI (abst) 254, 268, 400
Katz LA (abst) 187, 249
Katz R (abst) 262
Katz SM (abst) 280
Kaude J (abst) 429
Kauffman S (abst) 254
Kawaguchi Y, Oda Y, Imamura N, Shigematu T, Kimura Y, Aizawa S, Fujimaki H, Shoji R, Tsukui I, Ogura Y, Miyahara T: Unresponsiveness of bone to parathyroid hormone in aluminum-related renal osteodystrophy S-49
Kawahara K (abst) 399
Kaye M (abst) 173, 318
Kaylin M (abst) 216
Kaysen GA (abst) 193, 320, 321, 344
Kaysen GA, Gambertoglio J, Jimenez I, Jones H, Hutchinson FN: Tubulopathy in nephrolithiasis: Consequence rather than cause 572
Keane WF (abst) 175, 316, 319, 324, 336, 381
Keeley P (abst) 243
Keen M (abst) 217
Kelleher S (abst) 198, 217
Kelley C (abst) 280
Kelley GG (abst) 337
Kelley V (abst) 289
Kelley VE (abst) 280
Kelly C *See* Agus D et al 635
Kelly CJ (abst) 286
Kelly DR *See* Herrera GA et al 725
Kelly RA (abst) 249
Kempson SA (abst) 246
Kendrick PW (abst) 272
Kennaert P (abst) 430
Kennedy TL (abst) 216
Kenney M (abst) 250
Kenny MA (abst) 240
Keown P (abst) 182
Kerb W (abst) 1256
Kerr DNS, Ward MK, Arze RS, Ramos JM, Grekas D, Parkinson IS, Ellis HA, Owen P, Simpson W, Dewar J, Martin AM, McHugh MF: Aluminum-induced dialysis osteodystrophy: The demise of "Newcastle bone disease"? S-58
Kershaw G (abst) 337
Kershaw M (abst) 202
Keshaviah P (abst) 214, 215, 217
Keveney Jr JJ *See* Llach F et al S-74
Keyzer JJ (abst) 206
Khalil F (abst) 339
Khan PM (abst) 181
Khanna R (abst) 233, 238
Khawar R (abst) 206
Kiberd B (abst) 338, 418
Kidroni G (abst) 298
Kiebzak GM (abst) 161
Kiesel G (abst) 328, 342
Kiil F *See* Langberg H et al 820
Kilates T (abst) 195
Kilidar HS (abst) 179
Kim HJ (abst) 373, 377
Kim J (abst) 424
Kim JK (abst) 321
Kimmel PL (abst) 321
Kimura G (abst) 247, 258
Kimura Y *See* Kawaguchi Y et al S-49
Kincaid-Smith P *See* Walker RG et al 875
Kincaid-Smith PS *See* Ihle BB et al S-80
Kindermans C *See* Bourdeau AM et al 924
Kino M (abst) 338
Kinsella J (abst) 370, 374
Kinter LB (abst) 242, 418
Kipnowski J (abst) 1255
Kipnowski J (abst) 400, 401
Kirchner KA (abst) 337
Kirk KA (abst) 428
Kirkpatrick R (abst) 269
Kirschenbaum MA (abst) 339, 346
Kirste G (abst) 1261
Kjellstrand C (abst) 220
Kjellstrand CM (abst) 433
Klahr S (abst) 182, 316, 413
Klassen D (abst) 208, 312
Klassen DK (abst) 338
Klebanoff SJ (abst) 271, 278
Kleeman C (abst) 166, 175
Klein JB (abst) 217
Klein MH (abst) 265
Kleinman H (abst) 283
Kleinman J (abst) 363
Kleinman K (abst) 190
Kleyman TR (abst) 400
Klok M (abst) 218
Klotman PE (abst) 242, 249, 332
Kluger MJ (abst) 221
Kluthe R (abst) 436
Knauf H (abst) 1257
Knauss TC (abst) 304
Knecht R (abst) 1250
Knepper MA (abst) 366, 370, 372, 377, 406, 418
Knox FB (abst) 155, 358, 380, 390
Knudsen PJ (abst) 431
Ko H (abst) 325
Koch KM (abst) 1258
Koch KM (abst) 1260
Koch KM (abst) 1262
Koch KM (abst) 219, 357
Kock KM (abst) 266
Koderisch J (abst) 1256
Koene RAP (abst) 941
Koene RAP (abst) 942
Koene RAP (abst) 943
Koepke JP (abst) 249
Koeppen BM (abst) 400

Kohnen PW (abst) 313
Koitabashi Y (abst) 365
Kojima I (abst) 329
Kojima K (abst) 329
Kojima S (abst) 248
Kokko JP (abst) 368, 422, 430
Kokot F (abst) 1260
Kol R (abst) 315
Kolbeck PC (abst) 432
Koldovsky U (abst) 1262
Kompf J (abst) 286
Kone BC (abst) 304
Konforti A (abst) 315
Konieczkowski M (abst) 401
Koomans HA (abst) 1251
Koomans HA (abst) 188, 190, 193, 194, 420, 477
Koopman MG (abst) 942
Kopecky RT (abst) 338
Kopp JB (abst) 176, 218
Kopp UC (abst) 250
Kopple JD (abst) 190, 228
Kopple JD, Monteon FJ, Shaib JK: Effect of energy intake on nitrogen metabolism in nondialyzed patients with chronic renal failure 734
Kopyt N (abst) 355
Korbert SM (abst) 278
Korkor AB (abst) 162
Korn M (abst) 262
Kortas C (abst) 178, 278
Kortas C *See* Bichet DG et al 1188
Kortlandt W (abst) 279
Koster P (abst) 242
Kostis J (abst) 258
Kotchen TA (abst) 256, 349, 410
Kovithavongs T (abst) 432
Koyle M (abst) 338
Kozeny GA (abst) 279
Krall K (abst) 316
Kramer HJ (abst) 1255
Kramer HJ (abst) 341, 400, 401
Kramer MS (abst) 222
Kraus E (abst) 321, 326
Kraut JA (abst) 248
Krediet RT (abst) 941
Krediet RT (abst) 942
Kreisberg JI (abst) 238, 247, 248
Kreisberg JI *See* Troyer DA et al 530
Kren SF (abst) 384
Krensky AM (abst) 270, 281
Kribben A (abst) 1258
Krishna GG (abst) 182, 279
Kristensen C (abst) 279
Kriz W (abst) 1248
Kriz W (abst) 1252
Kriz W (abst) 259
Kronfeld DS *See* Robertson JL et al 511
Kruz P (abst) 1258
Ksirsagar B *See* Wiggins RC et al 591
Kubat B (abst) 419
Kudelka S (abst) 1250
Kudelka S (abst) 247
Kuehnel E (abst) 304
Kuhn K (abst) 181, 281
Kulbe KD *See* Schneider HW et al S-120
Kumar AM (abst) 356
Kumar AM, Spitzer A, Gupta RK: ^{23}Na NMR spectroscopy of proximal tubule suspensions (Technical Note) 747
Kumar S (abst) 380
Kunau RT (abst) 385
Kunin AS (abst) 305
Kunis CL (abst) 427
Kunkel SL (abst) 221
Kunneman ME (abst) 420
Kuntz D (abst) 229
Kupiec-Weglinski JW (abst) 432
Kupin W (abst) 187, 195
Kuramochi M (abst) 248, 259
Kuriyama S (abst) 339
Kurnik BRC (abst) 162, 174
Kurokawa K (abst) 337, 342, 373, 393
Kurth J (abst) 1263
Kurtin P (abst) 223
Kurtz I (abst) 275, 370
Kurtz SB (abst) 163, 169
Kurtz TW (abst) 340
Kurtzman NA (abst) 168, 301, 371, 375
Kurz P (abst) 1248
Kurz P, Köhler H, Meuer S, Hütteroth T, Meyer zum Buschenfelde K-H: Impaired cellular immune responses in chronic renal failure: Evidence for a T cell defect 1209
Kusano E (abst) 336
Kuzniak SA (abst) 266
Kwok C (abst) 374
Kyser BA (abst) 216
La Greca G *See* Ronco C et al 908
La Horra M (abst) 314
Labelle EF (abst) 352
Labib S (abst) 311
Lacave R (abst) 339, 344
Lacave R (abst) 340
Lacour B (abst) 213, 252
Lacour B *See* Drüeke TB et al S-45
Lagrue G (abst) 776
Lagrue G (abst) 776
Lal S (abst) 233
Lalonde L (abst) 340
Lambotte R *See* Foidart JM et al 1050
Lameire N (abst) 943
Lamm ME (abst) 274
Lamoureux C (abst) 342
Lampainen E (abst) 233
Lamperi S (abst) 610
Landini S (abst) 241
Landolfo S (abst) 608
Landwehr DM (abst) 316, 321
Landwehr K (abst) 316
Lane B (abst) 303
Lang A (abst) 200
Lang F (abst) 1251
Lang R (abst) 210, 273
Lang RE (abst) 1254
Lang RE (abst) 334, 340, 348, 428
Lang RE *See* Luft FC et al 1004
Langberg H, Hartmann A, Østensen J, Mathisen Ø, Kiil F: Hypernatremia inhibits $NaHCO_3$ reabsorption and associated NaCl reabsorption in dogs 820
Lange J (abst) 250
Lange M (abst) 283

Langman C (abst) 244
Langman CB (abst) 162
Langs C (abst) 322
Lapiere CM *See* Foidart JM et al 1050
Lapierre L (abst) 227
Laprade R (abst) 432
Lapuerta L Jr (abst) 356
Laragh JH (abst) 257
Larson EA, Ash SR, White JL, Hem SL: Phosphate binding gels: Balancing phosphate adsorption and aluminum toxicity 1131
Larson T (abst) 337
Lasheras C (abst) 419
Laski ME (abst) 371
Lasmar E (abst) 430
Lau K (abst) 159, 161, 163, 173, 244, 260
Lauer A (abst) 218
Laungani GB (abst) 429
Laurent G (abst) 311
Laurent J (abst) 776
Laurent J (abst) 776
Lauwerys R (abst) 211
Lawton A (abst) 296, 356
Lax D (abst) 218
Lazarus JM (abst) 214, 221, 226
Lazzari E (abst) 611
Le Hir M (abst) 1253
LeWinter M *See* Cheung AK et al 799
Leber R (abst) 1250
Lechene C (abst) 397, 401, 402, 406
Lechleider RJ (abst) 156
Leclerq M (abst) 213
Ledingham JGG (abst) 358
Lee DBN (abst) 163, 172, 251, 307
Lee DBN (abst) 316
Lee DBN *See* Corry DB et al 1197
Lee HB (abst) 195, 232
Lee J (abst) 154, 350
Lee SM (abst) 195
Lee W (abst) 226
Leehey DJ (abst) 195, 200, 231
Leflon P (abst) 775
Leflon P (abst) 778
Leflon P *See* Fournier A et al S-114
Legrimellec C (abst) 271
Leibach FH (abst) 1252
Leichter HE (abst) 196, 238
Leichtman AB (abst) 432, 433
Leimenstoll G (abst) 1262
Lelong B (abst) 281, 283
Lemann Jr J, Gray RW, Maierhofer WJ, Cheung HS: The importance of renal net acid excretion as a determinant of fasting urinary calcium excretion 743
Lenhart M (abst) 356
Lenz T (abst) 1258
Leonard E (abst) 230
Lerner AM (abst) 222
Lesavre P (abst) 287
Leung F (abst) 190
Leunissen KML (abst) 1263
Leunissen KML (abst) 941
Leveille M (abst) 227
Levey AS (abst) 232
Levi J (abst) 156
Levi M (abst) 163, 252, 262, 360
Levi-Setti R (abst) 164
Leviel F (abst) 363, 415
Levin NW (abst) 187, 195
Levin TN (abst) 235
Levine BS (abst) 163
Levine BS *See* Smothers RL et al 578
Levine DZ, Jacobson HR: The regulation of renal acid secretion: New observations from studies of distal nephron segments (Editorial Review) 1099
Levine MA (abst) 339
Levine SD (abst) 417, 419
Levinsky NG (abst) 347, 401
Levis G (abst) 212
Levison SP (abst) 176
Levitz JB (abst) 437
Levy GA (abst) 370
Lew S (abst) 196
Lew WYW *See* Cheung AK et al 799
Lewand D (abst) 363
Lewis EJ (abst) 193, 196, 290, 314
Lewis J (abst) 230
Lewis SL (abst) 281
Lewis-Finch J (abst) 218
Lewy JE (abst) 331
Leypoldt JK (abst) 234, 236
Li JB, Wassner SJ: Protein synthesis and degradation in skeletal muscle of chronically uremic rats 1136
Liang CT (abst) 171
Lianos EA (abst) 339
Lieberherr M *See* Cournot-Witmer G et al S-37
Lieberthal W (abst) 347, 401
Lief PD (abst) 368
Light JA (abst) 429
Lim VS (abst) 323
Limbowo G (abst) 943
Lin JJ (abst) 305
Lin SY (abst) 357
Linas SL (abst) 196, 255
Lindheimer M (abst) 194
Lindner A (abst) 250
Lindsay RM (abst) 300, 305
Ling KY (abst) 303
Linker A (abst) 276
Linne T (abst) 282
Linton AL (abst) 300, 305
Linz W (abst) 1254
Lipkowitz MS (abst) 371, 402, 411, 412, 422
Lipman RD (abst) 402
Lips PTAM (abst) 168
Lips PTAM (abst) 943
Lisker W (abst) 359
Littleton R (abst) 187
Littman MP (abst) 242
Liu D (abst) 325
Liviano D'Arcangelo G (abst) 613
Livio M (abst) 282
Ljungman S (abst) 241, 251
Llach F (abst) 158, 164, 168, 170, 323
Llach F, Felsenfeld AJ, Coleman MD, Keveney Jr JJ, Pederson JA, Medlock TR: The natural course of dialysis osteomalacia S-74
Lobo PI (abst) 298
Lockhart P (abst) 300
Lockwood CM (abst) 200, 202, 266, 290
Loertscher R (abst) 433, 434

Logan JL (abst) 339
Loghman-Adham M (abst) 164
Lohr J (abst) 419
London RD (abst) 371
Long CA (abst) 280
Long D (abst) 438
Lonnemann G (abst) 219
Looman JHM (abst) 944
Lopes AG (abst) 371
Lopez J (abst) 221
Lopez M, Nakagawa Y, Coe FL, Tsai C, Michael AF, Scheinman JL: Immunochemistry of urinary calcium oxalate crystal growth inhibitor (CGI) 829
Lopez-Hilker S (abst) 164
Lopez-Novoa JM (abst) 281, 343, 381, 383, 385
Lorentz WB (abst) 282
Lorenz JN (abst) 410
Lorenzen M (abst) 419
Lorenzo V (abst) 164
Loschiavo C (abst) 609
Loute G (abst) 776
Loutzenhiser R (abst) 386, 395
Lovett D (abst) 282
Lowder JG (abst) 223, 429
Lowe AG (abst) 402
Lowenthal DT (abst) 251
Lowrie EG (abst) 213
Lowry RP (abst) 282
Lubansky H (abst) 377
Lucas P (abst) 252
Lucas PA (abst) 155, 165
Lucas PA, Meadows JH, Roberts DE, Coles GA: The risks and benefits of a low protein-essential amino acid-keto acid diet 995
Luchici D (abst) 179
Lüdersdorf M (abst) 1258
Lüscher T (abst) 1260
Ludecke G (abst) 341
Ludwig KS (abst) 1261
Luft F (abst) 259, 334
Luft FC (abst) 340
Luft FC, Sterzel RB, Lang RE, Trabold EM, Veelken R, Ruskoaho H, Gao Y, Ganten D, Unger T: Atrial natriuretic factor determinations and chronic sodium homeostasis 1004
Luke RG (abst) 364, 366, 411, 428
Luke RG *See* Galla JH et al 977
Luke RG *See* Herrera GA et al 725
Lumlertgul D, Burke TJ, Gillum DM, Alfrey AC, Harris DC, Hammond WS, Schrier RW: Phosphate depletion arreests progression of chronic renal failure independent of protein intake 658
Lumsden C (abst) 424
Lund K (abst) 176, 197, 224
Luong K (abst) 358
Lupo A (abst) 609
Luscher TF (abst) 251, 256, 261
Lustig S (abst) 251
MacCarthy EP *See* Gehr M et al 1203
Macdougal DF, Cook T, Steward AP, Cattell V: Canine chronic renal disease: Prevalence and types of glomerulonephritis in the dog 1144
MacDougall M (abst) 425
MacDougall ML (abst) 371
MacKay K (abst) 283
MacNeill D (abst) 250
Macher AM (abst) 178
Mackow RC (abst) 234
Macon EJ (abst) 219
Madaio MP (abst) 283, 285, 288
Madapallimattam A *See* Sole MJ et al 689
Maddalena J (abst) 305
Maddox DA (abst) 372
Maddux MS (abst) 434
Madias NE (abst) 368
Madias NE, Zelman SJ: The renal response to chronic mineral acid feeding: A re-examination of the role of systemic pH 667
Madias NE: Lactic acidosis (Nephrology Forum) 752
Madsen KM (abst) 372
Maesaka JK (abst) 311
Magbuhos C (abst) 320
Mahajan SK (abst) 154, 234, 326
Mahan JD (abst) 432
Maher JF (abst) 232
Mahieu P *See* Foidart JM et al 1050
Mahieu Ph (abst) 1257
Mahoney C (abst) 359
Maidannik V (abst) 269
Maierhofer WJ *See* Lemann Jr J et al 743
Maiorca R (abst) 612
Makino H (abst) 268, 281, 283
Makker SP (abst) 279, 284
Mako A (abst) 205
Malagon M (abst) 207, 284
Malangone J (abst) 176, 197, 224
Malavasi F (abst) 290
Malavasi F (abst) 608
Maldague P (abst) 309
Malis CD (abst) 305
Mallick NP *See* Short CD et al 1224
Mallon JP *See* Smothers RL et al 578
Malluche HH (abst) 165, 184, 213
Malluche HH, Faugere MC, Smith Jr AJ, Friedler RM: Aluminum intoxication of bone in renal failure—Fact or fiction? S-70
Malnic G (abst) 365
Maloney N (abst) 218
Maloney NA *See* Ott SM et al S-108
Malorey P *See* Elalouf JM et al 807
Manara G (abst) 269
Manara GC (abst) 608
Mancia G (abst) 610
Mancilla-Jimenez R (abst) 272
Mandel J (abst) 433
Mandel LJ (abst) 310, 357, 399
Mandel LJ *See* Schnellmann RG et al 858
Manillier C (abst) 340
Mann J (abst) 1252
Mann J (abst) 1255
Mann JFE (abst) 189, 252
Mann R (abst) 286, 286
Mann R *See* Agus D et al 635
Mann W (abst) 232
Mannik M (abst) 295
Manns M (abst) 1248
Manohar L (abst) 216
Manohar LN (abst) 219
Manrique-Najere M (abst) 293
Mansour J (abst) 425

Manuel MA (abst) ... 236
Manzini C (abst) ... 178, 412
Manzini C *See* Bichet DG et al ... 1188
Marc-Aurele J (abst) ... 178, 315, 412
Marc-Aurele J *See* Bichet DG et al ... 1188
Marchini F (abst) ... 609
Marconi J (abst) ... 252, 262, 360
Margolis K (abst) ... 216
Marik J (abst) ... 428
Marin-Grez M (abst) ... 388
Markovich H (abst) ... 308
Maroni BJ (abst) ... 306
Marsden P (abst) ... 188
Marsh D (abst) ... 199
Martin AM *See* Kerr DNS et al ... S-58
Martin C (abst) ... 178
Martin CJ (abst) ... 337
Martin G (abst) ... 350
Martin K (abst) ... 164, 174, 218, 319
Martina G (abst) ... 608
Martinez E (abst) ... 306, 393
Martinez-Maldonado M (abst) ... 330, 382
Marton LJ (abst) ... 357
Marumo F (abst) ... 325, 420
Maschio G (abst) ... 409
Maschio G (abst) ... 609
Maschio-Ist G (abst) ... 223
Mason J (abst) ... 1254
Mason J (abst) ... 306
Massry SG (abst) ... 193, 248, 315
Massry SG (abst) ... 611
Mastrolitti G (abst) ... 290
Masur SK (abst) ... 411, 420
Masurel N (abst) ... 942
Materson BJ (abst) ... 204
Mathias M (abst) ... 387
Mathisen Ø *See* Langberg H et al ... 820
Matons C (abst) ... 365
Matsumoto A (abst) ... 225
Matsunaga H (abst) ... 336
Matthews C (abst) ... 165, 213
Matthys E (abst) ... 943
Matzke GR (abst) ... 175
Mauer SM (abst) ... 273, 294
Mauer SM *See* Ellis EN et al ... 889
Mavichak V (abst) ... 306
Mavrikakis M (abst) ... 296
May RC (abst) ... 323
Mayer E (abst) ... 165, 170
Mayer H (abst) ... 172
Mazoujian G (abst) ... 289
McAnaney D (abst) ... 424
McAteer JA (abst) ... 161, 323
McCarron D (abst) ... 166, 173, 198, 205, 252, 259
McCarron DA (abst) ... 165, 243, 247, 248, 250
McCarthy D (abst) ... 382
McCarthy JT (abst) ... 165, 171
McCarty RC (abst) ... 266
McClellan W (abst) ... 197
McClung DE (abst) ... 263
McCoy RN (abst) ... 307
McCullough AJ (abst) ... 435
McDonald FD (abst) ... 154, 234, 326
McDonald J (abst) ... 418
McDonald JWD (abst) ... 300, 305
McDonald M (abst) ... 431
McGarry L (abst) ... 325
McGloin C (abst) ... 176, 197, 224
McGonigle RJS (abst) ... 167
McGowan JA (abst) ... 197, 402
McGrath KE (abst) ... 267
McHugh MF *See* Kerr DNS et al ... S-58
McIntosh SL *See* Hale GM et al ... 718
McKenna BA (abst) ... 199
McKinney TD (abst) ... 420
McLaughlin NL (abst) ... 285
McLeish K (abst) ... 298
McLeish KR (abst) ... 217
McMahon JT (abst) ... 275
McMorrow RG (abst) ... 209
McNamara ER (abst) ... 363
McNamee P (abst) ... 231
McNeely E *See* Shemesh O et al ... 916
McRoy C (abst) ... 229, 327
Meadows JH *See* Lucas PA et al ... 995
Meckstroth S (abst) ... 230
Medlock TR *See* Llach F et al ... S-74
Meeks LA (abst) ... 386
Mees EJD (abst) ... 420
Meggs LG (abst) ... 252
Mehler PS (abst) ... 253
Meijer S (abst) ... 942
Mejia R (abst) ... 377
Melendez O (abst) ... 210
Mellas J (abst) ... 372
Mello L (abst) ... 430
Menard J *See* Michel J-B et al ... 1011
Menczel J *See* Talwar HS et al ... 1038
Mendes V *See* Cournot-Witmer G et al ... S-37
Mendez RE (abst) ... 340
Mendrick DL (abst) ... 284, 360
Mene P (abst) ... 340
Mené P (abst) ... 610
Menton DN (abst) ... 160
Mercier O (abst) ... 363
Merke J (abst) ... 1256
Merke J (abst) ... 165, 170
Merrill DC, Skelton MM, Cowley Jr AW: Humoral control of water and electrolyte during water restriction ... 1152
Merrow M (abst) ... 216
Messina A (abst) ... 611
Metselaar HJ (abst) ... 944
Mettauer B (abst) ... 193
Mettauer B *See* Bichet DG et al ... 1188
Metz J (abst) ... 166, 173, 254
Metz JA (abst) ... 247, 248
Meuer S (abst) ... 1258
Meuer S *See* Kurz P et al ... 1209
Meyer DH (abst) ... 305
Meyer JL *See* Talwar HS et al ... 1038
Meyer JL, Thomas Jr WC: Aluminum and aluminum complex. Effect of calcium phosphate precipitation ... S-20
Meyer MM (abst) ... 421
Meyer TW (abst) ... 289, 328
Meyer WL (abst) ... 305
Meyer zum Büschenfeld K-H (abst) ... 1248
Meyer zum Büschenfelde KH (abst) ... 1258
Meyer zum Buschenfelde K-H *See* Kurz P et al ... 1209
Meyer-Lehnert H (abst) ... 341

Meyrier A (abst) 166, 197
Mezger MS (abst) 198
Michael A (abst) 279
Michael AF *See* Lopez M et al 829
Michael UF (abst) 386
Michaels S (abst) 327
Michaud L (abst) 270
Michaud L *See* Agus D et al 635
Michel J-B, Dussaule J-C, Choudat L, Auzan C, Nochy D, Corvol P, Menard J: Effects of antihypertensive treatment in one-clip, two kidney hypertension in rats 1011
Michel JB (abst) 386
Michelis MF (abst) 238, 263
Michelsen P (abst) 942
Michet CJ (abst) 182
Miele BD (abst) 234
Mielke G (abst) 1257
Miemietz R (abst) 252
Migdal SD (abst) 154, 238
Migliorini P (abst) 285
Mihatsch MJ (abst) 1261
Mihatsch MJ (abst) 282
Mihtsch MJ (abst) 1249
Milford EL (abst) 428
Miller JH (abst) 215, 227
Miller JH *See* Milliner DS et al S-100
Miller N (abst) 209
Miller NL (abst) 1261
Miller ON *See* Smothers RL et al 578
Miller RT (abst) 372
Milliner DS (abst) 199
Milliner DS *See* Nebeker HG et al S-96
Milliner DS *See* Ott SM et al S-108
Milliner DS, Hercz G, Miller JH, Shinaberger JH, Nissenson AR, Coburn JW: Clearance of aluminum by hemodialysis: Effect of desferrioxamine S-100
Millington DS (abst) 202
Mills S (abst) 310, 433
Mimram A (abst) 777
Minetti L (abst) 610
Minetti L (abst) 613
Minuth W (abst) 1252
Minuth W (abst) 396
Mion C (abst) 778
Miranda B (abst) 257
Mishkind M (abst) 230
Mishler DR (abst) 163
Misra BC (abst) 307
Misra RP (abst) 285
Mitch WE (abst) 306, 323
Miyahara T *See* Kawaguchi Y et al S-49
Miyata J (abst) 329
Mizelle HL (abst) 253, 389
Moatamed F (abst) 285
Mocelin A (abst) 430
Moel DI (abst) 323
Moffitt C (abst) 239
Mohrmann I (abst) 167
Mohrmann M (abst) 167
Molina M (abst) 221
Molitoris BA (abst) 209, 403
Molzahn M (abst) 1262
Monnens L (abst) 943
Montagnac R (abst) 777
Montagnino G (abst) 612
Montani JP (abst) 253
Montcalm E (abst) 232
Monteiro RC (abst) 287
Monteon FJ *See* Kopple JD et al 734
Mookerjee BK (abst) 286
Moonen CTW (abst) 358
Moore EE (abst) 196
Moore H (abst) 233
Moore LC (abst) 304
Moore M (abst) 211
Moore MA (abst) 198, 226
Moorthy AV (abst) 176
Moorthy R (abst) 178
Morachiello P (abst) 241
Moraes E (abst) 430
Moran A (abst) 373
Morganti A (abst) 610
Morgenstern B (abst) 235
Mori T *See* Ueda S et al 539
Mori Y *See* Ueda S et al 539
Moriau M (abst) 776
Moriggi M (abst) 612
Morigi M (abst) 282
Moriniere P *See* Fournier A et al S-114
Morris C (abst) 174, 198, 203
Morris DJ (abst) 242, 253
Morris M (abst) 404
Morris RC Jr (abst) 170, 191, 251, 297
Morrison AR (abst) 334, 344, 422
Morrison AR, Pascoe N: Modification of renal cortical subcellular membrane phospholipids induced by mercuric chloride 496
Morrison G (abst) 237, 239
Morrison J (abst) 219
Morrison TK (abst) 281, 381
Morrissey J (abst) 156, 166, 174, 319
Morrissey J, Slatopolsky E: Effect of aluminum on parathyroid hormone secretion S-41
Morse G (abst) 239, 438
Moskowitz D (abst) 174
Moskowitz DW (abst) 321
Moss NG (abst) 329
Moullier P *See* Brunisholz M et al 971
Moulopoulos S (abst) 297
Moyer TP (abst) 165
Mozes MF (abst) 433
Muallem S (abst) 166
Muirhead N (abst) 191
Mujais S (abst) 254
Muller C (abst) 286
Muller EW (abst) 944
Müller GA (abst) 1249
Müller GA (abst) 1262
Müller GH (abst) 1262
Müller GH (abst) 1263
Müller GH (abst) 1263
Muller GA (abst) 286
Mulroney S (abst) 160
Mundy C (abst) 380
Munger KA (abst) 386
Muntzel MS (abst) 247, 254
Murayama N (abst) 167, 352
Murdaugh S (abst) 357
Murer H (abst) 167, 373

Murray BM (abst) 434, 438
Mussmann GV (abst) 171
Muto S (abst) 403, 406
Myer M (abst) 358
Myers BD *See* Shemesh O et al 916
Myers BD (abst) 323
Nabeker HG (abst) 200
Nagakura K (abst) 167
Nagakura K, Abe E, Suda T, Hayakawa M, Nakamura H, Tazaki H: Inhibitory effect of 1α,25-dihydroxyvitamin D_3 on the growth of the renal carcinoma cell line 834
Nagami GT (abst) 373
Nagineni CN (abst) 307
Nahman NS (abst) 431
Nakagawa Y (abst) 167, 296
Nakagawa Y *See* Lopez M et al 829
Nakagawa YN (abst) 316
Nakamoto S (abst) 427
Nakamura A (abst) 338
Nakamura H *See* Nagakura K et al 834
Nakamura R (abst) 173
Nakazawa M (abst) 343
Nakhoul NL (abst) 373
Nakhoul SA (abst) 403
Nally JV (abst) 190, 254
Nanni Costa A (abst) 611
Naor D (abst) 280
Napoli A (abst) 611
Naqui MH (abst) 286
Narang N (abst) 395
Narasimhan N (abst) 324
Nardini R (abst) 609
Narins RG (abst) 355
Nasemann J (abst) 1252
Nash M (abst) 272
Nath KA (abst) 341
Navar LG (abst) 281, 381
Naveh T (abst) 172
Navis GJ (abst) 254
Navis GJ (abst) 945
Nawab ZM (abst) 215, 218, 221
Neal LA (abst) 157
Nebeker HG *See* Ott SM et al S-108
Nebeker HG, Andress DL, Milliner DS, Ott SM, Alfrey AC, Slatopolsky E, Sherrard DJ, Coburn JW: Indirect methods of diagnosis of aluminum bone disease: Plasma aluminum, the desferrioxamine infusion test, and serum PTH S-96
Nedev N (abst) 231
Neff MS (abst) 224
Neilson E (abst) 280
Neilson EG (abst) 160, 240, 270, 284, 286
Neilson EG *See* Agus D et al 635
Nerzig S (abst) 421
Nesser D (abst) 437
Neu KM (abst) 157
Neu S (abst) 221
Neugarten J (abst) 187, 322, 324
Neumann HPH (abst) 1258
Neumayer HH (abst) 1262
Neus H (abst) 258
Neuweg M (abst) 1253
Neves R (abst) 251
Newell GC (abst) 421
Neylan JF (abst) 428
Nguyen VD (abst) 307
Nicholls K (abst) 184
Nichols WK (abst) 238
Nicholson JP (abst) 257
Nicoloso G (abst) 213
Nidus BD (abst) 235
Niedermeyer W (abst) 1262
Nielsen LH (abst) 235
Nies AS (abst) 388
Nieva EB (abst) 294
Nirenstein JE (abst) 202
Nissenson AR (abst) 235
Nissenson AR *See* Milliner DS et al S-100
Nissim I (abst) 357
Nitta K (abst) 387
Nix CT (abst) 287
Nix L (abst) 262
Noble B (abst) 267, 268
Noble B, Van Liew JB, Brentjens JR: A transition from proliferative to membranous glomerulonephritis in chronic serum sickness 841
Nochy D (abst) 775
Nochy D *See* Michel J-B et al 1011
Noel J (abst) 254
Noel LH (abst) 229, 266, 287
Nöel LH *See* Boucher A et al 1043
Nolan C (abst) 198
Nolan CR (abst) 255
Nolasco F (abst) 267
Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG: Adult-onset minimal change nephrotic syndrome: A long-term follow-up 1215
Nolph K (abst) 233
Nolph KD (abst) 233, 235, 238
Nomura K (abst) 341
Nooyen WJ (abst) 309
Nord EP (abst) 396, 397, 405
Norris KC (abst) 199, 215
Northrup T (abst) 364
Norton DR (abst) 313
Norton JB (abst) 240
Novick A (abst) 436
Novick AC (abst) 425
Nowak T (abst) 199
Nuland DM (abst) 337
Nunley R (abst) 276
Nunley RR (abst) 264
Nusgens B *See* Foidart JM et al 1050
O'Connor DT (abst) 198, 255
O'Connor RP (abst) 303, 307
O'Donnell MP (abst) 316, 319, 324, 336, 381
O'Dowd G (abst) 427
O'Neil RG (abst) 397
Oberleithner H (abst) 1251
Oberleithner H (abst) 404
Ochi RF (abst) 271, 287
Ochs T (abst) 410
Oda Y *See* Kawaguchi Y et al S-49
Oe PL (abst) 168
Oe Pl (abst) 943
Oemar B (abst) 1256
Oettinger CW (abst) 220
Offermann G (abst) 1262
Offord KP (abst) 189, 436

Ogg C *See* Nolasco F et al 1215
Ogino T (abst) 396
Ogura Y *See* Kawaguchi Y et al S-49
Oh MS (abst) 373, 377
Oh Y *See* Okuda S et al 502
Ohnuma N (abst) 336
Ojo B (abst) 236
Okamura M (abst) 182
Okubo M (abst) 327
Okuda K *See* Ueda S et al 539
Okuda S, Oh Y, Tsuruda H, Onoyama K, Fujimi S, Fujishima M: Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease 502
Okuda T (abst) 341
Olbricht CJ (abst) 293, 357
Oldrizzi L (abst) 609
Olgaard K (abst) 168, 351
Oliver JA (abst) 255
Oliver JC (abst) 220
Olsen DB (abst) 389
Olson JL, Wilson SK, Heptinstall RH: Relation of glomerular injury to preglomerular resistance in experimental hypertension 849
Omae T (abst) 247, 258
Onoyama K *See* Okuda S et al 502
Onsgard M (abst) 155
Oosting E (abst) 206
Opgenorth TJ (abst) 384, 393, 406
Orci L (abst) 413
Oreopoulos DG (abst) 231
Ornt DB (abst) 374, 435
Orsoni G (abst) 611
Ortalda V (abst) 609
Osborne M (abst) 176
Østensen J *See* Langberg H et al 820
Oster JR (abst) 324, 363, 372
Otsu K (abst) 372
Ott CE (abst) 255, 349, 410
Ott SM *See* Andress DL et al S-87
Ott SM *See* Nebeker HG et al S-96
Ott SM, Andress DL, Nebeker HG, Milliner DS, Maloney NA, Coburn JW, Sherrard DJ: Changes in bone histology after treatment with desferrioxamine S-108
Ovary Z (abst) 274
Owen P *See* Kerr DNS et al S-58
Pabico RC (abst) 199
Pabst W (abst) 1261
Pacholski MA (abst) 240
Pacini L (abst) 610
Packer W (abst) 299
Packer W (abst) 314
Padovese P (abst) 211
Padovese P (abst) 610
Paganini E (abst) 427
Paganini EP (abst) 214
Pagano G (abst) 292
Paillard F (abst) 166
Paillard M (abst) 199, 363
Painter P (abst) 434
Palant CE (abst) 322
Paller MS (abst) 308, 434
Paller MS, Sikora JJ: Hypothyroidism protests against free radical damage in ischemic acute renal failure . 1162
Palmer LG (abst) 404
Panebianco R (abst) 409
Panebianco R (abst) 609
Pankewycz OG (abst) 285, 288
Panzetta G (abst) 223
Panzetta G (abst) 609
Papadakis J (abst) 212
Papendick R (abst) 297
Paraskevakou H (abst) 296
Pardo V (abst) 204, 288
Parfrey PS (abst) 220
Parham P (abst) 270
Park C (abst) 221
Park H (abst) 250
Parker CJ (abst) 269
Parker HL (abst) 234
Parkinson IS *See* Kerr DNS et al S-58
Parks J (abst) 194
Parmer RJ (abst) 255
Partin JS (abst) 304
Parving HH *See* Jensen PK et al 490
Pascoe N *See* Morrison AR et al 496
Pascual JF (abst) 221
Pasiecznik KA (abst) 163
Pasquier R (abst) 775
Passmore J (abst) 335
Passon J (abst) 1255
Pastore A (abst) 290
Pastoriza E (abst) 274, 421
Pastoriza-Munoz E (abst) 366
Patchin D (abst) 301, 331
Patchin DS (abst) 303
Paton T (abst) 236
Patron P (abst) 199
Patrono C (abst) 282
Patscheke H (abst) 1257
Pattyn V (abst) 312
Paul LC (abst) 944
Paul R (abst) 288
Paulmichl M (abst) 1251
Pauls A (abst) 199
Pauly JL (abst) 286
Pauw W (abst) 207
Pavlopoulcu G (abst) 221
Pawlowska D (abst) 358
Payen D (abst) 415
Pearson FC (abst) 211
Pearson PL (abst) 181
Pederson J (abst) 168
Pederson JA *See* Llach F et al S-74
Pedrazka-Chaverri J (abst) 302, 342
Pehrisch H (abst) 1259
Pei Y (abst) 200
Pelayo JC (abst) 334, 387
Pelletier L (abst) 775
Pena JC (abst) 172, 302, 342
Peppler R (abst) 229, 227
Perego A (abst) 610
Perez GO (abst) 224
Perez JM (abst) 260
Perez-Stable E (abst) 204
Perfetto M (abst) 275
Perfumo F (abst) 189
Perlmutter N (abst) 200
Perras ST (abst) 239, 240
Perrino ML (abst) 610

Pertuit C (abst) 219
Pertuz Y (abst) 185
Perzanowski (abst) 221
Pesigan M (abst) 173, 244
Petersen J (abst) 221, 227, 325, 358
Peterson J (abst) 429
Pettinger WA (abst) 346
Pettinger WA *See* Umemura S et al 703
Pezzullo J (abst) 176, 197, 224
Pfitzer P (abst) 1262
Phifer T *See* Holloway JC et al 989
Philipp Th (abst) 1258
Philippe P *See* Elalouf JM et al 807
Phillips GS (abst) 161
Phillips TM (abst) 321
Piccoli G (abst) 608
Piccoli G (abst) 608
Pichlmayr R (abst) 1262
Pickard L (abst) 289
Picken M (abst) 288
Pidikiti N (abst) 335
Piepsz A (abst) 200
Piesco N (abst) 214
Pieters D (abst) 776
Pietravalle P (abst) 611
Piette Y (abst) 227
Pilia PA (abst) 270
Pill J (abst) 1257
Pillai VK (abst) 422
Pincott J (abst) 202
Pinkert C (abst) 283
Pion I (abst) 342
Piraino AJ (abst) 222
Piraino BH (abst) 168
Pitts T (abst) 402
Pitts TO (abst) 169
Pityer R (abst) 218
Placot JJ *See* Cournot-Witmer G et al S-37
Placot JJ *See* Drüeke TB et al S-45
Planch A (abst) 236
Planelles G (abst) 158, 275
Plant SB (abst) 158
Plante GE (abst) 342
Plantilla M (abst) 221
Ploth DW (abst) 256
Podraza M (abst) 342
Poliklinik M (abst) 400
Polinsky M (abst) 148
Pollak R (abst) 433
Pollak V (abst) 329, 336
Pollak VE (abst) 279
Pollock AS (abst) 272
Ponticelli C (abst) 612
Ponticelli C (abst) 612
Ponticelli C: Prognosis and treatment of membranous nephropathy (Nephrology Forum) 927
Pontillon F *See* Brunisholz M et al 971
Poortema K *See* Beukhof JR et al 549
Popli S (abst) 200, 231
Popovtzer M (abst) 172
Popovtzer MM (abst) 308, 405, 410
Popowniak KL (abst) 275
Poptic E (abst) 263
Pordy WT (abst) 322
Port FK (abst) 136, 149
Portale AA (abst) 169
Porter RS (abst) 251
Porter WR (abst) 137
Portilla D (abst) 322
Portmann L (abst) 192
Portman L *See* Jaeger P et al 563
Porush JG (abst) 282
Posner AS, Blumenthal NC, Boskey AL: Model of aluminum-induced osteomalacia: Inhibition of apatite formation and growth S-17
Posner J (abst) 311
Posner M (abst) 342
Possato M (abst) 608
Potter DM (abst) 343
Potvin WJ (abst) 189, 254
Poujeol P (abst) 360
Powers DV (abst) 232
Powers K *See* Barajas L et al 965
Prada J (abst) 308
Prasad AS (abst) 154
Prati E (abst) 612
Pratt JW (abst) 226
Pratz J (abst) 414
Preisig P (abst) 227
Preud'homme JL (abst) 287
Preuschof L (abst) 1262
Preuss HG (abst) 353, 356
Price PA (abst) 186
Prichard S (abst) 173
Prowant BF (abst) 238
Prud'Homme M (abst) 227
Puckett D (abst) 325
Pugliese F (abst) 610
Pugliese F (abst) 611
Pullen G (abst) 243
Puschett JB (abst) 168, 169, 197, 294, 402
Pusey CD (abst) 200, 202
Pust AH (abst) 236
Puyol DR (abst) 343
Pyle WK (abst) 235
Quamme G (abst) 169, 323
Quarello F (abst) 608
Quarles LD (abst) 169
Queirolo C (abst) 189
Quiggins PA (abst) 209
Rabin BR (abst) 294
Rabito CA (abst) 404, 419
Rabkin R (abst) 325, 355, 358, 359
Racker E (abst) 378
Racusen LC (abst) 304
Radcliffe L (abst) 177
Radda GK (abst) 358
Rademacher R (abst) 256
Rafizadeh C (abst) 423
Rahman MA (abst) 343
Raij L (abst) 256, 274, 319
Raja RM (abst) 222
Rajfer J (abst) 438
Rakowski TA (abst) 234
Ralston AJ *See* Ackrill P et al S-104
Rambausek M (abst) 1257
Ramee MP (abst) 777
Ramey K (abst) 313
Ramirez A (abst) 172
Ramos JM *See* Kerr DNS et al S-58

Ramsammy L (abst) 303, 308, 333
Rance C (abst) 200
Randazzo J (abst) 244
Rao KV (abst) 434
Rao TKS (abst) 201
Rapoport DM (abst) 223
Rapp N (abst) 164
Rascher W (abst) 1254
Rascher W (abst) 1259
Rascher W (abst) 388
Rashad A (abst) 185
Raskin P (abst) 209
Rasmussen H (abst) 300, 329
Ratcliffe PJ (abst) 358
Rauch AL (abst) 404
Rault R (abst) 168
Rauterberg EW (abst) 1249
Rauterberg EW (abst) 1249
Rawer P (abst) 1261
Raymond A (abst) 239
Raymond KH (abst) 323
Read AE (abst) 435
Reale E (abst) 282, 319
Reams GP (abst) 256, 259
Rector FC Jr (abst) 190
Reddi AH *See* Talwar HS et al 1038
Redman B (abst) 216
Reed WP *See* Gardner Jr KD et al 1116
Reeders ST (abst) 181
Reilly JJ Jr (abst) 188
Reiser IW (abst) 382
Reitz RE (abst) 186
Remuzzi A (abst) 343
Remuzzi G (abst) 282, 343
Renaud H (abst) 778
Renaud H *See* Fournier A et al S-114
Renda SA (abst) 327
Rennke HG (abst) 272, 284, 289, 314, 328, 360, 390
Resch K (abst) 282
Resnick D (abst) 222
Resnick LM (abst) 257
Rettberg C (abst) 340
Reubi FC (abst) 288
Reutter FW (abst) 1263
Reznicek MJ (abst) 265
Rhee HL (abst) 179
Ribeiro C (abst) 423
Ribeiro C, Suki WN: Acidification in the medullary collecting duct following ureteral obstruction 1167
Riberio-Neto F (abst) 423
Riblet R (abst) 270
Ribstein J (abst) 357
Ricanati ES (abst) 335
Riccobono XJ (abst) 189
Richard A (abst) 778
Richards GK (abst) 232
Richardson RMA (abst) 188, 208
Richet G *See* Brunisholz M et al 971
Riechers G (abst) 1262
Riegel W (abst) 1257
Riesen W (abst) 212
Rifai A (abst) 278
Rigden LB (abst) 235
Righetto F (abst) 241
Ringe B (abst) 1262
Ripoche P (abst) 414
Risler T (abst) 1249
Risler T (abst) 1262
Risler T (abst) 286
Ritman EL (abst) 380
Ritter W (abst) 1255
Ritz E (abst) 1252
Ritz E (abst) 1255
Ritz E (abst) 1256
Ritz E (abst) 1256
Ritz E (abst) 1257
Ritz E (abst) 1259
Ritz E (abst) 165, 170, 189, 191, 252
Ritz E (abst) 266
Ritz JE (abst) 1249
Rivas ML (abst) 209
Rivero D (abst) 411
Rivolta E (abst) 612
Robert D (abst) 213, 222
Roberts CE (abst) 227
Roberts DE *See* Lucas PA et al 995
Robertson CR (abst) 418
Robertson HT (abst) 223
Robertson JL, Goldschmidt M, Kronfeld DS, Tomaszewski JE, Hill GS, Bovee KC: Long-term renal responses to high dietary protein in dogs with 75% nephrectomy 511
Robillard JE (abst) 186, 333, 385
Robinette JB (abst) 299
Robinson RD (abst) 201
Robson JS *See* Winney RJ et al S-91
Roccatello D (abst) 608
Rocco VK (abst) 405
Roch-Ramel F (abst) 423
Rodicio JL (abst) 257
Rodman JS (abst) 170
Rodriguez GR (abst) 363, 374
Rodriguez M (abst) 158, 164, 168, 170
Rodriguez-Puyol D (abst) 383, 385
Rodriquez M (abst) 322
Roe C (abst) 202
Roels F (abst) 312
Roels L (abst) 942
Rogers P (abst) 219
Rogez P (abst) 775
Rogez P (abst) 778
Roggero S (abst) 292
Rohrbach R (abst) 1248
Rohrbach R (abst) 1258
Roinel N *See* Elalouf JM et al 807
Roland J (abst) 369
Rollino C (abst) 608
Roman RJ (abst) 257
Rome L (abst) 405
Romeo L (abst) 289
Romero JC (abst) 257, 380, 406
Ronco C, Brendolan A, Bragantini L, Chiaramonte S, Feriani M, Fabris A, Dell'Aquila R, La Greca G: Treatment of acute renal failure in newborns by continuous arterio-venous hemofiltration 908
Ronco P (abst) 360, 369
Ronco P (abst) 608
Ronco PM *See* Brunisholz M et al 971
Rondeau E (abst) 339, 344
Rook AH (abst) 178

Rosansky SJ (abst) 201, 203
Rose C (abst) 255
Rose M (abst) 269, 402
Rosen MD (abst) 310
Rosen RA (abst) 201
Rosen S (abst) 298, 310
Rosen S *See* Shanley PF et al 1021
Rosen S *See* Shanley PF et al 1033
Rosenberg B (abst) 270
Rosenberg L (abst) 192
Rosenberg ME (abst) 325
Rosenstock J (abst) 209
Rosenthal C (abst) 321
Rosenthal CJ (abst) 206
Rosman J (abst) 325
Rosman JB *See* ter Wee PM et al 870
Ross EA (abst) 428, 434
Ross J (abst) 323, 325
Rossi F (abst) 409
Rosskopf H (abst) 1255
Roth D (abst) 288
Roth R (abst) 1259
Rothbarth PhH (abst) 944
Rother K (abst) 277
Rothstein M (abst) 231
Rouleau J-L *See* Bichet DG et al 1188
Rouleau JL (abst) 193
Rowinski C (abst) 239
Roy DR (abst) 405
Roy R (abst) 256
Rozing J (abst) 944
Rozing J (abst) 945
Rubin E (abst) 305
Rubin J (abst) 236
Rubin JE (abst) 223
Rubinger D (abst) 405
Rubinstein J (abst) 187
Ruddel H (abst) 258
Ruddy M (abst) 257
Rugiu C (abst) 609
Rugstad HE *See* Berg KJ et al 1180
Ruilope L (abst) 257
Ruiz-Morales N (abst) 207
Rummeny E (abst) 1259
Rumrich G (abst) 1256
Rush PJ, Baumal R, Shore A, Balfe JW, Schreiber M: Correlation of renal histology with outcome in children with lupus nephritis 1066
Ruskoaho H (abst) 334, 340
Ruskoaho H *See* Luft FC et al 1004
Ruzany F (abst) 430
Ryan LP (abst) 233, 238
Rye D (abst) 326
Ryffel B (abst) 1261
Sabadini E (abst) 610
Sabanovic S (abst) 1248
Sabatini S (abst) 170, 301, 358
Sabatini S (abst) 375
Sabbaga E (abst) 430
Saccoccio NA (abst) 242, 251
Sachs C *See* Bourdeau AM et al 924
Sacks H (abst) 358
Sacktor B (abst) 161, 171, 321, 326, 376, 380, 396
Sadler J (abst) 228, 229, 327
Sadler JH (abst) 216
Safirstein R (abst) 309, 312
Safirstein RL (abst) 323
Sainte-Laudy J (abst) 776
Sainte-Laudy J (abst) 776
Saito F (abst) 247, 258
Sakai T (abst) 259
Sakhrani LM (abst) 611
Sala C (abst) 610
Salant DJ *See* Feintzeig ID et al 649
Salant DJ (abst) 272, 390
Salazar FJ (abst) 406
Saleh F (abst) 242
Salehmoghaddam S (abst) 434
Salinas-Madrigal L (abst) 289
Salomon D (abst) 289, 429
Salusky IB (abst) 196, 236, 238
Salvi D (abst) 260
Salvidea JC (abst) 245
Salzenstein D (abst) 177
Samet MK (abst) 275
Sanaka T (abst) 387
Sanchez P (abst) 180
Sancho J (abst) 257
Sanders PW (abst) 309
Sandrini S (abst) 612
Sandro M (abst) 430
Sandroni S (abst) 202
Sands JM (abst) 406, 418
Sandstrom D (abst) 289
Sandyk R (abst) 195
Sanfilippo F (abst) 432, 435
Sansom SC (abst) 403, 406
Santos F (abst) 202
Santos JC (abst) 281, 343, 381, 385
Sanz E (abst) 281, 381, 383
Sapin C (abst) 775
Saris SD (abst) 251
Sarnacki P (abst) 158
Sasaki S (abst) 369, 375
Sastrasinh M (abst) 359
Sastrasinh S (abst) 359
Satlin LM (abst) 375, 376
Sato M (abst) 258, 260
Sato N (abst) 327
Satriano JA (abst) 344
Saubermann AJ, Dobyan DC, Scheid VL, Bulger RE: Rat renal papilla: Comparison of two techniques of x-ray analysis of proximal tubule cells 675
Saunders A (abst) 192
Savage COS (abst) 200, 202
Savige J (abst) 290
Savin VJ (abst) 406
Savoldi S (abst) 612
Sawin LL (abst) 244
Sayed A (abst) 283
Scaduto RC Jr (abst) 387
Scaer SS (abst) 343
Scaini P (abst) 612
Scandling JD (abst) 374, 435
Scanferla F (abst) 241
Schölkens BA (abst) 1254
Schömig A (abst) 1259
Schütterle G (abst) 1261
Schaafsma W *See* Beukhof JR et al 549
Schaar H (abst) 1257

Schacht RG (abst) 322, 324
Schaefer JW (abst) 196
Schaefer K (abst) 199
Schaefer RM (abst) 309
Schaffer R (abst) 233
Schafferhans K (abst) 159
Schalekamp MADH (abst) 944
Schali C (abst) 423
Schambelan M (abst) 190, 320, 344
Schardijn GHC (abst) 309
Schareck W (abst) 1263
Schareck W (abst) 1263
Scharschmidt L (abst) 325
Scharschmidt LA (abst) 345
Schattner A (abst) 283
Schattner M (abst) 283
Schedel I (abst) 1258
Scheer RL (abst) 183, 435
Scheid VL *See* Saubermann AJ et al 675
Scheinman JI (abst) 202
Scheinman JL *See* Lopez M et al 829
Scheinman SJ (abst) 171, 358
Schena FP (abst) 290
Schepers G (abst) 1257
Scherberich JE (abst) 1255
Scherf H (abst) 388
Scherzer P (abst) 308, 410
Schiavon R (abst) 223
Schild L (abst) 407
Schilling JJ (abst) 223
Schillinger F (abst) 777
Schimdt B (abst) 404
Schlatter E (abst) 1255
Schlebusch H (abst) 258
Schlondorff D (abst) 344
Schluessel R (abst) 224
Schmelzer H (abst) 172
Schmidt B (abst) 1251
Schmieder R (abst) 258
Schnaper HW (abst) 290
Schneider E (abst) 365
Schneider HW, Kulbe KD, Weber H, Streicher E: In vitro and in vivo studies with a non-aluminum phosphate-binding compound S-120
Schnellmann RG (abst) 310
Schnellmann RG, Mandel LJ: Multiple effects of presumed glutathione depletors on rabbit proximal tubules 858
Schnermann J (abst) 259, 387, 414
Schnermann J, Gokel M, Weber PC, Schubert G, Briggs JP: Tubuloglomerular feedback and glomerular morphology in Goldblatt hypertensive rats on a varying diet 520
Schniepp BJ (abst) 171
Schoenfeld P (abst) 224
Schoeppe W (abst) 1255
Schoeppe W (abst) 1260
Schollmeyer P (abst) 1249
Schollmeyer P (abst) 1250
Schollmeyer P (abst) 1258
Schollmeyer P (abst) 1261
Schollmeyer P (abst) 237, 292, 347, 436
Schollmeyer P *See* Steinhauer HB et al 584
Schoolwerth AC (abst) 387
Schröder C (abst) 943
Schramm M (abst) 1251
Schreiber M *See* Rush PJ et al 1066
Schreiber MJ (abst) 184
Schreiner GE (abst) 234
Schreuder JE (abst) 309
Schrier R (abst) 184, 203, 299, 310, 424, 433
Schrier RW (abst) 298, 313, 319, 418
Schrier RW *See* Bichet DG et al 1188
Schrier RW *See* Lumlertgul D et al 658
Schrier RW *See* Wilson PD et al 1172
Schrinner E (abst) 1256
Schroeder ET (abst) 183, 303, 331, 338
Schryver S (abst) 406
Schubert G *See* Schnermann J et al 520
Schubert P (abst) 356
Schulman G (abst) 210, 214, 224, 226
Schultze G (abst) 1262
Schulz DR (abst) 181
Schulz I *See* Thévenod F et al 695
Schulz W (abst) 291
Schuster V (abst) 409
Schuster VL (abst) 376
Schuurmans MMJ (abst) 943
Schwab SJ (abst) 182, 203
Schwab TR (abst) 245, 407
Schwartz GJ (abst) 375, 376
Schwartz JH (abst) 363, 376
Schwartz MM (abst) 193, 196, 279, 290, 291, 314
Schwartz RS (abst) 283
Schweitzer S (abst) 429
Schwertschlag U (abst) 388, 433
Sciacca RR (abst) 255
Scicli AG *See* Barajas L et al 965
Scolari F (abst) 612
Scoltock A (abst) 329
Scott JA (abst) 404
Sebastian A (abst) 190, 262
Sebert J L *See* Fournier A et al S-114
Sedor J (abst) 345
Sedor J (abst) 345
Sedor JR (abst) 268, 291
Segal GM *See* Delwiche F et al 641
Segal S (abst) 350, 357
Segel DP (abst) 181, 187, 237
Segoloni G (abst) 609
Segoloni GP (abst) 612
Seidel D (abst) 1248
Seidman G (abst) 329
Seifter JL (abst) 360, 379, 397, 403, 404, 408
Sela J (abst) 156
Seldin DW (abst) 368
Sellinger M (abst) 1257
Selvaggio AM (abst) 376
Sena LM (abst) 608
Seney FD Jr (abst) 388
Seri I (abst) 390
Sermasi G (abst) 613
Servilla K (abst) 224
Sethi K (abst) 122
Severs WB (abst) 246
Sexton DJ (abst) 271
Sexton J (abst) 279
Shade R (abst) 203
Shah SV (abst) 291, 311, 349
Shaib JK *See* Kopple JD et al 734

Shainkin R (abst) 315
ShaldonS (abst) 219
Shankel SW (abst) 203
Shanley P (abst) 298, 299, 310, 433
Shanley PF (abst) 310
Shanley PF, Brezis M, Spokes K, Silva P, Epstein FH, Rosen S: Hypoxic injury in the proximal tubule of the isolated perfused rat kidney 1021
Shanley PF, Brezis M, Spokes K, Silva P, Epstein FH, Rosen S: Transport-dependent cell injury in the S_3 segment of the proximal tubule 1033
Shapiro H (abst) 280
Shapiro HS (abst) 426
Shapiro J (abst) 310, 433
Shapiro JI (abst) 336
Shapiro M (abst) 184, 203
Shapiro RJ (abst) 326
Shaw L (abst) 159
Shaw S (abst) 310, 348, 388
Shayman JA (abst) 344, 422
Shea-Donohue T (abst) 232
Sheffer FV (abst) 160
Sheil AGR *See* Bishop GA et al 708
Sheldon JP (abst) 206
Shemesh O (abst) 323
Shemesh O, Deen WM, Brenner BM, McNeely E, Myers, BD: Effect of colloid volume expansion on glomerular barrier size-selectivity in humans 916
Shen F (abst) 225
Shen S (abst) 229, 327, 435
Sherman RA (abst) 186, 210, 225
Sherrard DJ (abst) 176, 199, 218
Sherrard DJ *See* Andress DL et al S-87
Sherrard DJ *See* Nebeker HG et al S-96
Sherrard DJ *See* Ott SM et al S-108
Shigematu T *See* Kawaguchi Y et al S-49
Shiigai T (abst) 369, 375
Shimada H (abst) 327
Shimamura T (abst) 286, 311, 345
Shimamura YO (abst) 345
Shinaberger JH (abst) 215, 227
Shinaberger JH *See* Milliner DS et al S-100
Shine N (abst) 359
Shirahama T (abst) 213
Shizume K (abst) 341
Shneider R (abst) 302
Shoji R *See* Kawaguchi Y et al S-49
Shore A *See* Rush PJ et al 1066
Short CD, Durrington PN, Mallick NP, Hunt LP, Tetlow L, Ishola M: Serum and urinary high density lipoproteins in glomerular disease with proteinuria . 1224
Shoshan V (abst) 315
Shulman R (abst) 299, 315
Shulman RG (abst) 396
Shultz P (abst) 345
Shusterman N (abst) 237
Shusterman N (abst) 239
Siebens AW (abst) 371, 376
Sieberth HG (abst) 1257
Siegel N (abst) 299, 315
Siegel NA (abst) 171
Siegel NJ (abst) 300, 353
Siegenthaler W (abst) 1260
Siegler R (abst) 204
Siegler RL (abst) 179
Sierra RI (abst) 172
Sikes W (abst) 379
Sikora JJ *See* Paller MS et al 1162
Silbernagl S (abst) 1252
Silis V (abst) 172, 251
Silva F (abst) 207, 273, 282, 285, 289
Silva FG (abst) 189
Silva P (abst) 310, 350, 351, 379
Silva P *See* Shanley PF et al 1021
Silva P *See* Shanley PF et al 1033
Silver J (abst) 172
Silverberg M (abst) 210, 224
Silverman M (abst) 424
Simenhoff ML (abst) 315
Simiplaceanu V (abst) 372
Simmons R (abst) 355, 358, 359
Simon GM (abst) 232
Simon P (abst) 197, 225
Simon P (abst) 777
Simonson M (abst) 340, 379
Simpson W *See* Kerr DNS et al S-58
Sims N (abst) 240
Sinaiko AR (abst) 345
Singal K (abst) 237
Singer FR *See* Smothers RL et al 578
Singer GG (abst) 208
Singh AK (abst) 279, 291
Singhal PC (abst) 345
Sinico R (abst) 608
Sires R (abst) 183
Sirois P (abst) 342
Sirota RA (abst) 228
Skelton MM *See* Merrill DC et al 1152
Skinner M (abst) 213
Sklar AH (abst) 346
Skorecki KL (abst) 424
Skrede S *See* Talseth T et al 1072
Slatopolsky E (abst) ... 164, 174, 199, 218, 226, 231, 236, 319
Slatopolsky E *See* Morrissey J et al S-41
Slatopolsky E *See* Nebeker HG et al S-96
Slayman CW (abst) 369
Slifkin RF (abst) 223
Slooff MJH (abst) 942
Sluiter WJ (abst) 942
Sluiter WJ *See* ter Wee PM et al 870
Smith AJ (abst) 186
Smith Jr AJ *See* Malluche HH et al S-70
Smith KJ (abst) 342
Smith LA (abst) 249
Smith W (abst) 333
Smith WL (abst) 424
Smith-Powell L (abst) 258
Smolens P (abst) 416
Smothers RL, Levine BS, Singer FR, Bryce GF, Mallon JP, Miller ON, Coburn JW: Relationship between urinary calcium and calcium intake during calcitriol administration 578
Smyth DD (abst) 346
Smyth DD *See* Umemura S et al 703
Snowdowne KW (abst) 157
Snyder NA (abst) 204
Soares V (abst) 292
Soderblom RE (abst) 235
Soffer O (abst) 219
Soila KP (abst) 206

Sole MJ, Madapallimattam A, Baines AD: An active pathway for serotonin synthesis by renal proximal tubules ... 689
Solez K (abst) ... 300, 304, 305, 435
Solomon L (abst) ... 210
Solomon RJ (abst) ... 330, 342, 346, 349
Soltoff SP (abst) ... 357
Sombolos K (abst) ... 231
Sondheimer JH (abst) ... 234, 326
Sone M (abst) ... 387
Song Y (abst) ... 426
Sonke P (abst) ... 386
Sonne O *See* Hellfritzsch M et al ... 983
Sonneberg H (abst) ... 394
Sonnenberg H (abst) ... 208, 407
Sonnenberg WK (abst) ... 424
Soreth J (abst) ... 205
Sorger K (abst) ... 1250
Sorkin MI (abst) ... 237
Sosnowski G (abst) ... 395
Sotelo-Avila C (abst) ... 289
Soyeux N *See* Elalouf JM et al ... 807
Spar B (abst) ... 301, 311
Spector AA (abst) ... 335
Spector D (abst) ... 321, 326
Spielman WS (abst) ... 424
Spilman PS (abst) ... 208
Spital A (abst) ... 408
Spitzer A (abst) ... 356
Spitzer A *See* Kumar AM et al ... 747
Spitzer RE (abst) ... 310
Spokes K (abst) ... 350
Spokes K *See* Shanley PF et al ... 1021
Spokes K *See* Shanley PF et al ... 1033
Spring KR (abst) ... 206
Spry L (abst) ... 361
Spry LA (abst) ... 360
Squires RV (abst) ... 1264
Sraer J (abst) ... 346
Sraer JD (abst) ... 339, 344, 346
St-Louis G (abst) ... 227
Stahl RA (abst) ... 1250
Stahl RAK (abst) ... 347
Stanfel L (abst) ... 317
Stannek K (abst) ... 336
Stanton B (abst) ... 398, 399, 407
Stanton RC (abst) ... 360
Stapleton FB (abst) ... 204
Star R (abst) ... 370
Star RA (abst) ... 377
Starling JF (abst) ... 198, 226
Stassen F (abst) ... 418
Statius Van Eps LW (abst) ... 207
Staton GW (abst) ... 220
Steele TH (abst) ... 259
Steffes MW (abst) ... 273
Steffes MW *See* Ellis EN et al ... 889
Stefoni S (abst) ... 611
Stegmeier K (abst) ... 1257
Steigerwalt S (abst) ... 408
Stein HD (abst) ... 228
Stein J (abst) ... 260
Stein JH (abst) ... 307, 416
Steinhauer HB (abst) ... 1261
Steinhauer HB (abst) ... 237, 436
Steinhauer HB, Schollmeyer P: Prostaglandin-mediated loss of proteins during peritonitis in continuous ambulatory peritoneal dialysis ... 584
Steinmuller DR (abst) ... 427, 436
Stekle B (abst) ... 401
Stelkens H (abst) ... 401
Stemmer C (abst) ... 324
Stemmer CL (abst) ... 204
Stenstrøm J *See* Talseth T et al ... 1072
Stenzel KH (abst) ... 436
Stephens GW (abst) ... 347
Steplock D (abst) ... 408
Sterioff S (abst) ... 1264
Stern L (abst) ... 238, 437
Stern LZ (abst) ... 195
Sterns R (abst) ... 205, 408
Sterrett JR (abst) ... 234
Sterzel RB (abst) ... 259, 275, 277, 334, 340
Sterzel RB *See* Luft FC et al ... 1004
Steven K *See* Jensen PK et al ... 490
Steward AP *See* Macdougal DF et al ... 1144
Stiller C (abst) ... 182
Stinson MW (abst) ... 264
Stirati G (abst) ... 611
Stitzel AE (abst) ... 292
Stivelman J (abst) ... 226
Stoff J (abst) ... 337
Stokes J (abst) ... 409
Stokes JB (abst) ... 399
Stolpe AVD (abst) ... 190
Stom MC (abst) ... 226, 421
Stone DK (abst) ... 291, 364, 477, 478
Stossel T (abst) ... 413
Stote R (abst) ... 313
Stote RM (abst) ... 205
Stout TL (abst) ... 208, 312
Stover J (abst) ... 233
Stowe N (abst) ... 436
Strauss F (abst) ... 527
Streb H *See* Thévenod F et al ... 695
Strebel FR (abst) ... 300
Streem S (abst) ... 527
Streicher E *See* Schneider HW et al ... S-120
Striker G (abst) ... 283
Striker L (abst) ... 283
Strom TB (abst) ... 280, 431, 432, 433
Stromski M (abst) ... 299, 315
Stupak W (abst) ... 180
Sturgill BC (abst) ... 180, 266, 269
Suda T *See* Nagakura K et al ... 834
Sudhaker Rao D (abst) ... 187
Sudhof T (abst) ... 291
Sugino N (abst) ... 387
Suki WN (abst) ... 362, 423
Suki WN *See* Ribeiro C et al ... 1167
Sullivan LP (abst) ... 405
Summer SN (abst) ... 418
Sunderland B (abst) ... 300, 301
Sunderrajan SS (abst) ... 259
Sunderrrajan S (abst) ... 201
Surian M (abst) ... 610
Suthanthiran M (abst) ... 206, 436
Sutherland DER *See* Ellis EN et al ... 889
Sutton J (abst) ... 205
Sutton RAL (abst) ... 175, 306

Svetkey LP (abst) 259
Swanson JE (abst) 325
Sweeney WE (abst) 314
Sweeney WE Jr (abst) 352
Swenson RS (abst) 221, 227
Szczepanska-Konkel M (abst) 164, 172, 174, 361
Szerlip H (abst) 351, 408
Taft E (abst) 373
Tago K (abst) 409
Takabatake T (abst) 1253
Takano T (abst) 357
Takeda K (abst) 424
Takeda K, Torikai S, Asano Y, Imai M: Modulation by verapamil of hormonal action on the Henle's loop of mice 863
Takeuchi J (abst) 369, 375
Takeuchi K (abst) 258, 260
Talor Z (abst) 377, 425
Talseth T, Fauchald P, Skrede S, Djøseland O, Berg KJ, Stenstrøm J, Heilo A, Brodwall EK, Flatmark A: Long-term blood pressure and renal function in kidney donors 1072
Talwar HS, Reddi AH, Menczel J, Thomas Jr WC, Meyer JL: Influence of aluminum on mineralization during matrix-induced bone development 1038
Tamayo A (abst) 172
Tan AA (abst) 327
Tan S (abst) 161, 173
Tan$_{b}$ WW (abst) 192
Tanke HJ (abst) 944
Tapia E (abst) 260
Tapp DC (abst) 183, 205
Tarantino A (abst) 612
Tarcic N (abst) 280
Tardanico R (abst) 612
Tarkowski A (abst) 277
Tartarotti D (abst) 609
Tasby J (abst) 362
Tauc M (abst) 360
Tavill M (abst) 379
Tavora E (abst) 430
Taylor PC (abst) 427
Taylor RP (abst) 277
Tazaki H *See* Nagakura K et al 834
Tealey J (abst) 230
Teatini U (abst) 610
Tegtmeyer CJ (abst) 298
Tegzess AM (abst) 942
Teitelbaum S (abst) 218
Teitlebaum I (abst) 425
Tejani A (abst) 206
Teller D (abst) 321, 326
Teller EB (abst) 321
Temler E *See* Jaeger P et al 563
Ten Cate JW (abst) 207
Teplick RS (abst) 184
Terao N (abst) 173
Terry LC (abst) 458
Terwee JA (abst) 263
ter Wee PM, Rosman JB, van der Geest S, Sluiter WJ, Donker AJM: Renal hemodynamics during separate and combined infusion of amino acids and dopamine 870
Tessitore N (abst) 223, 409
Tessitore N (abst) 609
Tessitore N (abst) 611
Tetlow L *See* Short CD et al 1224
Tetta C (abst) 292
Tetta C (abst) 609
Textor SC (abst) 206, 358
Thaiss F (abst) 1249
Thaiss F (abst) 1250
Thaiss F (abst) 292
Thévenod F, Streb H, Ullrich KJ, Schulz I: Inositol 1,4,5-trisphosphate releases Ca^{2+} from a nonmitochondrial store site in permeabilized rat cortical diney cells 695
Thibault G (abst) 340
Thiede H-M (abst) 1258
Thier SO (abst) 192
Thoenes W (abst) 1250
Thoenes W (abst) 1259
Thomas BL (abst) 325
Thomas D (abst) 163, 260
Thomas Jr WC *See* Meyer JL et al S-20
Thomas Jr WC *See* Talwar HS et al 1038
Thomasson DL (abst) 347
Thompson R (abst) 429
Thulin G (abst) 299, 300, 315, 353
Thurau K (abst) 1251
Thurau K (abst) 391
Tidwell RR (abst) 275
Tielemans C (abst) 185, 211
Tilgen W (abst) 1256
Tiller DJ *See* Bishop GA et al 708
Tilney NL (abst) 432
Tisher C (abst) 429
Tisher CC (abst) 293, 372
Tobian L (abst) 250, 260
Tobias JA (abst) 206
Tolins JP (abst) 293
Tomaszewski JE *See* Robertson JL et al 511
Tomita K (abst) 375
Tomura S (abst) 293
Torhorst J (abst) 1254
Torikai S *See* Takeda K et al 863
Torok J (abst) 173
Torres J (abst) 207
Torres VE (abst) 182, 376, 429, 436
Torricelli P (abst) 613
Toth M (abst) 340
Touam M (abst) 223
Touam M *See* Drüeke TB et al S-45
Touchard G (abst) 287
Toueg S (abst) 216
Trabold EM *See* Luft FC et al 1004
Trachtman H (abst) 206
Trapp GA: Interactions of aluminum with cofactors, enzymes, and other protein S-12
Trebbin W (abst) 349
Tremblay JM (abst) 261
Tresco PA (abst) 253
Tribout B (abst) 775
Tribout B (abst) 777
Tribout B (abst) 778
Trimble ME (abst) 171, 301, 332
Triolo G (abst) 292
Triolo G (abst) 612
Trivedi B (abst) 352, 356
Troy JL (abst) 340, 382
Troyer DA (abst) 338, 347, 348

Troyer DA, Kreisberg JI, Venkatachalam MA: Lipid alterations in LLC-PK$_1$ cells exposed to mercuric chloride ... 530
Tsai C *See* Lopez M et al. ... 829
Tsai CC (abst) ... 347
Tsokos GC (abst) ... 378
Tsukui I *See* Kawaguchi Y et al. ... S-49
Tsuruda H *See* Okuda S et al. ... 502
Tubbs RR (abst) ... 375
Tuck ML (abst) ... 316
Tuck ML *See* Corry DB et al. ... 1197
Tulassay T (abst) ... 1254
Tulkens PM (abst) ... 311
Tungsanga K (abst) ... 326
Turbat EA (abst) ... 388
Turner DR (abst) ... 202
Turner MW (abst) ... 173
Turocy JF (abst) ... 352
Turolo L (abst) ... 610
Tuttle E (abst) ... 197
Twardowski Z (abst) ... 233
Twardowski ZJ (abst) ... 233, 338
Tyson T (abst) ... 266, 269
Ucci A (abst) ... 388
Uchida S (abst) ... 412
Ueda S, Wakashin M, Wakashin Y, Yoshida H, Iesato K, Mori T, Mori Y, Akikusa B, Okuda K: Experimental gold nephropathy in guinea pigs: Detection of autoantibodies to renal tubular antigens ... 539
Uehara Y (abst) ... 260
Uehlinger DE (abst) ... 348, 388
Uhlmann A (abst) ... 213
Uhteg LC (abst) ... 432
Ulan RA (abst) ... 230
Ulate G (abst) ... 362
Ullrich KJ (abst) ... 1256
Ullrich KJ *See* Thévenod F et al ... 695
Ulm K (abst) ... 250
Umemura S (abst) ... 346
Umemura S, Smyth DD, Pettinger WA: Regulation of renal cellular cAMP levels by prostaglandins and α_2-adrenoceptors: Microdissection studies ... 703
Umen A (abst) ... 434
Unger PH (abst) ... 1252
Unger T (abst) ... 340
Unger T *See* Luft FC et al ... 1004
Unwin R (abst) ... 308
Ura N (abst) ... 348
Urbaitis B (abst) ... 311, 327
Urbaitis BK (abst) ... 301
Uribarri J (abst) ... 373, 377
Vaamonde CA (abst) ... 297, 311, 363, 374
Vacca C (abst) ... 354
Vaessen LMB (abst) ... 944
Valdes Cepeda A (abst) ... 207
Valeri A (abst) ... 232, 431
Valeyre D (abst) ... 166
Valvo E (abst) ... 609
Van Adelsberg J (abst) ... 378
Van Deventer SJH (abst) ... 207
Van Epps DE (abst) ... 381
Van Eps LWS (abst) ... 309
Van Es LA (abst) ... 181
van Es PN (abst) ... 944
van Geelen JA (abst) ... 944
Van Geertruyden J (abst) ... 430
van Goor H (abst) ... 945
Van Gossum M (abst) ... 185
van Hoof JP (abst) ... 941
van Hooff JP (abst) ... 1263
van Leendert R (abst) ... 1263
van Leendert R (abst) ... 941
Van Liew J (abst) ... 268
Van Liew JB *See* Noble B et al ... 841
Van Scoik KG (abst) ... 437
van Son WJ (abst) ... 942
Van Thiel DH (abst) ... 188
Van den Ende A (abst) ... 309
van der Geest S *See* ter Wee PM et al ... 870
van der Hem GK (abst) ... 944, 945
van der Hem GK *See* Beukhof JR et al ... 549
Van der Hem GK (abst) ... 184, 254
van der Meer J (abst) ... 943
Van der Meer J (abst) ... 184
Van der Meer W (abst) ... 163, 363
van der Meulen J (abst) ... 943
Van der Meulen J (abst) ... 168
van der Woude FJ (abst) ... 942
van der Woude FJ (abst) ... 944
Vanamee P (abst) ... 191
Vandekerkhove KM (abst) ... 221
Vandewalle A (abst) ... 363
Vangelista A (abst) ... 613
Vanhoutte PM (abst) ... 251, 256
Vannini P (abst) ... 611
Vanrenterghem Y (abst) ... 942
Vanscoy M (abst) ... 164, 172
Vari RC (abst) ... 409
Vasilevsky ML (abst) ... 401
Vaughn WK (abst) ... 435
Vecsei P (abst) ... 1259
Veelken R *See* Luft FC et al ... 1004
Vegeto A (abst) ... 612
Velasquez-Forero F (abst) ... 207, 293
Velazquez H (abst) ... 394, 409
Velez RL (abst) ... 427
Velosa JA (abst) ... 189, 429, 436
Venkatachalam MA (abst) ... 265, 302, 338, 347, 348
Venkatachalam MA *See* Troyer DA et al ... 530
Venturi A (abst) ... 609
Venuto RC (abst) ... 438
Verani RR (abst) ... 437
Verbalis JG *See* Craven PA et al ... 1110
Verberckmoes R (abst) ... 942
Verburg KM (abst) ... 409
Vercellone A (abst) ... 609
Vercellone A (abst) ... 612
Veremis SA (abst) ... 433
Vergne-Marini P (abst) ... 437
Verhoef GEG (abst) ... 190
Verkman AS (abst) ... 370, 378, 393, 421
Verlander JW (abst) ... 372
Vernier RL (abst) ... 294
Vernocchi L (abst) ... 238
Verpooten GA (abst) ... 312
Verroust P (abst) ... 269, 360
Verroust P (abst) ... 608
Verroust P *See* Brunisholz M et al ... 971
Versluis DJ (abst) ... 942
Vertuno L (abst) ... 194

Vetter W (abst) 1260
Vetter W (abst) 261
Vial MC (abst) 775
Viale G (abst) 288
Viberti G (abst) 389
Vidt DG (abst) 427
Vigneron N *See* Karsenty G et al 1058
Villamediana LM (abst) 281, 381, 383
Villarreal D (abst) 397
Vinay P (abst) 227, 340, 354, 392
Vinet B (abst) 227
Viriya S (abst) 174
Vismans F (abst) 1263
Vismans F (abst) 941
Vitting K (abst) 238
Vogt A (abst) 1248
Vogt A (abst) 1249
Vogt A (abst) 292
Volker K (abst) 1252
Volkmann R (abst) 277
Von Herrath D (abst) 199
Von Lilien (abst) 427
Von Lilien T (abst) 238
Vonalbertini B (abst) 227
Voyles WF (abst) 379
Wade JB (abst) 416, 417
Wadgymar A (abst) 264, 276, 294
Wagner K (abst) 1262
Wagoner RD (abst) 182
Wahl P (abst) 289
Wakabayashi Y (abst) 327
Wakashin M *See* Ueda S et al 539
Wakashin Y *See* Ueda S et al 539
Wald H (abst) 308, 405, 410
Waldherr R (abst) 259
Waldo FB, Beischel L, West CD: IgA synthesis by lymphocytes from patients with IgA nephropathy and their relatives 1229
Walker J (abst) 169
Walker JA (abst) 210
Walker PD (abst) 311
Walker RG, Escott M, Birchall I, Dowling JP, Kincaid-Smith P: Chronic progressive renal lesions induced by lithium 875
Walker S (abst) 236
Walker ST (abst) 159
Walker WG (abst) 183, 338
Walli A (abst) 1248
Wallin JD (abst) 349
Walling MM (abst) 163, 172
Wallsh E (abst) 263
Walser M (abst) 326
Walshe J (abst) 239
Waltzer W (abst) 431
Wang J (abst) 379
Wanner C (abst) 1260
Wanner C (abst) 261
Ward H (abst) 292, 438
Ward MK *See* Kerr DNS et al S-58
Warden D (abst) 409
Warnock DG (abst) 372, 377, 402, 405
Warshaw BL (abst) 294
Warvariv V (abst) 294
Wasserman M (abst) 328, 389
Wasserstein A (abst) 237, 239
Wassner SJ *See* Li JB et al 1136
Wathen RL (abst) 217
Watkins DW (abst) 321
Watson AJ (abst) 208, 312
Wayman AL (abst) 227, 269
Weary M (abst) 211
Weatherall DJ (abst) 181
Weaver M (abst) 173
Weaver ME (abst) 173
Weber A (abst) 1256
Weber A (abst) 169
Weber H *See* Schneider HW et al S-120
Weber M (abst) 1248
Weber M (abst) 1258
Weber M (abst) 1259
Weber MR (abst) 391
Weber PC *See* Schnermann J et al 520
Webster JG (abst) 261
Webster S (abst) 173
Webster SK (abst) 160
Wedeen RP (abst) 312
Wedel SK (abst) 213
Weening JJ (abst) 265
Weening JJ (abst) 944
Weening JJ, Beukers JJB, Grond J, Elema JD: Genetic factors in focal segmental glomerulosclerosis (Editorial Review) 789
Weerts C (abst) 226
Wegener L (abst) 261
Wehrheim C (abst) 1255
Weidanz W (abst) 280
Weidmann P (abst) 310, 348, 388
Weidmann P *See* Bianchetti MG et al 882
Weidner N (abst) 282
Weimar W (abst) 942
Weimar W (abst) 944
Weinberg JM (abst) 296, 302, 352, 356
Weinberg MS (abst) 330, 342, 346, 349
Weiner MW (abst) 359
Weinhold PA (abst) 307
Weininger J (abst) 302
Weinman EJ (abst) 355, 378, 408
Weinstein GS (abst) 263
Weir M (abst) 228
Weir M (abst) 229, 327, 435
Weir MR (abst) 216
Weiss J (abst) 159
Weiss M (abst) 329
Weissberger LE (abst) 220
Welbourne TC (abst) 361, 365, 370
Welbourne TC *See* Holloway JC et al 989
Welch WJ (abst) 255, 349
Welik R (abst) 229, 327
Welling DJ (abst) 410
Welling LW (abst) 410
Wells JO (abst) 261
Wells S (abst) 156
Welsch J (abst) 1254
Welsch J (abst) 306
Wen SF (abst) 261
Wener MH (abst) 295
Wens R (abst) 185, 211
Wenting GJ (abst) 944
Wenzl J (abst) 207
Werness J (abst) 167, 425

Wesson DE (abst) 388
West CD *See* Waldo FB et al 1229
West CD: Childhood membranoproliferative glomerulonephritis: An approach to management (Nephrology Forum) 1077
West M (abst) 192
West ML (abst) 208, 367
Westberg G (abst) 277
Westbrook S (abst) 421
Westenfelder C (abst) 192, 297, 330, 385, 389
Westervelt F (abst) 228
Westervelt FB (abst) 229, 298
Westre B *See* Berg KJ et al 1180
Wetzels JFM (abst) 941
Wetzels JFM (abst) 942
Whelchel JD (abst) 428
Whelton A (abst) 208, 304, 312, 338
White JL *See* Larson EA et al 1131
White MD (abst) 312
White MG (abst) 213
Whitescarver SA (abst) 255, 400
Whitney D (abst) 325
Whitty M (abst) 320
Wiegmann T (abst) 425
Wiegmann TB (abst) 371
Wiemer JG (abst) 1254
Wieslander J (abst) 282
Wigfall DR (abst) 208
Wiggins RC (abst) 295
Wiggins RC, Glatfelter A, Ksirsagar B, Brukman J: Procoagulant activity in normal human urine is associated with subcellular particles 591
Wilcox C (abst) 208
Wilfinger WW (abst) 248
Wilhelms H (abst) 266
Wilke T (abst) 250
Wilke WL (abst) 327
Wilkes B (abst) 327
Wilkes BM (abst) 342
Wilkinson AH (abst) 295
Willems W (abst) 1261
Williams AV (abst) 270
Williams DG (abst) 295
Williams DG *See* Nolasco F et al 1215
Williams JJ (abst) 170
Williams JM (abst) 432, 433
Williamson-Pahl S (abst) 267
Wilms H (abst) 1261
Wilson CB (abst) 296, 380, 383
Wilson DJ (abst) 262
Wilson DM (abst) 436
Wilson DR (abst) 407
Wilson J (abst) 405
Wilson M (abst) 238
Wilson P (abst) 252
Wilson P (abst) 262, 270, 433
Wilson PA (abst) 426
Wilson PD, Schrier RW: Nephron segment and calcium as determinants of anoxic cell death in renal cultures 1172
Wilson SK *See* Olson JL et al 849
Wilstrand J (abst) 251
Winaver J (abst) 384, 389
Winchester JF (abst) 234
Windham JP (abst) 189
Windus D (abst) 226, 231
Wingen A-M (abst) 1249
Wingen AM (abst) 1249
Wingo C (abst) 429
Wingo CS (abst) 372, 400
Winkelmann M (abst) 1262
Winney RJ, Cowie JF, Robson JS: Role of plasma aluminum in the detection and prevention of aluminum toxicity S-91
Winston J (abst) 312
Wirquin V (abst) 405
Wirthensoh G (abst) 1252
Wise D (abst) 262
Wiseman MJ (abst) 389
Witkowski M (abst) 1262
Witte P (abst) 241
Wittner M (abst) 1255
Witzgall H (abst) 1253
Woittiez AJJ (abst) 944
Wold L (abst) 250
Wolf C (abst) 239
Wolfe JA (abst) 432
Wolfson M (abst) 228
Wolthers BG (abst) 206
Wong MW (abst) 339
Wong NLM (abst) 175
Wong NLM (abst) 306
Wongsurawat N (abst) 175
Wonigeit K (abst) 1256
Wonigeit K (abst) 1262
Wood CA (abst) 313
Woodford SY (abst) 209
Woodhead JS (abst) 155
Woodroffe AJ *See* Hale GM et al 718
Woods LL (abst) 253, 389
Worcester E (abst) 295
Worcester EM (abst) 315
Work J (abst) 288, 411
Wright FS (abst) 388, 394
Wright N (abst) 236
Wu G (abst) 231
Wyatt RJ (abst) 209
Xie XS (abst) 378
Yamaguchi D (abst) 164, 175, 396, 397
Yamamoto K (abst) 173
Yamamoto T (abst) 296
Yamashita N (abst) 341, 393
Yamashita W (abst) 336
Yan T (abst) 169
Yanagawa N (abst) 161, 307, 411
Yanagawa N *See* Corry DB et al 1197
Yanase M (abst) 411
Yang CS (abst) 247
Yang GS (abst) 262
Yarbrough S (abst) 262
Yarger WE (abst) 259, 332
Yasujima M (abst) 258, 260
Yee B (abst) 203, 438
Yee VJ (abst) 395
Yen M (abst) 228
Yick DG (abst) 402, 405
Yokouchi M (abst) 247
Yoshida H *See* Ueda S et al 539
Yoshinaga K (abst) 258, 260
Yoshioka K (abst) 279
Yoshioka T (abst) 390

Young E (abst) 262
Yudis M (abst) 228
Yulo T (abst) 400
Yurko M (abst) 369
Yusufi ANK (abst) 164, 172, 174, 352, 361
Zabel P (abst) 1262
Zabetakis PM (abst) 238, 263
Zachariah P (abst) 257
Zager RA (abst) 313
Zahavi I (abst) 156
Zanchetti A (abst) 610
Zappacosta AR (abst) 239, 240
Zatti M (abst) 223
Zatz R (abst) 289, 328
Zavala DC (abst) 322
Zawada ET Jr (abst) 263
Zawalich K (abst) 329
Zayas I (abst) 231
Zeidel ML (abst) 379
Zelikovic I (abst) 413
Zeller KR (abst) 209
Zelman SJ *See* Madias NE et al 667
Zemel S (abst) 229, 327
Zenser TV (abst) 347, 360, 361
Zikos D (abst) 159
Zimmerman A *See* Elalouf JM et al 807
Zimmerman S (abst) 434
Zimmerman SW (abst) 240
Zingraff J (abst) 229
Zingraff J *See* Karsenty G et al 1058
Ziroyanis P (abst) 212
Ziroyanis PN (abst) 296
Zizian L (abst) 354
Zoja C (abst) 282, 343
Zuan A (abst) 359
Zucchelli P (abst) 613
Zull JE (abst) 169
Zuyderhoudt FMJ (abst) 941
Zuyderhoudt FMJ (abst) 942

Subject Index For Volume 29

Ablation, renal, hypertension (abst) 260
ABP assay, diagnosis 142
ACE inhibitor
  enalaprilat (abst) 243
  ramipril (abst) 241
  sodium restrict (abst) 254
Acetate
  endothelium in (abst) 215
  intolerance prediction (abst) 215
  metabolism, acid-base (abst) 227
Acetazolamide
  ammoniagenesis (abst) 354
  cell pH (abst) 366
Acetohyroxamic acid, stones (abst) 170
Acetylated alkyl phosphoglycerides, PAF 469
Acetylcholine
  decreased endothelium-dependent relaxations (abst) ... 256
Acid
  cyclosporine stimulates secretion (abst) 368
  regulation of renal secretion, distal nephron segments . 1099
  sulfated bile, inhibition of Na-H antiport (abst) 1257
Acid fast bacillus in dialysis (abst) 230
Acid-base
  balance, urea formation (abst) 367
  disturbance, bicarbonate conductance to HCO3- (abst) . 375
  disturbance, edema (abst) 197
  metabolism after ischemia 989
  respiratory during HD (abst) 220
  status in HD (abst) 227
  systemic effects, regulation of glutamine metabolism in dog 68
Acidemia
  systemic, chronic mineral acid feeding and pH 667
Acidification
  cellular, activates Na-H exchange and Na-K pump (abst) 397
  clathrin-coated vesicle, by vanadate (abst) 364
  metabolic alkalemia, IMCD (abst) 363
  ureteral obstruction 1167
  urinary, PTH (abst) 363
Acidosis
  acid-base metabolism after ischemia 989
  anion gap, hemodialysis (abst) 197
  extracellular on active transport processes (abst) 409
  Fanconi syndrome (abst) 296
  lactic 752
  nephrectomy, effect on glutamine homeostasis (abst) ... 365
  newborns, treatment of ARF with CAVH 908
  potassium depletion (abst) 363
  potassium depletion during chronic metabolic (abst) ... 374
  respiratory inhibits cAMP HCO3 secretion (abst) 362
  respiratory, stimulates ammoniagenesis (abst) 355
  substrate oxidation, ammoniagenic adaptation (abst) ... 356
  systemic, proton-ATPase in tubules (abst) 368
Acids
  heterpolyuronic, non-aluminum S-120
  polyunsaturated 279
Acivicin effect on glutamine (abst) 359
Acquired renal cystic disease
  magnetic resonance imaging, ultrasound in (abst) 196
Actin-regulatory proteins
  are in apical cytoplasm of kidney collecting duct (abst) . 413
Acute oliguric renal failure
  monoclonal antibodies in diagnosis of renal disease 142
Acute postinfections GN (abst) 1250
Acute renal failure
  changing patterns and outcome of (abst) 176
  chronic uremia, mouse model (abst) 318
  cisplatin (abst) 312
  endotoxemic (abst) 306
  endotoxin-mediated, theophylline (abst) 308
  HR effect on cisplatin-induced (abst) 300
  insulin (abst) 306
  ischemia, hypothyroidism protects against free radical. 1162
  ischemic, dipyridamole (abst) 305
  laser Doppler velocimetry (abst) 297
  mannitol in high risk patients (abst) 298
  metabolic adaptations in renal disease 80
  nephrotoxic in streptozotocin treated rats (abst) 301
  nifedipine on carbohydrate metabolism (abst) 1257
  norepinephrine-induced, vascular congestion 306
  outcome prediction in (abst) 184
  prostaglandins induced by captopril (abst) 338
  proton magnetic resonance (abst) 302
  reduced blood pressure (abst) 256
  renal blood flow, prostaglandin in glycerol-induced (abst) 342
  reversal due to urinary tract infection (abst) 176
  ribonuclease II iszyme activity (abst) 305
  TXA2 in glycerol-induced (abst) 42
  vascular aberrancies of (abst) 299
  verapamil (abst) 312
Acute renal injury
  gasoline injestion (abst) 304
Acute renal insufficiency
  reversible due to diuretic, Maxzide (abst) 198
Acute tubular necrosis
  autofluorescence (abst) 289
  diabetes mellitus protects against (abst) 308
  monoclonal antibodies in diagnosis 142
Adenine nucleotide degradation (abst) 296
Adenosine
  inhibits chloride secretion in shark rectal gland (abst) .. 337
  triphosphate levels ischemic insult (abst) 310
  transport (abst) 332
Adenyl cyclase, PTH, H2O flow (abst) 170
Adenylate cyclase, vasopressin (abst) 424
Adrenal
  corticosteroids, transport(abst) 407
  steroids, permeability (abst) 417
  unilateral medullary hyperfunction (abst) 245
Adrenalectomized
  rabbit, K bicarbonate on Na-K-ATPase CCD (abst) 395
Adrenalectomy, protein in uremic (abst) 309
Adrenoceptor
  alpha, assessment (abst) 244

posterior hypothalamic B-2 in SHR (abst) 249
Adult idiopathic nephrotic syndrome
membranoproliferative glomerulonephritis in (abst) 207
Adult-onset nephrotic syndrome 1250
Age
and PTH (abst) 175
donor influence on transplant(abst) 942
renal cortical brush border membrane enzyme activity (abst) 360
AIDS
associated renal failure, national perspective (abst) 201
nephrotic syndrome (abst) 288
Albumin
homeostasis, dietary protein 572
homeostasis in nephrotics 572
hyperoncotic, natriuresis (abst) 392
Albumin, bovine serum, binding (abst) 265
Albuminuria
enalapril blocks (abst) 320
hyperlipimia (abst) 193
Aldosterone
changes in short-circuit current and conductance (abst). 408
induced glycoproteins in toad (abst) 351
induces Cl transport in CCT (abst) 1252
in vivo 208
mineralcorticoid (abst) 242
19-NOR potent (abst) 253
19-OH, 19-NOR (abst) 242
Alkali
nural regulation of excretion (abst) 365
therapy in CRF (abst) 323
Alkaline
growth of proximal tubular cells occurs (abst) 402
Alkalinization
canine renal proximal tubular cells, phorbol ester (abst) .. 372
Alkalosis
chloride corrects without volume expansion (abst) 364
chloride depletion, new dog model (abst) 364
volume expansion not correct acute chloride depletion (abst) 365
Allergy, food, and idiopathic NS (abst) 776
Allograft
age of donor impact on survival (abst) 942
deposits of cyclosporine in (abst) 612
Alpha 2-adrenoceptors
dopamine receptors in diuresis (abst) 395
Alpha-ketoisocaproate, uremic (abst) 326
Alport's syndrome
epidermal basement membrane antigens (abst) 279
expression of Goodpasture antigen in 202
Alsosterone secretion, PTH (abst) 168
Aluminum
addition on parathyroid tissue incubation medium 924
and iron removal after DFO in CAPD, HD and HF (abst) 171
Australia, and bone disease in S-65
binding protein in bovine duodenal extracts (abst) 154
bone biopsy and storage of (abst) 173
bone, longitudinal study 218
CaCO3 on K, Ca, and Mg balance in ESRD (abst) 219
carbon, microencapsulated, used for removal (abst) 226
changes in bone histology after desferrioxamine treatment S-108
clearance of by hemodialysis, desferrioxamine S-100
desferoxamine treatment of anemia in dialysis (abst) ... 210
diagnosing bone disease S-96
dialysis encephalopathy S-53
effect on bone and cell localization S-37
effect on bone and cell localization S-37
elevated levels in CRF patients (abst) 176
enhanced gastrointestinal adsorption in uremic (abst) .. 1260
erythropoiesis (abst) 610
experimental induced bone disease S-32
geochemistry S-3
hematopoiesis S-45
hemoperfusion in treatment of bone disease (abst) 214
in genesis of osteodystrophy 169
interactions with cofactors, enzymes and proteins S-12
intoxication of bone in renal failure S-70
metabolism S-8
Mg hydroxide, low Mg dialysate in CAPD (abst) 232
mineralization during matrix-induced bone development 1038
non, phosphate-binding compound S-120
parathyroid glands function despite exposure (abst) 170
phosphate binding gels balance adsorption, toxicity ... 1131
plasma, toxicity S-91
PTH and vitamin D on intestinal and renal handling of (abst) 173
PTH and vitamin D3 affect accumulation (abst) 213
PTH not prevent osteomalacia 168
related bone disease, clinical & laboratory features (abst) 199
related osteodystrophy 169
removal during HD and CAPD, effect of DFO infusion (abst) 190
removal in home dialysis 209
serum and spinal fluid levels in HD uremics (abst) 211
serum levels in dialysis patients (abst) 165
suppression of DNA synthesis by bone cells (abst) 157
toxicity resembles aplastic bone disease (abst) 164
toxicity, experimental renal failure (abst) 175
Amiloride
effect on bicarbonate (abst) 375
protects antiporter vs EEDQ (abst) 405
on transport (abst) 163
Na+ channel (abst) 1255
Amino acid
combined infustion of, and dopamine, renal hemodynamics 870
low protein, keto acid diet, risk and benefit 995
mercury in basolateral cell membrane (abst) 416
Na transport, lipid events, adaptive response to (abst) . 413
renal hemodynamics during infustion of, and dopamine. 870
Aminoaciduria in rejection (abst) 436
Aminonucleoside
nephrosis, heparin(abst) 273
of puromycin 478
Ammonia
ammonium on Na/H antiporter, kinetic effects (abst) ... 402
concentration in inner medulla (abst) 366
genic adaptation to substrate oxidation, acidosis (abst) . 356
inhibits tubule cell energy metabolism (abst) 352
K transport in turtle bladder (abst) 377
transport, transepithelial (abst) 366
tubular C3 deposit (abst) 293
Ammoniagenesis
acetazolamide (abst) 354
acute respiratory acidosis stimulates (abst) 355
AT-125 on renal (abst) 361

gluconeogenesis, 13C NMR, 15N GC-MS (abst). 357
plasma glutamine concentration (abst). 351
regulaton of glutamine metabolism in dog kidney. 68
renal cortical mitochondrial, PGE2 (abst) 355
valproate (abst). 350
Ampflex connector (abst) 237
Amphiuma
apical membrane conductance (abst). 398
Amphiuma collecting tubule (abst) 398
Amyloid
lambda 2 light chain (abst). 288
type, diagnosis (abst) 274
B2 microglobulin, carpal tunnel syndrome (abst) 213
Amyloidosis
incidence in population of 250,000 (abst). 777
in heroin abusers (abst) 187
Anabolism in hemodialysis (abst) 209
Analogs, adenosine on GFR (abst) 358
Anaphylactic reactions, dialyzers (abst) 212
Anaphylatoxin
cardiopulmonary effect of cuprophane-activated plasma . . 799
cobra venom factor(abst) 269
Anemia
in hemodialysis (abst). 214
chronic renal failure 641
Anencephalic neonate donor
transplantation of cadaver kidneys from (abst) 430
Aneurysm, glomerular (abst). 286
ANFT, metabolic/excretory coupling(abst). 360
Angiotensin
vasomotor response to reflex sympathetic activation (abst) 610
Angiotensin converting enzyme
clipped kidney in hypertensive rats during prolonged (abst) 246
experimental nephrotic syndrome (abst) 302
Angiotensin II
aldosterone secretion, protein phosphorylation (abst) . . 329
binding sites in segments of rat nephron (abst). 254
blood pressure, vascular reactivity (abst) 383
BP control in normotensive members of hypertensive families 882
Ca kinetics 424
calcium, cyclooxygenase modulate renal function (abst) . . 336
chronic salt loading, glomeruli (abst). 385
hypertrophy vs. hyperplasia (abst) 318
in nephrotoxic serum nephritis (abst) 293
PGE2 synthesis by pertussis toxin (abst) 344
role for water intake (abst). 1252
Antiotensin II
segmental vascular diameter response to (abst) 381
vasopressin, cause membrane depolarization (abst) 341
22Na+ washout from VSMCs (abst). 338
Anion exchange, band 3 (abst) 376
Anionic sites
albumin excretion (abst). 294
phosphate (abst). 285
Anisotonic media regulation (abst) 419
Anoxia, adenine nucleotides (abst) 357
Anoxic cell death, Ca, nephron segment. 1172
Anoxic renal PT, acidosis (abst) 299
Anti-diuretic hormone
cAMP, regulation of water permeability in bladder (abst) 417
fluorescent markers study membrane retrieval in (abst) . 416
Anti-glomerular basement membrane
antibody mediated disease, outcome (abst). 200
Anti-inflammatory drug
sulinas effect during hemorrhage 484
Anti-interleukin-2 receptor (abst) 280
Anti-thymocyte globulin, CyA (abst) 427
Antibiotic induced renal failure (abst) 177
Antibiotic schedule for CAPD (abst) 231
Antibodies
auto-anti-idiotypic in anti-GBM GN (abst) 290
heparan sulfate proteoglycans of GBM (abst). 283
monoclonal, to mononuclear cell markers. 708
MRL nephritogenic, share dominant ideotype (abst) . . . 285
to laminin in preeclampsia 1050
viral glycoprotein, endocytosis (abst) 420
immune complex (abst) 271
monoclonal Enkephalin degrading enzyme (abst) 271
monoclonal in diagnosis 142
Antibody
anti-GBM in auto-immune nephritis 266
antigen, in heymann nephritis (abst) 608
antigliadin in IgA glomerulonephritis (abst). 776
characterization of monoclonal, Tamm-Horsfall protein . . 971
monoclonal anti-rat-thymocyte, glomerulonephritis (abst) 945
reaginic ETO response (abst). 266
to acidic protein MAUP in urine (abst). 264
urinary calcium oxalate crystal growth inhibitor. 829
Antibody binding
tubular C3 deposition by ammonia (abst) 293
Antidiuresis
increased urinary excretion of PGE2. 1110
Antidiuretic hormone
mechanism of in natriuresis (abst). 422
nucleotide regulatory protein mediates (abst) 423
type B syndrome of inappropriate (abst). 421
Antigen
antibody, glomerular capillary wall charge interactions . 649
exogenous cationized, Heymann Nephritis (abst). 264
immunocytochemical localization of renin and kallikrein 965
nucleic acid, membranous lupus autoantibodies (abst) . . 288
of antiglomerular basement membrane antibody (abst). 1248
Antigen-antibody systems
Heymann Nephritis (abst) 263
70KD, HN (abst) 291
Antigens
HLA-DR, DP, DQ, on human tissue (abst). 1261
immunodissection and culture of CCT (abst) 424
microheterogeneity, nephritis, 2D-SDS immunoblotting (abst) 1249
MHC minimal change glomerulonephritis, focal sclerosis (abst) 286
multiple, MRL antibody (abst). 285
Antihypertensive
drug, guanabenz 1203
hepatic dysfunction in transplant (abst). 438
treatment, effects in one-clip, two kidney hypertension. . 1011
therapy, decrease of NAG after (abst) 258
Antiport
Na activates Na-H activity at internal locus (abst). 396
Na-H activity in LLCPK1-CL4 cells (abst). 403
Antiporter
kinetics of Na-H, pH in MDCK cells (abst) 376
Na+/H+, amiloride protects vs inactivation (abst). 405

Na+/H+, CL-/HCO3-(OH-) transport NaCl (abst) 390
Na/H and PTH (abst) 372
with exchanger, BBM (abst) 367
APD, hyperparathyroidism (abst) 1262
Apical membrane vesicles
LLC-PK1, new type of exchange system of Na+/H+ (abst) 373
Aplastic bone disease, dialysis S-74
Arachidonate acid epoxygenase (abst) 356
Arachidonic acid
metabolites, prostaglandins in the kidney 108
Arginine infusion
on renal plasma flow and GFR in humans (abst) 190
Arginine vasopressin
action (abst) 328
action cellular calcium uptake modulates in CCT (abst). 415
analysis 178
mechanism in MAL (abst) 418
pertussis toxin, adenylate cyclase activity (abst) 426
modulation of hormonal action by 863
receptor characteristics of human platelet (abst). 412
Arterial
dopamine-2 receptor in canine kidney (abst). 385
Arterial line, blood in HD (abst) 943
Arteries, renal
endothelium-deptndent relaxation (abst) 251
Arterioles
isolated renal afferent, PGE2 (abst) 385
glomerular, APII (abst) 333
Arteriovenous shunting (abst) 195
Arthritis
rheumatoid, CyA, Aza side effects in treatment of.... 1180
Aspirin, GFR (abst) 323
Assay
D valine medium (abst) 353
new chromogenic endotoxin (abst) 207
PTH in CAPD (abst) 239
AT-125, ammoniagenesis (abst) 361
Atenolol in hypertensives (abst). 205
Atomic absorption spectroscopy
electrothermal determination of aluminum S-28
Atomic emission spectrometry, aluminum S-24
ATPase
acetate intolerance during HD (abst) 223
activity in proximal tubule brush border membrane (abst) 368
clathrin-coated vesicle proton translocating (abst) 378
depletion 302
distribution and function along the nephron 21
luminal active transport processes in cortical cells (abst) 611
mechanism, produced by exogenous nucleotides (abst) . 356
monoclonal antibody to bovine medulla H+ 369
mutant clathrin-coated vesicle proton translocating (abst) 377
Na-K, in streptozotocin-induced diabetes mellitus (abst) 410
recovery, postischemic (abst). 299, 315
sodium pump in salt gland, gut tube of brine shrimp (abst) 394
sodium transport, oxygen consumption and 3
to sodium transport (abst) 359
Atrial extracts, properties, rat (abst) 248
Atrial natriuretic factor
acute hormonal and hemodynamic effects of in man (abst) 1253
aorto-caval fistula (abst) 389
causes glomerular hyperfiltration, cAMP, TGF (abst) .. 384
changes in dietary protein (abst) 384
chronic sodium homeostasis 1004
furosemide induced natriuresis (abst) 398
in salt-sensitive DAHL rats (abst) 334
in vascular smooth muscle cells (abst) 258
increase excretion, GFR (abst) 332
induce a natriuresis, GFR (abst) 402
intrarenal effects of (abst) 408
medullary solute gradients (abst) 414
ouabain factor, high Na diet (abst) 404
plasma and urine levels following ANF infusion (abst) . 409
plasma, hypervolemia (abst) 395
relationship between, and renal kallikrein (abst). 1254
respiration (abst). 340
Atrial natriuretic peptide
acute hemodynamic effect of (abst) 383
angiotensin II and hyperoncotic albumin (abst) 340
artificial heart transplant (abst) 192
atrial resection limits in sodium excretion (abst). 407
blood levels, cardiovascular, endocrine, excretory (abst) 348
diabetes insipidus, natriuretic effect (abst) 390
dopamine (abst) 336
during mineralocorticoid escape (abst) 329
effect of on kidney and juxtamedullary nephron (abst).. 405
effects of on kidney function in man (abst) 388
hydraulic pressures, natriuresis (abst) 382
in plasma of children with ESRD and volume expansion (abst) 1254
increase plasma insulin (abst) 348
inhibitory effect of on cAMP in glomeruli (abst). 425
levels during saline volume expansion (abst) 406
release in calves with artificial heart (abst) 389
sodium intake (abst) 384
synthetic, control of GFR (abst) 393
mechanism of natriuretic (abst) 383
Atriopeptin III
atrial extract in rat (abst) 401
influence on rabbit aortic smooth muscle, cGMP (abst).. 1254
in primate (abst) 392
kinetics (abst) 340
Atriopeptins, glomerular effects (abst) 379
Australia, aluminum, bone disease in S-65
Autoantibodies
membranous lupus crossreact with nucleic acid antigen (abst) 288
to tubular antigens, gold nephropathy 539
lupus SLE (abst). 283
Autoantibody, Goodpasture Syndrome(abst) 287
Autoflorescence
diagnosis of acute tubular necrosis (abst) 289
Autoimmunity
DNA (abst) 268
murine, Ia (abst) 289
Autosomal dominant polycystic
kidney disease, cyst infection in (abst) 203
kidney disease 315
AVP
increased urinary excretion of PGE2 during antidiuresis 1110

Axotemia, trends after HD (abst) 224
Azathioprine
  CyA, rheumatoid arthritis 1180
  in renal transplantation (abst) 435
  measure 6TU (abst) 437
Azlocillin's kinetics (abst) 208
Azotemia
  rats, B6 deficiency (abst) 228
  trends after HD (abst) 224
a2-adrenoceptor, PGE2, cAMP levels 703

B cell hyperactivity in IgA 718
B cell in aTBM (abst) 270
Bacterial microcolonies
  in peritonitis associated with CAPD (abst) 230
Bartter syndrome
  diluting segment function abnormal (abst) 416
  enalapril (abst) 190
  tests of renal diluting ability determine cause (abst) 190
Basement membrane
  anti-glomerular, antibody mediated disease (abst) 200
Basolateral amiloride
  acidification (abst) 371
Basolateral membrane vesicles
  cotransport of NaHCO3 (abst) 362
  Na-HCO3 cotransport (abst) 367
  membranes, IGF I (abst) 354
Bence Jones Protein, toxicity (abst) 309
Berger's Disease (abst) 191
Beta blockade, ISA alters (abst) 257
Beta 2 microglobulin, ADPKD (abst) 315
Bicarbonate
  amiloride effect on permeability (abst) 375
  buffered, solution for parenteral use (abst) 369
  diuresis, PCO2 (abst) 373
  PK of at high, low concentrations (abst) 377
  reabsorption across distal tubule 365
  regulation of glutamine metabolism in dog kidney 68
  renal acid-base metabolism after ischemia 989
binding sites, AII (abst) 254
Binding, glomerular, BSA (abst) 265
Biophosphonate, APD, parathyroid (abst) 941
Biopsy
  adolescents with renal disease (abst) 207
  fine needle aspiration, transplanted kidney (abst) 430
  renal allograft, value in cyclosporine era (abst) 438
  renal and fine-needle aspiration in transplantation (abst) 612
  renal in elderly (abst) 204
  65 teenagers with primary nephrotic syndrome (abst) . . 284
Blocking agents
  Ca++ activated K+ channels in MTAL (abst) 396
Blood
  flow measurement, noninvasive Doppler method (abst) . 379
  flow, temporal and spatial analysis (abst) 380
  red cells, sodium transport in, dialyzed uremics 1197
  transfusion, HLA-A, B compatible in transplantation (abst) 612
Blood pressure
  after radical operation in secondary hypertension (abst) . . 247
  altered by maternal dietary calcium in dogs (abst) 254
  captopril on renal hemodynamics (abst) 382
  cardiovascular response to hemofiltration 901
  Ca2+ in hypertensive (abst) 262
  determinants of in renal transplantation (abst) 436
  effects of Ca are prevented by magnesium (abst) 263
  elevated and rapid loss of renal function in NIDDM (abst) 182
  glomerular injury to preglomerular resistance, hypertension 849
  house officers during on call (abst) 253
  lead exposure, calcium intake (abst) 198
  NaCl effect in rat (abst) 255
  normotensive members of hypertensive families 882
  pregnancy, renin angiotensin aldosterone system (abst) . 777
  reduced, acute renal dysfunction in hypertension (abst) . . 256
  renal function in kidney donors 1072
  renal function preservation due to reduction (abst) 320
Bone
  accumulation of aluminum, osteomalacia S-17
  AL intoxicated rats, increased 1,25(OH)2D3 receptors (abst) 165
  aluminum metabolism S-8
  Aluminum, longitudinal study (abst) 218
  aluminum, PTH and vitamin D3 affect (abst) 213
  aluminum, transferrin-dependent, suppression of DNA (abst) 157
  aplastic disease, AL toxicity (abst) 164
  biopsy and Al storage (abst) 173
  biopsy, aluminum and bone disease in Australia S-65
  changes in histology after desferrioxamine treatment . S-108
  children, renal disease in dialyzed (abst) 236
  density in hypertension 205
  development, Al on mineralization during matrix-induced 1038
  diagnosis of aluminum disease S-96
  disease, aluminum-related S-80
  disease, experimental aluminum-induced S-32
  disease, PTH in aluminum S-87
  effects of dietary calcium and sodium on (abst) 173
  formation, aluminum influence S-32
  formation, calcium efflux (abst) 156
  fracturing disease, dialysis encephalopathy S-53
  increased receptors in AL intoxicated rats (abst) 165
  ion microprobe determination of surface elements (abst) 164
  marrow transplant, cytomegalovirus glomerulopathy . . . 725
  Newcastle disease, aluminum-induced osteodystrophy . S-58
  protective effect of verapamil on resorption (abst) 156
  scan, 99mTc-methylene diphosphonate in osteodystrophy 1058
  unresponsiveness of, to PTH in Al-related osteodystrophy S-49
  1,25(OH)2D3 and PTH maintain activity of cells (abst) . 164
Bone marrow transplantation
  renal vasodilation and hyperfiltration (abst) 206
Bovine hemoglobin, renal function (abst) 301
Bowel infarction in dialysis (abst) 212
Bowman's capsule
  crescents in CGn (abst) 266
Bradkyinin
  cortical interstitial cells (abst) 347
  kallidin metylsbradykinin 121
  kallikrein 953
  lipid peroxidation (abst) 333
  quin 2 flourescence in papillary collecting tubule (abst) . 344
  radioimmunoassay using monoclonal antibodies (abst) . . 342
Brain buffering, K depletion (abst) 362
Brain infarcts, K diet reduces (abst) 250
Bright's disease 779

Bronchopneumonia, IgA 557
Brush border membrane
age related changes in water, solute permeability (abst) .. 414
basolateral, fluidity differences in (abst) 403
carbonic anhydrase in S3 segment (abst)..... 370
cortical, effects of aging on (abst) 360
heterogeneity of fractions isolated by centrifugation (abst) 361
Na+/H+ antiporter with exchanger (abst) 367
permeabilities and fluidity of in cortex (abst) 412
phorbol esters stimulate Na+/H+ (abst)..... 408
phospholipids induced by mercuric chloride..... 496
proteins, phosphatidylcholine transfer (abst)..... 174
transport of H+/OH- (abst) 378
vesicles, cimetidine uptake (abst) 420
Brush border membrane vesicle
Cl/OH exchange coupled by electrical potential (abst).. 370
electrolyte gradients in, 3 techniques (abst) 402
fraction from human renal cortex (abst) 352
kinetic studies of Na+-H+ (abst) 370
phosphate uptake (abst)..... 155
presteady state kinetics of Na+-H+ exchange (abst)... 374
proximal convoluted tubules (abst) 352

c-sis mRNA in renal tissue (abst) 272
Calcification, vascular in HD (abst) 213
Calcitonin metabolism (abst)..... 359
Calcitriol
effects of diuretics (abst) 160
hyperparathyroidism (abst) 199
relationship between urinary calcium and calcium intake 578
vitamin D3 (abst) 1255
Calcium
absorption in spontaneously hypertensive rat (abst).... 159
activated K+ channels in MTAL (abst) 396
alters blood pressure in dogs (abst)..... 254
and cyclic AMP messenger function..... 90
antagonists in hypertension (abst)..... 241
antagonists on vasoconstrictor prostacyclin (abst)..... 260
arginine vasopressin action in CCT (abst)..... 415
augments glomerular capillary hypertension, injury (abst)..... 244
a2 and b2 adrenoceptors and free intracellular (abst).. 1258
carbonate responsible for acid-induced release (abst)... 156
carbonate, aluminum free agent for control in uremia. S-114
Ca2+ efflux rate constant in isolated SHR enterocytes (abst)..... 252
Ca2+, body composition changes in SHR (abst) 248
channel blockade, antihypertensive efficacy of (abst)... 257
channel blocker following ischemia (abst)..... 433
compensatory renal growth by Ca PTH, 1,25(OH)2D3. 1124
cortical mitochondria transport (abst) 315
creatinine, renal net acid excretion 743
cyclooxygenase products modulate renal function (abst)..... 336
cytosolic Ca2+, fura 2, quin 2 measurement (abst) 399
dietary effect in hypertension..... 166
dietary supplementation in hypertension (abst)..... 241
dietary, genetic variability in response to (abst)..... 247
effect of Al on parathyroid tissue incubation medium .. 924
effect on BP and Na, K-ATPase in SHR (abst) 262
efflux (abst)..... 156
gentamicin induces abnormalities (abst) 298
hypercalcemia, role of loop segment in urinary concentrating 977
hyperpolarization of proximal tubule cells (abst) 393
impaired vasopressin, cAMP formation by increased (abst)..... 425
increased intestinal transport in hypertensive rat (abst). 244
influx and H2o distribution in aorta, hypertensive (abst)..... 243
inositol triphosphate-sensitive pool (abst)..... 157
inositol 1,4,5-triphosphate releases 695
insulin, reactivity in diabetic (abst) 315
intracellular free, circulating plasma factor (abst)..... 250
ionized modulates renal function (abst)..... 381
kinetics, angiotensin II (abst)..... 424
lead exposure and blood pressure (abst)..... 198
measurement by FURA-2 (abst) 335
mobilization of vasopressin receptors (abst)..... 415
mobilizing hormones on brush border and sytoskeleton (abst)..... 160
modulation by verapamil of hormonal action 863
mucosal removal on a leaky epithelium (abst) 422
Na+, pressor response to norepinephrine (abst)..... 261
nephron segment and, determinants of anoxic cell death 1172
net acid excretion determines fasting urinary calcium .. 743
overload in ischemic renal injury (abst)..... 300
oxygen free radical injury (abst) 305
phosphate precipitation, aluminum S-20
phospholipid dependent protein kinase (abst)..... 355
PTH activated, conductive pathway in brush border (abst)..... 166
PTH stimulates cellular absorption of (abst)..... 159
renal channel abnormality in hypertensive rat (abst) ... 259
sequential changes, PTH secretion and UcAMP excretion (abst) 172
sequestration in LLC-PK1 cells (abst)..... 302
stone former, hydrochlorothiazide (abst)..... 775
stone formers, soft vs. hard water (abst)..... 778
stress, hypertension in SHR (abst) 247
toxicity to renal medulla (abst) 298
urinary and intake relationship during calcitriol therapy .. 578
urinary, oxalate crystal growth inhibitor..... 829
urine excretion post renal mass reduction (abst)..... 321
Calcium oxalate, uremic serum (abst) 315
Calelectrin in renal tissue (abst)..... 291
cAMP
acidosis inhibits HCO3 secretion in turtle (abst)..... 362
mediates PTH stimulation of 25-OH-vitamin D3 activity (abst) 162
process for K groups in glomerular polyanion complex (abst)..... 285
protein kinase and Na+/H+ exchange (abst) 378
regulation of levels by PGE2 and a2 adrenoceptors 703
system, AII, AVP, Bradykinin, Meclofenamate on PG and (abst) 341
system,beta-adrenoceptors coupled to (abst) 335
Campylobacter pericarditis (abst)..... 228
Cancer
renal, inhibitory effect of 1a,25-dihydroxyvitamin D3... 834
Cancer chemotherapy
acute hyponatremia during forced diuresis (abst) 191
CAPD
air under diaphragm significance (abst)..... 233
an initial dialysis modality? (abst) 235
antibiotic delivery, new (abst) 231
biofilm producing peritonitis (abst) 230

CCPD, children, peritoneal membrane function (abst) .. 238
high dialysate Ca, i.p. 1,25(OH)2D3 on PTH (abst) 231
introperitoneal contrast, C-T scan (abst) 237
levels of catecholamines, plasma renin activity, PA (abst) 238
limulus lysate assay diagnose GNP (abst) 239
malignancies in (abst) 231
peritoneal transport assessment 941
peritonitis by eicosanoids (abst) 237
peritonitis, leukocyte esterase testing (abst) 234
prostaglandin-mediated loss of proteins during peritonitis 584
protein binding of cefamandole during (abst) 239
renal osteodystrophy in (abst) 237
treatment of peritonitis with vancomycin (abst) 229
Trimethoprim-sulfamethoxazole pharmacokinetics (abst) 236
zinc metabolism (abst) 234
Capillary leak syndrome
systemic edema (abst) 181
Captopril
altered renin-angiotensin-aldosterone system (abst) 257
BP without kinins (abst) 1259
enhanced renal flow study, hypertension (abst) 254
geriatric hypertensives (abst) 249
hemodynamics and BP during pregnancy (abst) 382
improves lupus nephritis in mice (abst) 277
peritoneal transport (abst) 233
prostaglandins during ARF (abst) 338
uropathy (abst) 331
vasopressin induced bladder water flow, PGE2 (abst) .. 420
Carbon dioxide
stimulates growth of proximal tubule cells (abst) 363
Carbonic anhydrase
inhibitor (abst) 379
pH in tubule (abst) 364
S3 tubule (abst) 370
Cardiac
blood membrane contact during hemodialysis (abst)... 1260
modulation of plasma, platelet vasopressin by function.. 1188
output, renal blood flow, leukotriene (abst) 379
rehabilitation after renal transplantation (abst) 1263
Cardiopulmonary, cuprophane plasma, pig 799
Cardiovascular
atrial natriuretic peptide release, artificial heart (abst) .. 389
BP control in normotensive members of hypertensive families 882
effects of atrial natriuretic peptide (abst) 348
response to hemofiltration 901
Carpal tunnel syndrome amyloid (abst) 213
Cateholamines in IRF (abst) 310
Cathepsin activity, protein (abst) 293
Catheter
covering membrane probably focus of infection (abst) .. 232
jugular vein cannulation with two silastic (abst) 778
need for swan neck tunnel peritoneal dialysis (abst).... 238
peritoneal dialysis, urokinase restores (abst) 235
silastic tenckhoff in CAPD (abst) 239
subclavian HD, complications of (abst) 226
Cation
Na,K-ATPase in kidney 13
organic, competition with transport of TEA, morphine (abst) 423
regulation of renal acid secretion in distal nephron segment 1099
Cefamandole during CAPD (abst) 239
Cell
anoxic death, nephron segment and Ca as determinants of 1172
electrical properties of collecting duct (abst) 1252
human glomerulus, lipoprotein receptor activity (abst). 1248
hypoxic injury in proximal tubule 1021
MDCK, regulation of potassium conductance in (abst). 1251
physiology of glandular kallikrein 953
T and B markers, mononuclear cell subsets 1043
T, defect, impaired immune responses in CRF 1251
Cephalosporin transport (abst) 1256
Cerebrovascular disease, stenosis (abst) 262
cGMP
atrial natriuretic factor causes, hyperfiltration (abst) ... 384
atriopeptin III on rabbit aortic smooth muscle (abst) .. 1254
ANF 258
atriopeptin III (abst) 1254
Channel, Na
solubilization of epithelial (abst) 400
Channels, K and Cl+ in membrane (abst) 399
Chelation kinetics during DFO (abst) 226
Children
hemolytic-uremic syndrome in (abst) 179, 204
immune complexes and immunoglobulins (abst) 269
Chlorhexidine, SEP (abst) 234
Chloride
acute volume expansion on tubuloglomerular feedback (abst) 388
channel in bovine kidney medullary vesicles (abst) 398
concentrations, hospital-associated hyponatremia..... 1237
corrects alkalosis without volume expansion (abst) 364
deficiency in neonates (abst) 187
depletion in alkalosis in dog (abst) 364
dietary determines NaCl-sensitive hypertension (abst).. 250
KCl loading increases absorption (abst) 411
raw foods and sodium content 262
secretion in A6 epithelia (abst) 411
secretion in shark (abst) 37
urine samples (abst) 186
volume expansion not correct alkalosis (abst) 365
Chlorpromazine, Heymann Nephritis (abst) 268
Cholera toxin
increases water permeability (abst) 417
Cholesterol metabolism in ESRD (abst) 224
Chromosome 16 and PKD (abst) 181
Chronic desferrioxamine therapy
bone aluminum intoxication S-70
Chronic liver disease
hypercalcemia, a new complication of (abst) 188
Chronic obstructive bronchiolitis, IgA 557
Chronic peritoneal dialysis
associated with progressive thrombocytosis (abst) 240
Chronic renal disease
Bright's 779
clonidine abates (abst) 327
glomerulonephritis types, prevalance in dogs 1144
Chronic renal failure
acute hyperaluminemic encephalopathy (abst) 178
alkali therapy suppresses muscle proteolysis (abst) 323
aluminum effect on parathyroid hormone secretion ... S-41
Australian aluminum and renal bone disease..... S-65
BP and renal function preservation (abst) 320
changes in bone histology after desferrioxamine treatment S-108

children, different dialysis modalities on growth (abst). . 233
elevated free copper (abst) 326
energy intake on nitrogen metabolism in nondialyzed . . 734
evolution (abst) 317
heart, secondary hyperparathyroidism (abst) 317
hematopoietic inhibitors 641
hyperlipidemia (abst) 326
immunodeficiency in early stage of (abst) 1257
impaired immune responses, T cell defect. 1209
increased oxalate (abst) 321
non-aluminum phosphate binding compound. S-120
phosphate depletion arrests progression 658
prolactin levels with MD therapy (abst) 322
PTH secretion in aluminum bone disease S-87
reduced circulating 1,25(OH)2D3 in development of (abst) 155
response to dopamine blockade (abst). 194
role of plasma aluminum in toxicity. S-91
verapamil (abst) 319
Chronic renal injury, salt (abst) 244
Chronic renal insufficiency
furosemide in, (abst). 180
protein restriction (abst). 318
Chronic serum sickness, GLN 841
Cimetidine, BBMV (abst). 420
Circadian rhythum, nephrotics (abst). 942
Circulation, remnant nephron (abst) 384
Cirrhosis
interstitial fluid in (abst) 381
liver IgA nephropathy in patients with (abst) 1258
prostaglandins in rats (abst) 343
prognostic factors (abst). 184
renal dysfunction 598
unable to increase GFR after protein loading (abst) 185
Cisplatin, ARF (abst) 312
PST, cations (abst) 306
WR-2721 against (abst). 311
Cl/OH exchange, BBV (abst). 370
Clearance
human antibody/DNA immune complexes, circulation (abst) 277
Clofibric acid, nephrectomy (abst) 324
Clonidine
chronic renal disease (abst) 327
transdermal (abst). 251
CMV antibody, IgA, transplant (abst) 277
CMV-prophylaxis after transplant (abst) 1262
Cobra venom factor anaphylatoxins (abst) 269
Collagen binding reduced. Fn-N (abst) 267
Collecting duct
apical membrane, cation conductance channels (abst) . . 393
cells, apical sodium uptake by papillary (abst) 399
electrical (abst) 1252
H-pump (abst). 369
kidney,actin-regulatory proteins locate in (abst) 413
medullary, function during medullary vasodilation (abst) 394
mesonephric, H+ secretion (abst). 376
outer medullary, electrophysiologic identification (abst) . . 400
Colloid volume
expansion on glomerular barrier 916
Compensatory renal growth, modulation. 1124
Compensatory renal typertrophy
ornithine decarboxylase activity and polyamines (abst) . 357
Complement
alternate pathway by B cell in MPGN (abst) 278
antibody-inducedmesangial cell damage (abst) 296
C5 in glomerulonephritis (abst) 274
erythrocytes inhibit (abst) 273
induced cell injury (abst) 272
Concentric ventricular hypertrophy(abst) 217
Congestive heart failure, CAVH (abst). 226
Connecting tubules
beta adrenoceptors coupled to cAMP system (abst). . . . 335
Connector, ampflex (abst) 237
Conn's syndrome
hypertension with increased 18-OH-B (abst). 1259
Contamination of aluminum
control. S-24
electrothermal determination S-28
Continuous arterio-venous hemofiltration
in newborns with ARF. 908
hemodynamic consequences of in intractable fluid (abst) 218
routine filter life of (abst). 219
Contraceptive, oral, HUS (abst) 777
Converting enzyme inhibition
effects of antihypertensive treatment. 1011
renal hemodynamic stability in hypertension (abst) 255
Copper, free, in CRF (abst). 326
Coronary angiography, RCA (abst). 309
Coronary revascularization (abst) 427
Cortex
inner, outer, brush border membrane vesicle fluidity (abst) 412
Cortical cells
extracellular acidosis on active transport (abst) 409
Cortical collecting duct
lumen, radial pH gradient in (abst) 377
Na-dependent aldosterone stimulation of (abst) 397
Cortical collecting tubule
chloride transport pathways (abst). 409
Cortical interstitial cells
sensitivity of hydronephrotic kidney to bradykinin (abst) 347
Cortical mitochondria, CyA (abst) 311
Creatinine
chronic renal failure, evolution (abst) 317
clearance, glomerular filtration surface in diabetes. 889
clearence in NIDDM (abst) 179
prognosis and treatment of membranous nephropathy . . 927
reciprocal of serum, reliable to assess change (abst) . . . 325
Crescentic glomerulonephritis (abst). 189
Crescentic proliferative GN (abst). 267
Crescents
cellular, CGn-Bowman's (abst) 266
glomerular, epithelial origin (abst). 278
identification in crescentic glomerulopathies (abst). 775
Cryoglobulinemia, Fc receptor (abst) 608
Cryoprotective dimethyl sulfoxide (abst) 431
Crystal
bone, effect of aluminum on. S-37
growth inhibitor, THP, ALB(abst). 295
growth, Ca and K, Al effects S-20
urinary calcium oxalate growth inhibitor. 829
Cuprophane dialysis membranes
generation of activated Hageman factor (abst) 210
Cuprophane-induced hypertension (abst) 227

Cyclic AMP
cellular mechanism of hormone action in the kidney 90
in dopamine receptors (abst) 345
inositol
phospholipid metabolism in mesangial cells (abst) 347
metabolism and sites of action of vitamin D..... 98
prostaglandins, alpha 2 adrenoceptors (abst)..... 346
relaxation of cultured rat mesangial cells (abst) 345
stimulated neutrophils on (abst)..... 349
Cyclophosphamide
daily administration, primary interstitial nephritis 635
membranous glomerulonephritis (abst) 274
Cyclosporin A
acid secretion in turtle (abst)..... 368
altered renal tubular cells in cytology (abst)..... 1261
anti-thymocyte globulin for treatment of rejection (abst)..... 427
blood pressure in SHR (abst)..... 251
blood transfusions and, in transplantation (abst)..... 435
cadaveric renal transplantation (abst) 612
calcium channel blocker inhibition (abst) 307
cell proliferation in renal interstitium (abst) 303
chronic adaptation to unilateral nephrectomy (abst).... 426
chronically instrumented dogs (abst)..... 1262
conversion to Aza thioprine in renal allografts (abst).. 1261
corpulence index in dosage after transplantation (abst).. 1262
decrease in GFR is mediated by renal blood flow (abst).. 431
deposits in renal allograft (abst)..... 612
erythromycin drug interaction (abst)..... 438
exacerbates adriamycin-induced proteinuria (abst)..... 434
glomerulonephritis 182
induced hyperkalemia (abst) 435
inhibits trypanosomiasis-induced nephrotic syndrome (abst)..... 36
lipid peroxidation in cortical mitochondria (abst)..... 311
lymphocyte activation cascade 613
nephrotoxicity (abst) 303
nephrotoxicity in rat (abst)..... 304
nephrotoxicity, intraluminal obstruction (abst)..... 312
nephrotoxity in Wistar rat (abst) 1260
nephrotoxicity, urinary thromboxane (abst) 304
peripheral lymphocytes (abst) 1261
remission of NS (abst) 206
rescue of rejecting transplant (abst)..... 426
rheumatoid arthritis 1180
serum urate level in transplantation (abst) 426
sodium reabsorption (abst)..... 304
stable renal transplant recipients (abst)..... 437
systemic lupus erythematosus syndrome (abst) 294
value of allograft biopsy in (abst) 438
vasoconstriction in transplant recipients (abst)..... 428
Cyst
accelerated renal, development in germ-free rats 1116
infection in ADPKD (abst)..... 203
volume reduction in PKD (abst) 179
Cystic fibrosis
hospital-associated hyponatremia..... 1237
Cystine transport (abst)..... 350
Cystinuric, anti, and glutamine (abst)..... 192
Cystopathy, transplantation (abst)..... 429
Cytology
cyclosporine A altered renal tubular cells (abst)..... 1261
Cytomegalovirus glomerulopathy 725
Cytometalovirus infection
mononuclear subset monitor (abst) 944
Cytoplasmic edema, injury in S3 tubule 1033
Cytosolic calcium and PTH (abst)..... 175
Cytotoxic T lymphocytes, MHC (abst)..... 281
C3 deposition causes hematuria (abst) 274
C3D deposits as marker in GLN (abst)..... 1249

D valine medium, assay (abst)..... 353
D, vitamin
metabolism and site in the kidney..... 98
Deconditioned germ-free rats, cyst 1116
Deferoxamine therapy
Al removal (abst) 190
in CAPD, HD, HF (abst)..... 171
kinetics (abst)..... 226
Al removal (abst) 190
Deformylase activity, renal (abst) 361
Degradation of insulin (abst) 355
Desferrioxamine
changes in bone histology after treatment S-108
clearance of aluminum by hemodialysis..... S-100
diagnosis of aluminum bone disease S-96
dialysis encephalopathy S-104
Dexamethasone, sphingolipids (abst) 334
Dextran transfer, peritoneum (abst) 232
Diabetes
calcium and insulin (abst)..... 314
compensatory renal growth, modulation by Ca PTH, 1,25(OH)2D3 1124
creatinine clearence in non-insulin-dependent (abst).... 179
cystopathy and successful kidney transplantation (abst) .. 429
decreased gentamicin renal cortical uptake (abst)..... 297
degradation of basement membrane (abst) 1250
diet in type I (abst)..... 195
elevated Al in CRF patients (abst)..... 176
experimental, enhanced glomerular permeability (abst) . 264
experimental, hypertension in (abst)..... 261
features in insulin-requiring (abst)..... 611
GBM anionic sites, albumin excretion (abst) 294
glomerular injury (abst) 328
glucagon and PTH on juxtamedullary nephrons 807
glucose control in (abst)..... 196
glycemia, protein modulate GFR and albuminuria in (abst)..... 389
hemodialyzed, glycosylation not sole reason, low PTH (abst)..... 210
immunological
indomethacin on glomerular hemodynamics 490
insipidus and AVP (abst)..... 178
insulin therapy normalizes (abst)..... 316
less PTH gland response to hypocalcemia in patients (abst)..... 159
mellitus, foot process width and filtration slit (abst).... 273
nephropathy, early uremic pericarditis (abst) 186
nephropathy, hyperphagia (abst)..... 324
nephropathy, insulin therapy (abst)..... 325
NMR measures sodium in proximal tubules (abst)..... 356
non-insulin dependent, elevated blood pressure (abst).. 183
parenchymal histological changes in ureteric ligation (abst)..... 296
phosphate depletion, proteinuria (abst)..... 313
piroxicam (abst) 611
prostaglandins, hyperfiltration (abst)..... 332
proteinuria of type I and II influenced by BP (abst).... 189
reduced glomerular antiotensin II receptor density (abst)..... 327

role of dietary protein (abst) ... 289
streptozotocin-induced, HgCL2 induced ATN (abst) ... 308
streptozotocin-induced, tubular Na-K-ATPase (abst) ... 410
Tamm-Horsfall glycoprotein biochemistry in (abst) ... 1257
type I, glomerular filtration surface ... 889
Diagnosis of renal disease
monoclonal antibodies in ... 142
Dialysate
Al reduction in CAPD, Mg hydroxide, low Mg (abst) .. 232
calcium levels on BP during HD (abst) ... 225
detrimental effect to increase bicarbonate (abst) ... 222
release of interleukin-1 during HD ... 221
volume measurement (abst) ... 236
volume on peritoneal mass tranfer (abst) ... 235
Dialysis
acetate vs. bicarbonate in ventilated patients (abst) ... 944
Al on mineralization during matrix-induced bone development ... 1038
aluminum metabolism ... S-8
aluminum removal by microencapsulated carbon (abst) . 226
aluminum-induced encephalopathy, blood brain barrier (abst) ... 610
anemia in patients with Al overload, desferoxamine (abst) ... 210
ARF in newborns, treatment by CAVH ... 908
Austrialian aluminum and renal bone disease ... S-65
bicarbonate, predicting acetate intolerance (abst) ... 215
bowel infarction common in (abst) ... 212
campylobacter pericarditis with effusion (abst) ... 228
CAPD and initial modality (abst) ... 235
cardiovascular response to hemofiltration ... 901
children, different modalities effect on growth (abst) ... 233
children, features of renal bone disease (abst) ... 236
concentric ventricular hypertrophy (abst) ... 217
dementia, phosphate binding gels ... 1131
diagnosis of aluminum bone disease ... S-96
encephalopathy ... S-53
encephalopathy, non-aluminum phosphate binding compound ... S-120
encephalopathy, role of desferrioxamine in treatment. S-104
euthanasia, stopping chronic (abst) ... 220
extreme hyperglycemia in (abst) ... 200
hemofiltration without substitution fluid (abst) ... 610
high vascular recirculation rates cause increase time (abst) ... 219
home, removal of aluminum ... 209
impoverished centers, aluminum contamination of water ... S-58
membranes, activation of Hageman factor (abst) ... 224
membranes, polymorphonuclear neutrophils (abst) ... 609
osteodystrophy, aluminum related bone disease ... S-80
osteomalacia, natural course of ... S-74
peritoneal, outbreak of group IV bacillus (abst) ... 230
peritoneal, ultrafiltration maximum (abst) ... 235
plasma transferrin after DFO, with, without Al intox (abst) ... 225
platelet aggregation studies during (abst) ... 221
primary renal transplantation before (abst) ... 430
prostaglandin-mediated loss of proteins during peritonitis ... 584
risk of peritonitis in acute care hospital (abst) ... 238
role of plasma aluminum in toxicity ... S-91
routine short (abst) ... 210
schedule, nightly (abst) ... 233
serum aluminum levels in patients (abst) ... 165
transcapillary colloid osmotic gradient, body fluid volumes ... 895
transplantation of ESRD from hypernephroma (abst) ... 433
where are peritoneal membranes? (abst) ... 236
C102 a non-noxious disinfectant (abst) ... 227
Dialyzer
C102, neutropenia (abst) ... 221
formaldehyde kinetics and bacteriology (abst) ... 213
hollow fiber, variations (abst) ... 222
membranes, removal of Al (abst) ... 215
plate vs. hollow-fiber (abst) ... 212
therapy for rapid high efficiency hemodialysis (abst) ... 215
Diaphragm, air under, CAPD (abst) ... 233
Diatrizoate
on renal membranes (abst) ... 302
precitates membrane (abst) ... 312
Dibutyryl cAMP, phosphate (abst) ... 155
Dicyclohexylcarbodiimide (abst) ... 369
Diet
Ca and K on bone calcium, phosphorous and density (abst) ... 173
Ca2+ in hypertension (abst) ... 166
energy intake on nitrogen metabolism in CRF ... 734
fasting, renal net acid excretion determines calcium ... 743
phosphate manipulation (abst) ... 162
phosphorus-induced changes in 1,25(OH)2D3 (abst) ... 169
potassium as determinant of sodium excretion (abst) ... 182
protein limitation in type I diabetes (abst) ... 195
protein restriction in diabetic nephropathy (abst) ... 209
risk, benefit of low-protein, essential amino acid ... 995
varying protein in hypertension ... 520
varying protein levels, tubuloglomerular feedback ... 520
Diffuse proliferative lupus nephritis
renal histology correlates with outcome in children ... 1066
Digitalis-like factors, excretion (abst) ... 249
Digoxin antibodies, BP, SHR (abst) ... 252
Diltiazem monotherapy (abst) ... 259
Diluting segment, Bartter's Syn (abst) ... 416
Dipeptides, transport, metabolism (abst) ... 1234
Dipyridamole
and vasodilation (abst) ... 184
ischemic ARF (abst) ... 305
Disease, chronic renal, Bright's ... 779
Disinfectant in dialyzer (abst) ... 227
Distal nephron segments
regulation of renal acid secretion ... 1099
rubidium (abst) ... 391
Diuresis
atriopeptin II induced, dopamine, a2-adrenoceptor (abst) ... 395
PK of bicarbonate at low, high concentrations (abst) ... 377
forced (abst) ... 191
Diuretic
abnormal renal hemodynamics in rat (abst) ... 257
effects of on mineral contents of kidney and femur (abst) ... 160
hyponatremia, new formula for correction of (abst) ... 203
kallikrein-kininogen-kinin system (abst) ... 330
prolonged furosemide administration (abst) ... 208
torasemide (abst) ... 1254
Docpivalate treated, intercalated (abst) ... 372
Donor
living non-related kidney, for transplantation (abst) ... 430
long-term blood pressure and renal function in kidney . 1072

Dopamine
atrial natriuretic peptide (abst). 336
cAMP accumulation (abst). 345
proximal convoluted tubule NaKATPase activity (abst) . . 390
receptors, hypertensive (abst) 245
renal hemodynamics during infusion of, and amino acids 870
renal-adrenal responses to blockade of (abst) 194
2 receptor in canine kidney (abst) 385
receptors, hypertensive (abst) 245
1 agonist, hemodynamics (abst). 333
Doppler
measurement in grafts (abst) 217
method, noninvasive for renal blood flow measurement (abst) 379
Drug abusers, hemodialysis (abst). 223
Drug sieving coefficients, CAVH (abst) 214
Dyspnea, lactic acidosis. 752

Early renal failure, phosphate (abst) 609
Edema
prognosis and treatment of membranous nephropathy . . 927
CAVH for heart failure (abst) 226
Efferent vasodilation
antiproteinuric effect of dipyridamole (abst) 184
Eicosanoids
Heymann Nephritis (abst) 344
permeability in CAPD (abst) 237
Eicosapentaenoic acid (abst) 311, 325
Elalapril, parenchymal HT (abst) 256
Electrical charge
antibody, antigen, glomerular capillary wall charge 649
Electrical properties, duct (abst) 1234
Electrodense deposit in SLE (abst). 273
Electrolyte
concentrations, renal cortex under K adaptation (abst). 1203
dietary, disociation of renin and aldosterone (abst) 410
hospital-associated hyponatremia 21
humoral control of water and, excretion 1152
Electron microscopy
light chain deposition disease defined (abst) 288
Electrophysiological, renal cells (abst) 391
Electrophysiology amphiuma CT (abst) 398
Electrothermal determination of Al. S-28
Enalapril blocks albinuria (abst) 320
Enalaprilat hemodynamics (abst). 243
Enalaprilic acid, renal response (abst) 944
Enalpril, Bartter syndrome (abst) 190
Encephalopathy
aluminum-induced, blood brain barrier (abst) 610
associated with aluminum accumulation S-70
hyponatremia (abst) 177
role of plasma aluminum in toxicity. S-91
End stage renal disease
atrial natriuretic peptide in plasma of children (abst) . . 1254
beta 2 adrenoceptor stimulated potassium (abst) 324
cadaveric renal transplantation (abst) 942
childhood membranoproliferative glomerulonephritis . . 1077
children, caloric intake to erthrocyte insulin (abst). 177
children, successful hemofiltration (abst) 221
cholesterol metabolism (abst). 224
cholesterol metabolism in (abst) 224
comparative effects of Al, CaCO3, K balance (abst) . . . 219
creatine kinase and lactate dehydrogenase isoenzymes (abst) 212
desferrioxamine in dialysis encephalopathy treatment . . S-104
diagnosis of myocardial infarction (abst) 185
effects of age and, on lymphocyte mitogenic response (abst) 229
erythropoietin levels in children, CAPD/CCPD vs. HD (abst) 229
features of hypothyroidism (abst) 192
hepatitis B viral infection in (abst). 195
hyperlipasemia and hyperamylasemia (abst) 217
hypertensive in large population (abst) 197
individual prognosis of IgA nephropathy. 549
infants managed with CPD and NG (abst). 230
left ventricular failure in (abst) 220
less PTH gland response to hypocalcemia in diabetics (abst) 159
sodium transport in red blood cells of dialyzed. 1197
stress program for patients (abst) 201
treatment incidence rates by state (abst). 201
Endocytosis, endosomes (abst) 420
receptor-mediated (abst). 254
Endothelial
acetylcholine (abst). 256
cells release platelet-activating factor 469
cell binding (abst) 264
in acetate (abst) 215
microvascular, IL-1 (abst) 275
Endotoxemic ARF (abst). 306
Endotoxin induction, interleukin (abst). 219
Energy metabolism, NH4+ (abst). 352
Enkephalin degrading enzyme (abst). 271
Enzyme inhibitor
renal response to (abst) 944
Enzymes and aluminum S-12
Enzymes, serine proteases, kallikrein. 953
Eosinophilia, peritoneal (abst). 231
Eosinophiluria, detection of (abst) 198
Epithelia
A6, Cl secretion (abst) 411
cultured renal 49
cyst-derived PKD (abst). 323
fusion, study cell mechanisms of ion transport (abst). . . 404
hyperplastic in ADPKD (abst) 276
leaky, mucosal calcium removal on (abst). 422
membrane properties of fused (abst) 1251
permeability of inner medullary collecting duct (abst) . . 418
12-HETE (abst) 335
Epitope, antibodies for Tamm-Horsfall. 971
Epitrochlearis muscle, insulin (abst) 316
Erosive dialysis arthropathy (abst) 229
Erythrocyte
clearing mechanism (abst) 277
electrophroetic analysis of protein composition (abst) . . 242
morphology in urine (abst) 1258
Erythromycin
CyA drug interaction (abst) 438
Erythropoiesis
aluminum (abst) 610
Erythropoietin production (abst) 167
Ethacrynic acid
hypernatremia inhibits NaHCO3 reabsorption 820
Ethane, lipid peroxidation (abst) 308
ETO antibody response (abst). 266
Euthanasia, passive, dialysis (abst). 220
Exchanger
basolateral, in volume (abst) 398

Na/H in hypertensive (abst) . . . 245
Excretion
artifactual endogenous digitalis-like factors (abst) . . . 249
biliary conjugated small molecular wt compounds (abst) . . . 317
humoral control of water and electrolyte during restriction . . . 1152
of Pi by PFA (abst) . . . 174
potassium, chronic K loading in man (abst) . . . 1251
Exercise
impairment a characteristic of HD (abst) . . . 223
post-transplantation (abst) . . . 434
protein excretion (abst) . . . 191
Exocytosis, pH, H+ ATPase (abst) . . . 378
Extracellular matrix
modulates mesangial cell behavior (abst) . . . 275
Eye chamber, transplant of kidney cells . . . 1234

Failure, renal
loop diuretic muzalimine in hypertensive (abst) . . . 1255
protection form acute ischemic (abst) . . . 1254
risk, benefit of low protein-essential amino acid diet . . . 995
with nifedipine (abst) . . . 778
Fasting
urinary calcium excretion, renal net acid excretion . . . 743
Fc receptor in cryoglobulinemia (abst) . . . 608
Feeding, chronic alternate day (abst) . . . 319
Fenoldopam, protein feeding (abst) . . . 313
Ferritins, polymeric in GBM (abst) . . . 1248
Fibronectin
concentration, CAPD (abst) . . . 232
reduced binding (abst) . . . 267
Filtration
renal reserve in pregnant rats, acute glycine (abst) . . . 380
Filtration fraction
infusion of dopamine, amino acids on renal hemodynamics . . . 870
superficial nephron . . . 814
Filtration rate, GLN (abst) . . . 322
Fluorescent markers, ADH bladder (abst) . . . 416
Fluorocitrate, metabolism in dog (abst) . . . 353
Fluroescent probe, HCO3 (abst) . . . 371
Focal glomerular sclerosis
converting enzyme inhibition . . . 265
(abst) . . . 200
Focal segmental glomerulosclerosis
(abst) . . . 275
global (abst) . . . 179
prognosis of in adults (abst) . . . 193
Formate, NaCl transport (abst) . . . 407
Fragmentation, injury in S3 tubule . . . 1033
Free radical
damage in ischemic ARF, hypothyroidism . . . 1162
Fuels
metabolic along the nephron, mechanisms of interaction . . . 41
Function, renal
ionized calcium modulates (abst) . . . 381
Fura 2, Quin 2 measurement Ca2+ (abst) . . . 399
FURA-2, Ca measurement (abst) . . . 335
Furosemide
K+ efflux in proximal tubule (abst) . . . 396
natriuresis, atrial natriuretic factor (abst) . . . 398
natriuretic response during prolonged administration (abst) . . . 208
nephron response (abst) . . . 180
PGE2 (abst) . . . 337

Gap junctions, LLC PK1 (abst) . . . 404
Gasoline injestion, renal injury (abst) . . . 304
GC/MS isotope dilution, in assay (abst) . . . 202
Gelifundol, polyelectrolyte (abst) . . . 230
Genetic hypertension, suckling, BP(abst) . . . 241
Genetic variability to Ca (abst) . . . 247
Genomic mechanism
vitamin D and the kidney . . . 98
Gentamicin
bacteremia nephrotoxic synergy (abst) . . . 313
calcium abnormalities in renal proximal tubules (abst) . . . 298
decreased renal cortical uptake in diabetic (abst) . . . 297
phosphatidylinositol cascade (abst) . . . 308
phospholipidosis (abst) . . . 311
Geochemistry of aluminum . . . S-3
Germ-free rats, cyst development . . . 1116
GFR, cirrotics no increase (abst) . . . 185
Gibbsite
phosphate binder gels balance adsorption, Al toxicity . 1131
Glandular kallikrein . . . 120
Glomerular
action leukotriene D4 (abst) . . . 328
AII density reduced (abst) . . . 327
barrier colloid volume expansion . . . 916
capillary wall, antibody, antigen charge interactions . . . 649
crescents, epithelial origin (abst) . . . 278
function, protein intake (abst) . . . 325
hemodynamic alterations in Heymann Nephritis (abst) . 383
morphologic changes, proteinuria-role of oxygen free radical . . . 478
Glomerular basement membrane
degradation by PMA-stimulated neutrophils (abst) . . . 291
deoposition of cationised ferritins in (abst) . . . 1248
nephrotic plasma increases proteinuria (abst) . . . 295
Glomerular capillary hypertention (abst) . . . 244
Glomerular cells
culture and characterization of mesangial (abst) . . . 944
Glomerular charge barrier . . . 270
Glomerular disease
progressive, adriamycin-induced nephropathy . . . 502
Glomerular
complement depletion in passive Heymann Nephritis (abst) . . . 380
dynamics, PG2 and PGI2 (abst) . . . 334
thyroid (abst) . . . 318
epithelial cell, DM (abst) . . . 273
epithelial cells (abst) . . . 277
epithelial, cloning (abst) . . . 279
epithelium murine Ia alloantigen (abst) . . . 294
lesions in LGN (abst) . . . 196
mesangial cells, thromboxane A2 (abst) . . . 340
permeability, experimental diabetic nephropathy (abst) . 264
permeability, MVE-2 nephropathy (abst) . . . 265
polyanion complex (abst) . . . 285
prostaglandins, thromboxane synthesis in hypertension (abst) . . . 610
prostanoid synthesis (abst) . . . 339
sclerosis, focal segmental, prognosis in adults (abst) . . . 193
visceral epithelial cells (abst) . . . 339
Glomerular filtration rate
aspirin prevents reduced (abst) . . . 323
atrial natriuretic factor increases (abst) . . . 332

atrial natriuretic factor induce natriuresis (abst) 402
biology of renal hypertrophy 619
cAMP excretion, adenosine analogs effect on (abst). ... 358
glycemia and dietary protein modulate (abst) 389
hemodynamics during infusion of amino acids, dopamine. 870
infusion of amino acid, dopamine on renal hemodynamics 870
protein loading on remnant rat kidney (abst) 324
surface in type I diabetes mellitus 889
synthetic atrial natriuretic peptide (abst) 393
transplant patients receiving cyclosporine (abst). 428
tubuloglomerular feedback control of (abst) 388
tubuloglomerular feedback during volume expansion (abst) 1253
utility of 125I iothalamate clearance as marker (abst). .. 188
Glomerular injury
antihypertensive therapy, dietary protein (abst) 319
prevention in diabetes mellitus (abst) 328
Glomeruli
mesangial, renin (abst) 331
nephitic, cytotoxic (abst) 283
Glomerulonephrides
non immunological mechanisms in progressions (abst). 1250
Glomerulonephritis
anti-GBM, auto-anti-idiotypic antibodies in (abst) 290
autoimmune, induced my mercuric chloride (abst) 608
autoregulate filtration rate (abst) 322
canine chronic renal disease, prevalence and types ... 1144
childhood membranoproliferative. 1077
children, acute sporadic poststreptococcal (abst) 178
crescentic (abst) 189
cyclosporine treatment of patients with (abst) 182
C3d deposits as marker of complement activation (abst) 1249
C5 complement (abst). 274
experimental autoimmune, T cells (abst). 269
idiopathic membranous, IgG subclasses (abst) 287
IgA synthesis by lymphocytes from patients, their relatives 1229
IgA, antigliadin antibodies in (abst). 776
immune complex, role of lymphocytes (abst) 1249
immune complex, thromboxane B2 formation
immune-complex-mediated, scanning electron microscopy (abst) 282
in ANF negative SLE with low complement (abst) ... 1256
malarial (abst). 280
membranoproliferative, anti-idiotypic to C3NEF (abst) . 292
membranoproliferative in renal transplants 429
membranoproliferative, alternate complement pathway (abst) 278
minimal change, focal sclerosis, MHC antigens (abst) .. 286
minimal change, HLA-DR7 and MT3 association
monoclonal anti-rat-thymocyte antibodies (abst). 945
myeloperoxidase-hydrogen peroxide-halide system (abst) 278
necrotizing, protease inhibitor amelioration (abst) 275
neutrophil-mediated (abst) 271
proliferative, immune deposits in AIDS (abst) 272
proliferative, T cells in crescentic (abst) 267
pulse methylprednisolone therapy (abst) 180
rapidly progressive, long term follow-up (abst). 181
role of lymphocytes (abst) 292
subtypes of acute postinfectious (abst) 1250
transition from proliferative to membranous, serum sickness 841
1- and 12-hydroperoxyeicosatetraenoic acid (abst) 339
Glomerulopathy
crescentic, identification (abst) 775
cytomegalovirus, lesions 725
giant fibrillar deposits in renal transplants (abst). 1262
proliferative, analysis of extra-cellular granular (abst) .. 775
Glomerulosclerosis
focal and segmental study (abst) 275
focal segmental, early lesion (abst) 437
FGS (abst) 179
focal (abst) 200
focal
segmental, genetic factors 789
focal, tubuloglomerular feedback of rats on varying protein 520
progressive, high dietary protein in dogs. 511
proteinuria, prevention of by hypertension (abst). 281
transgenic mouse model (abst). 283
Glomerulus
degradation of diabetic, nondiabetic basement membrane(abst). 1250
immunocytochemical localization of renin and kallikrein 965
prognosis and treatment of membranous nephropathy .. 927
Glucagon
PTH effect on loop of Henle juxtamedullary nephrons. . 807
tubular effects in man (abst). 413
Glucocorticoid
cytosolic (abst) 352
metabolites effect on membrane transport (abst) 358
pressor response (abst). 246
sodium (abst) 330
transcription of interleukin 1-encoding RNA (abst) 431
Gluconeogenesis
ammoniagenesis, 13C NMR and 15N GC-MS (abst). 357
LLC-PK1 cells (abst) 354
nerve stimulation (abst) 349
phosphinositide metabolism regulation (abst) 353
Glucose
metabolism in renal tubular function. 54
reabsorption increased in POK (abst) 330
transporters in intestine (abst) 423
Glutamine
anticystinuric effect (abst) 192
homeostasis in metabolic acidosis (abst) 365
nitrogen (abst). 350
plasma concentration, ranal ammoniagenesis (abst) 351
regulation of metabolism in dog kidney. 68
uptake, effect of acivicin (abst) 359
Glutathione
depletors, proximal tubules 858
in proximal tubule (abst) 310
Glycerophosphorylcholine (abst) 1234
Glycine
infustion, renal reserve in pregnant rats (abst) 380
Glycolysis
phorbol myristate acetate stimulates (abst) 338
Glycoprotein
ALDO, in toad (abst) 351
isolation of inhibitor from calcium oxalate stones (abst) .. 167
laminin, antibodies to in preeclampsia. 1050
cellular physiology of glandular kallikrein 953
Glycosylation, low PTH in diabetic(abst) 210

Gold-insulin
luminal uptake and transport . . . 983
Goodpasture antigen in Alport's (abst) . . . 202
Goodpasture syndrome
autoantibody subclass restriction (abst) . . . 287
post-mycoplasma-pneumonia infection (abst) . . . 1256
Graft survival, risk factors (abst) . . . 434
Gram negative peritonitis, assay (abst) . . . 239
Granular material, PGN (abst) . . . 775
Granulomatosis, Wegener's (abst) . . . 185
Gravity, urine specific, neonates (abst) . . . 177
Growth
biology of renal hypertrophy . . . 619
compensatory renal, modulation by Ca PTH and 1,25-(OH)2D3 . . . 1124
Guanabenz
natriuretic antihypertensive drug . . . 1203
Guanine nucleotide, protein (abst) . . . 333

H-pump, electrochemical potential (abst) . . . 369
H+ATPASE reconstitution (abst) . . . 366
Hageman factor
activation (abst) . . . 224
by cuprophane dialysis membrane . . . 210
Hansel's staining technique (abst) . . . 198
Heart
artificial, ANP levels (abst) . . . 192
disease, phlebotomies (abst) . . . 776
failure, modulation of vasopressin by cardiac function . 1188
Hematologic malignancies (abst) . . . 187
Hematopoiesis
effect of aluminum on . . . S-45
transplantation (abst) . . . 427
Hematuria
childhood membranoproliferative glomerulonephritis . . 1077
hypercalciuria in children with (abst) . . . 204
red cell morphology (abst) . . . 201
states, lysis (abst) . . . 183
Hemodiafiltration, high flux, 1 yr(abst) . . . 227
Hemodialysis
acetate intolerance during (abst) . . . 223
acidosis and anion gap prior to (abst) . . . 197
age and HD effect lymphocyte mitogenic response (abst) . . . 229
aluminum and porphyrin metabolism in (abst) . . . 211
aluminum removal by (abst) . . . 215
aluminum toxicity in prolonged (abst) . . . 211
amyloidosis in population of 250,000 (abst) . . . 777
anabolism in subset of "nourished" (abst) . . . 209
anemia in long-term (abst) . . . 214
blood from arterial lines for gas analysis (abst) . . . 943
blood membrane contact, circulation (abst) . . . 1260
body composition changes in (abst) . . . 222
changing patterna and outcome of ARF . . . 176
clearance of aluminum, desferrioxamine . . . S-100
clinical, biological features of Al-related bone disease . S-80
dialysate calcium levels on BP (abst) . . . 225
end stage lupus nephritis, poor prognosis (abst) . . . 183
exercise impairment characteristic (abst) . . . 223
hematopoiesis, effect of aluminum on . . . S-45
hematopoietic inhibitors in chronic renal failure . . . 641
hepatitis B antigenemia in (abst) . . . 216
hepatitis B vaccination, seroconversion (abst) . . . 1260
high bicarbonate dialysate, acid-base, respiratory (abst) . . 220
hypertriglyceridemia factors (abst) . . . 327
i.v. drug abusers do well (abst) . . . 223
impaired immune responses in CRF, T cell defect 1209
influence of membrane biocompatibility (abst) . . . 225
interleukin 1 in allergic reactions during (abst) . . . 608
lactate/acetate buffer base cocktail for (abst) . . . 220
leaching of plasticizer from PVC tubing in (abst) . . . 217
leukocyte C5a receptor modulation (abst) . . . 281
limulus amebocyte lysate reactive material (abst) . . . 211
lipid and lipoprotein metabolism regulation (abst) . . . 222
luteinizing hormone in men on maintenance (abst) . . . 225
lymphocyte ATP (abst) . . . 327
maintenance, mortality risk (abst) . . . 228
membranes, comparative clearances (abst) . . . 228
method for measuring aluminum . . . S-24
modified, effect of on myocardial function, Ca level (abst) . . . 212
non-invasive Doppler measurement of flow (abst) . . . 217
osteodystrophy, disability and bone Al in patients (abst) . . . 168
osteomalacia, aluminum-induced . . . S-17
PAVP respond to decline in osmolality during (abst) . . . 203
rapid high efficiency therapy (abst) . . . 215
release of interleukin-1 during (abst) . . . 221
role of plasma aluminum in toxicity . . . S-91
routine short (abst) . . . 210
silastic catheters, internal jugular vein cannulation (abst) . . . 778
stragegies to reduce hypotension in unstable (abst) 224
subclavian cathethers, complications (abst) . . . 226
transcapillary colloid osmotic gradient, renal failure . . . 895
trends of azotemia after chronic (abst) . . . 224
uremic symptoms at start (abst) . . . 176
vitamin K disorders induce vascular calcification (abst) . 213
vs. CAPD/CCPD in children, erythropoietin levels (abst) . . . 229
99mTc-methylene diphosphonate bone scan in osteo-dystrophy . . . 1058
Hemodynamics
abnormal renal, pressure diruesis response in rat (abst) . 257
consequences of CAVH (abst) . . . 218
glomerular injury, preglomerular resistance in hyper-tension . . . 849
intermittant feeding (abst) . . . 319
natriuresis induced by dopamine-1 agonist (abst) . . . 333
renal, during infusion of amino acids and dopamine 870
Hemofilter, polysulfone (abst) . . . 216
Hemofiltration
arterio-venous, ARF in newborns . . . 908
ESRD children (abst) . . . 221
heterogeneity of cardiovascular response to . . . 901
without substitution fluid (abst) . . . 610
Hemoglobin, bovine on renal (abst) . . . 301
Hemolytic uremic syndrome (abst) . . . 204
Hemoperfusion
hemodialysis, effective in methotrexate overdose (abst) . . 216
hepato-renal syndrome managed by CAVH (abst) . . . 216
Hemophilia, lactic acidosis . . . 752
Hemorrhage, sulindac sulfide in plasma . . . 484
Heparin sulfate proteoglycans (abst) . . . 283
Heparin in AN (abst) . . . 273
Hepatic
congestion mechanism of altered renal function (abst) . . 385
dysfunction, transplant (abst) . . . 438
encephalopathy . . . 598
GLN homeostasis (abst) . . . 370

nephropathy (abst) 285
veno-occlusive disease (abst) 435
Hepatitis
B in ESRD patients (abst) 195
chronic B antigememia in HD (abst) 216
seroconversion rate in hemodialysis, zinc substitution(abst) 1260
Hepato-renal syndrome, CAVH (abst) 216
Hereditary
regionalization in IgA nephropathy (abst) 209
Heroin abuser, amyloidosis in (abst) 187
Herpes virus, CMV 725
Hexose monophosphate shunt (abst) 338
Heymann nephritis
antigen antibody interactions (abst) 608
chlorpromazine inhibits antigens (abst) 268
clone of glomerular visceral epithelial cells (abst) 279
cloning of glomerular visceral epithelial cells (abst) 279
glomerular hemodynamic alterations (abst) 383
glomerular hemodynamics, complement depletion (abst) 380
inhibits subepithelial immune deposit formation (abst) .. 264
nephritogenicity of 70KD subunit (abst) 291
newborn, transplacental transfer of autoantibodies (abst) 284
protein modulates GFR of eicosanoids (abst) 344
subepithelial electron dense immune deposit (abst) 269
two antigen-antibody systems (abst) 263
60kDa duplet polypeptide, antigenic determinant (abst) . 279
High flux hemodiafiltration, 1 yr (abst) 227
Histidine, prostaglandin (abst) 331
HLA-DR antigens
renal allograft rejection (abst) 944
HLA-DR7, MT3 association in MCGN (abst) 1249
Hormone
acute effects of ANF in man (abst) 1253
cellular mechanism in the kidney 90
humoral control of water and electrolyte excretion ... 1152
metabolic adaptations in renal disease 80
modulation by verapamil 863
systems and kallikrein-kinin system 120
vasoactive to sepsis (abst) 300
1,25-dihydroxyvitamin D3 step in action of (abst) 156
Hyalinosis, focal-segmental (abst) 197
genetic factors in FGS 789
Hydrochlorothiazide, CaSF (abst) 775
Hydrogen
ion secretion in distal nephron segments 1099
ion (H+) secretion by mesonephric collecting duct (abst) 376
Hydrogen peroxide
myeloperoxidase, -halide system (abst) 278
PGE2 (abst) 291
Hydronephrosis, hypertension (abst) 261
Hydroxyapatite
aluminum effect on calcium phosphate precipation S-20
Hydroxylase complex, PTH (abst) 171
Hymphocytes, transferrin receptor (abst) 294
Hyperactivity, B cell in Iga nephropathy 718
Hyperaluminemic encephalopathy (abst) 178
Hypercalcemia
aluminum related bone disease S-80
chronic liver disease (abst) 188
effect on urinary concentrating ability (abst) 423
hypertension, PTH (abst) 248
impairment of phosphate reabsorption in tubule (abst) .. 163
role of loop segment in urinary concentrating defect of . 977
Hypercalciuria
in children (abst) 204
prolactin excess (abst) 157
tubulopathy in nephrolithiasis 563
urinary calcium and Ca intake during calcitriol 578
Hyperchloremic metabolic acidosis
unine anion gap valuable diagnostic tool 188
Hyperfiltration
diet induced, glomerular vasodialtory prostaglandins (abst) 343
glomerular filtration surface in type I diabetes 889
indomethacin on protein induced glomerular (abst) 942
infusion of amino acids, dopamine on renal hemodynamics 870
Hyperglycemia
in dialysis (abst) 200
induces Na and K retention (abst) 417
macula densa feedback (abst) 389
Hyperkalemia
cyclosporine Ac-induced (abst) 435
Hyperlipidemia, CRF (abst) 326
Hyperlipimia, albuminuria (abst) 193
Hypernatremia
hypovolemic humoral control of H2O, electrolyte excretion 1152
inhibits NaHCO3 reabsorption 820
in elderly (abst) 204
Hyperoncotic albumin, AII to ANP (abst) 340
Hyperosmolarity
phorbol esters on cation fluxes in mTALH (abst) 395
Hyperparathyroidism
biogenesis (abst) 166
in early CRF (abst) 155
post-transplant treatment with APD biophosphonate (abst) 941
renal mass major determinant of (abst) 199
secondary, natural course of dialysis osteomalacia S-74
secondary (abst) 164
treatment with APD, new biphosphonate (abst) 1266
tubulopathy in nephrolithiasis 563
uremia, calcium carbonate controls S-14
Hyperperfusion, high protein diet in dog 511
Hyperphagia, diabetic (abst) 324
Hyperphosphatemia
calcium carbonate Al-free agent for control in uremia .. S-114
(abst) 174
Hyperpolarization, Ca loss (abst) 393
Hypersensitivity, delayed (abst) 280
Hypertensinogen 19-OH, 19-NOR (abst) 242
Hypertension
abnormal vitamin D in SHR (abst) 247
ACE-inhibition (abst) 945
adult-onset minimal change nephrotic syndrome 1215
ANF and renal kallikrein-kinin systems (abst) 1254
aortic coarctation, renal function (abst) 258
arresting progressive renal disease, drugs (abst) 314
atenolol decreases renal blood flow in (abst) 205
atrial natriuretic factor in salt-sensitive (abst) 334
arresting progressive renal disease, drugs (abst) 314
bone density (abst) 205
BP control in normotensive members of hypertensive familes 882
calcium antagonists, renal and metabolic effects (abst) . 241
calcium channel abnormality (abst) 259

calcium, increased intestinal and renal in (abst) 244
calcium, stress in (abst) 247
calcium supplementation, effect in aorta of (abst) 242
captopril-enhanced renal flow study (abst) 254
cell membrane Na/H exchanger in spontaneously (abst) .. 245
converting enzyme inhibition in (abst) 255
dietary calcium supplementation (abst) 241
effects of antihypertensive treatment 1011
emergancy, nipride in (abst) .....
emergancy, nipride in (abst) 243
end-stage renal disease in large population (abst) 197
essential, treated with diltiazem improves (abst) 259
experimental diabetes in rat (abst) 261
genetic factors in focal segmental glomerulosclerosis ... 789
glomerular injury, preglomerular resistance in 849
glomerular prostaglandins, thromboxane synthesis (abst) 610
Goldblatt, glomerular pressure and flow (abst) 260
guanabenz, natriuretic antihypertensive drug 1203
halides as determinant of Na+ (abst) 250
head-out water immersion, naloxone (abst) 1259
hemodynamic effects of vasodilator therapy for (abst) .. 175
hereditary in dogs (abst) 242
hydronephrosis, parallel (abst) 261
increased 18-OH-B and adrenal adenoma (abst) 1259
individual prognosis of IgA nephropathy 549
infants, prejuvenile, juveniles (abst) 240
intracellular free calcium (abst) 250
long-term blood pressure and renal function in donors. 1072
magnesium metabolism in SHR (abst) 262
Na/K pump inhibition, reduced renal mass not produce (abst) 253
NaCl-sensitive in man, dietary chloride determines (abst) 250
neonatal drug treatment (abst) 246
neurogenic mechanisms (abst) 256
oxidative metabolism of cortical renal tubules (abst) ... 242
parenchymal, renal, enalapril effect on (abst) 256
plasma polypeptides in pre- (abst) 260
potassium antihypertensive effect (abst) 255
pregnancy, excretion of prostaglandin (abst) 777
pregnancy, renin angiotensin aldosterone system (abst). 777
pressure-natriuresis relationship (abst) 258
prevention of glomerulosclerosis, proteinuria (abst) 281
prognosis and treatment of membranous nephropathy .. 927
reduced 1,25(OH)2D3, calcium flux in (abst) 165
remnant kidney, injury (abst) 314
renal disease preceeds (abst) 259
renal function, withdrawal of treatment (abst) 251
salt, Ca metabolism on calcium channel blockade (abst) 257
secondary, blood pressure after radical operation in (abst) 247
secondary, unilateral medullary adrenal hyperfunction (abst) 245
severe, in nephrotic syndrome 188
spontaneously, renal dopamine receptors in (abst) 245
trial of oral potassium (abst) 259
unilateral parenchymatous kidney disease (abst) 1259
varying protein diet, tubuloglomerular feedback 520
Hypertonic cell volume regulation (abst) 398
Hypertriglyceridemia (abst) 327
Hypertrophy
biology of 619
hyperplasia vs., antiotensin II epidermal growth (abst) . 318
Hypervolemia
plasma ANF (abst) 395
Hypocalcemia
calcium carbonate controls in uremia S-114
Hypokalemia, nephrocalcinosis (abst) 183
Hyponatremia
clinical, role of vasopressin (abst) 1258
correction of (abst) 203
during forced diuresis for cancer chemotherapy (abst) .. 191
encephalopathy (abst) 177
hospital associated 1237
prevention in Schwartz-Bartter Syndrome (abst) 418
prognosis (abst) 205
Hypoparathyroidism
Al induced osteomalacia (abst) 218
Hypoperfusion
R2 chemoreceptor activation (abst) 329
Hypophosphatemia, familial (abst) 157
Hypoprothrombinemia, ARF (abst) 177
Hyposic stress, lipid peroxidation(abst) 303
Hypotension
atrial natriuretic peptide induced (abst) 245
cardiopulmonary effects of cuprophane-activated plasma 799
cardiovascular response to hemofiltration 901
lactic acidosis 752
stragegies to reduce in unstable HD patients (abst) 224
Hypothyroidism
ESRD (abst) 192
protects against free radical damage in ischemia 1162
Hypotonic volume expansion (abst) 420
Hypotonicity, K and CL (abst) 406
Hypoxia
enhancement of erythropoietin production (abst) 167
injury in the proximal tubule 1021
isolated perfused kidney, 31P-NMR (abst) 358
Hypoxic heart patients, NaHCO3 (abst) 180

Idiopathic nephrotic syndrome
(abst) 189
asymptomatic renal vein thrombosis in (abst) 207
IgA
antiglomerular, antibodies common in children (abst) .. 282
Berger's disease in 50 renal biopsies (abst) 191
Ery-M, PU, UE (abst) 181
hereditary regionalization in (abst) 209
immune complexes, polyethylene glycol assay (abst) ... 278
in pulmonary diseases 557
individual prognosis 549
nephropathy in patients with liver cirrhosis (abst) 1258
nephropathy, B cell hyperactivity 718
scoring system (abst) 205
synthesis by lymphocytes from patients, their relatives .. 1229
IgG subclasses
idiopathic membranous glomerulonephritis (abst) 287
Immune complex
dissolution by antibodies (abst) 271
in children (abst) 269
stimulate superoxide (abst) 268
systemic lupus erythematosus (abst) 276
Immune deposits in SLE patients (abst) 295
Immunoblotting, 2D-SDS page (abst) 1249
Immunodeficiency in CRF (abst) 1257
Immunoflourescence, CMV antibody (abst) 277
Immunohistochemical, amyloid (abst) 274

Immunological, non-
mechanisms in progression of glomerulonephrides (abst) 1172
Immunoperoxidase
renin, kallikrein 965
Mo Ab 1043
Immunoregulation
1,25(OH)2D3 (abst) 264
Indocin, peroral administration (abst) 345
Indomethacin
hyperfiltration (abst) 942
in diabetes 490
natriuresis (abst) 336
renotropic effect of pooled sera (abst) 339
Indoxyl sulfate secretion (abst) 317
Infection
catheter (abst) 232
urinary, reversal of ARF due to (abst) 176
Influenza vaccination in dialysis (abst) 942
Injury
glomerular epithelial cell, complement-induced (abst) .. 272
glomerular, genetic factors of FSG 789
glomerular, hypertension 849
glomerular, PA nephrosis and oxygen free radicals 478
hypertensive glomerular (abst) 274
hypoxic in proximal tubule 1021
immune, glomerular leukotriene (abst) 339
immune, leukotriene B4 synthesis (abst) 343
immunological response (abst) 267
lipid alterations in LLC-PK1 cells, mercuric chloride .. 530
postischemic ATP recovery (abst) 299
proximal tubule, ischemia-reflow (abst) 310
renal, radiocontrast decreased GFR (abst) 300
tissue, characterization of mononuclear cell subsets... 1043
transport-dependent cell in S3 segment 1033
vascular, c-sis mRNA (abst) 272
Inositol
phosphatidyl hydrolysis, vasopressin (abst) 422
phospholipid phorbol myristate acetate (abst) 348
phospholipid metabolism (abst) 347
1,4,5-triphosphate releases Ca2+ 695
Insulin
ARF (abst) 306
atrial natriuretic peptide increase (abst) 348
degradation pathways (abst) 355
dependent diabetes, indomethacin, hemodynamics 490
effect of, role of pentose pathway (abst) 161
luminal uptake and intracellular transport in tubules ... 983
receptors, erythrocyte (abst) 177
renal hemodynamics in isolated perfused kidney (abst) . 382
therapy, diabetic (abst) 325
uremia, protein synthesis, degradation in skeletal muscle 1136
Intercalated cells
differ in CCT (abst) 375
docpivalate (abst) 372
Interferon, type I, indomethacin (abst) 276
Interleukin
glucocorticoids inhibit transcription of (abst) 431
1, allergic reactions during hemodialysis (abst) 608
1, endothelium (abst) 275
1, induction during HD (abst) 219
1, mesangial cell (abst) 282
1, induction during HD (abst) 219
2, mitogenic to peripheral blood T cells (abst) 286
2,1,25(OH)2D3 stimulates production (abst) 160
Interstitial
fluid volume, transcapillary colloid osmotic gradient ... 895
fluid in cirrhotic, non-ascitic rat (abst) 381
primary experimental nephritis, cyclophosphamide 635
renal, cyclosporine (abst) 303
intoxication, aluminum
hematopoiesis S-45
Intoxication, aluminum
in renal failure S-70
Intradialysis alimentation (abst) 222
Intrinsic sympathomimetric activity
renin response to beta blockade (abst) 257
Ion
ionic composition of body fluids 120
23Na NMR spectroscopy of proximal tubule suspensions 747
transport and glucose metabolism 54
Iron
suppression of PTH secretion by (abst) 173
Ischemia
catecholamines in (abst) 310
cyclosporine nephrotoxicity (abst) 304
cyclosporine nephrotoxicity by renal (abst) 436
hypothyroidism protects against free radical damage .. 1162
injury, enriched proximal tubules after (abst) 353
injury, intracellular Ca++ (abst) 300
lower ATP after insult (abst) 310
malonaldehyde measurement following (abst) 301
new Ca channel blocker following (abst) 433
oxidant stress (abst) 307
peripheral arterial, thromboxane synthetase (abst) 777
post, ATP recovery (abst) 315
proximal tubule injury (abst) 310
renal acid-base metabolism after 989
renal failure, protection against (abst) 1254
therapeutic plasma levels of sulindac sulfide, hemorrhage 484
veramapil and atriopeptin III (abst) 943
Isoenzymes in ESRD (abst) 212
Isolated perfused kidney
insulin effect on hemodynamics (abst) 382
liver (abst) 351
low molecular weight proteins (abst) 354
remnant, load dependence of H2O, HCO3 reabsorption (abst) 372
somatostatin 14, 28 metabolism in (abst) 358
Jaundice, renal dysfunction in 598
Juxtaglomerular epitheloid granular cell 1234

Kallikrein
cellular physiology of glandular 953
renin, innunocytochemical localization in renal cortex.. 965
Kallikrein-kininogen-kinin system (abst) 330
Keratinocyte proliferation, D3 (abst) 34A
Ketoacidosis
acute reversal with NaHCO3 on plasma phosphorus and K (abst) 374
Kidney disease
eicosapentaenoic delays (abst) 311
Kinase
Ca/phospholipid dependent (abst) 355
inhibition of aluminum S-12
Kinase-C regulation in tubules (abst) 334

Kinetic
atriopeptin III (abst) ... 340
azlocillin's (abst) ... 208
during CAVH (abst) ... 216
formaldehyde (abst) ... 213
presteady state, Na+-H+ exchange (abst) ... 374
stimulation Na+-H+ (abst) ... 370
Kininase inhibitor in excretion (abst) ... 348
Kininogen
urinary excretion, salt and water loading on (abst) ... 349

L-dopa in restless leg syndrome (abst) ... 195
L-platelet activating factor (abst) ... 388
Lactate stimulates K+ (abst) ... 350
Lactate/acetate cocktail in HD (abst) ... 220
Lactic acidosis ... 752
Laminin
antibodies to in preeclampsia ... 1050
heterogeneity (abst) ... 284
Lasix renography in utero (abst) ... 208
Lesion
bone, natural course of dialysis osteomalacia ... S-74
cytomegalovirus glomerulopathy ... 725
dietary protein intake on albumin homeostasis ... 572
effects of antihypertensive treatment in hypertensive rats ... 1011
focal segmental glomerulosclerosis (abst) ... 437
focal segmental hyalinosis and sclerosis (abst) ... 945
genetic factors in focal segmental glomerulosclerosis ... 789
glomerulosclerosis, transgenic mouse model (abst) ... 283
immunosuppressive therapy of nephrotic syndrome (abst) ... 1259
interstitial, prognosis and treatmen of membranous GN ... 927
polyarteritis nodosa (abst) ... 272
primary, tumor-associated, thrombotic microangiopathy (abst) ... 280
progressive, induced by lithium ... 875
renal, systemic lupus erythematosus study (abst) ... 287
Leukocyte
and platelet-activating factor ... 469
C5a receptor, HD (abst) ... 281
esterase testing, CAPD (abst) ... 234
Leukopenia
cardiopulmonary effects of cuprophane-activated plasma ... 799
Leukotriene
administration, renal blood flow, cardiac output (abst) ... 379
B4 synthesis (abst) ... 343
C4, allograft reject (abst) ... 332
D4(LTD4) (abst) ... 328
immune injury (abst) ... 339
urine osmolality (abst) ... 335
Liganded platinum, respiration (abst) ... 309
Light chain deposition disease (abst) ... 288
Light chain nephropathy, aneurysm (abst) ... 286
Limulus amebocyte lysate
reactive material in chronic hemodialysis patients (abst) ... 211
Lipid
alterations in LLC-PK1 cells exposed to mercuric chloride ... 530
chemical mediators, PAF ... 469
peroxidation bradykinin induces increased (abst) ... 333
peroxidation ethane production a measure (abst) ... 308
peroxidation vitamin E in gentamicin induced (abst) ... 303
peroxidation, hypoxic stress (abst) ... 303
phospho- and HgCl2 injury ... 496
procoagulant activity in normal human urine ... 591
Lipoid nephrosis (abst) ... 197
Lipoprotein
in glomerular disease with proteinuria ... 1224
receptor activity in epithelial cells ... 1248
Lithium
chronic progressive renal lesions ... 875
effect on kidney function (abst) ... 1255
Liver disease
renal, cardiovascular dysfunction ... 598
LLC PK1
gap junctions in polarization process of (abst) ... 404
gluconeogenis strain (abst) ... 354
lipid alterations in cells exposed to mercuric chloride ... 530
Na-sugar cotransport (abst) ... 418
Na+/H+ exchange system (abst) ... 373
sodium transport (abst) ... 331
LLCPK1-CL4
cells, Na-H antiport activity in quiescent (abst) ... 403
Luminal bicarbonate concentration (abst) ... 364
Lupus erythematosus, MPCA (abst) ... 270
Lupus nephritis
captopril improves (abst) ... 277
circulating immune complex (abst) ... 295
features of glomerular lesions (abst) ... 196
renal tubular function disturbances (abst) ... 194
transitions in renal histology (abst) ... 293
HD (abst) ... 183
Lupus SLE, antibodies (abst) ... 283
Luteinizing hormone, HD (abst) ... 225
Lymphocyte
activation cascade, cyclosporine effect (abst) ... 613
ATP, hemodialysis (abst) ... 327
culture, soluble suppressor factor (abst) ... 432
IgA synthesis by, patients and their relatives ... 1229
in ICGN (abst) ... 292
peripheral, Cya influence (abst) ... 1261
role in experimental immune complex GN (abst) ... 1249
T4, T8 in rejection (abst) ... 432
Lymphokine
nephrosis (abst) ... 290
release, T cells (abst) ... 433
Lyosomal enzymes, protein load (abst) ... 357
Lysine
potassium depletion (abst) ... 421
Lysis in hematuria states (abst) ... 183

Macrophage procoagulant activity (abst) ... 270
Macula densa feedback (abst) ... 389
Magnesium hydroxide
phosphate binder for maintence hemodialysis (abst) ... 943
K binder (abst) ... 168
Magnesium metabolism in SHR (abst) ... 262
Magnetic resonance imaging
and ultrasound, in acquired renal cystic disease (abst) ... 196
detection of renal allograft rejection (abst) ... 434
in diagnosis of renal vein thrombosis (abst) ... 206
in primary hyperoxaluria (abst) ... 187
loss of corticomedullary demarcation on (abst) ... 429
NMR & biochemistry ... 131
Maleic acid, glucose loading (abst) ... 296
Malignancies in CAPD patients (abst) ... 231

Malonaldehyde measure, ischemia (abst) 301
Mannitol and acute renal failure (abst) 298
Maxzide, reversible ARF (abst) 198
MDCK cells
  Na inhibits H-driven Na-H exchange (abst) 397
Measurement
  aluminum S-24
  dialysate (abst) 236
Medulla
  H+-ATPase bovine, reconstitution (abst) 366
  inner, ammonia concentration (abst) 366
Medullar collecting duct
  Cl/HCO3 exchange, carbonic anhydrase inhibitor (abst) .. 379
Medullary
  blood flow, ANF (abst) 337
  dialation, inner medullary collecting duct function (abst) 394
  solute gradients, ANF (abst) 414
  sponge kidney nephrolithiasis and hyperparathyroidism (abst) 187
  thick ascending limb, transport inhibitor (abst) 351
  washout, natriuresis (abst) 407
Membrane
  antibodies to laminin in preeclampsia 1050
  apical and basolateral transporters, cell pH (abst) 362
  apical, cation conductance channels in (abst) 393
  apical, basel cell, ionic conductances of (abst) 396
  apical, conductance of amphiuma (abst) 399
  apical, K transport in (abst) 405
  apical, single sodium channel events in (abst) 397
  BBM, BLM, differences in surface, inner core fluidity (abst) 403
  biocompatibility 225
  childhood membranoproliferative glomerulonephritis .. 1077
  cuprophane, cardiopulmonary effects of 799
  depolarization, AII, AVP (abst) 341
  optical measurement, DiS-C3-(5) response (abst) 393
  peritoneal dialysis (abst) 236
  podocyte plasma, internal heterogeneity (abst) 1248
  properties of fused renal epithelial cells (abst) 1251
  renal, basolateral, Na-Ca exchange (abst) 425
Membranoproliferative glomerulonephritis
  adult idiopathic nephrotic syndrome (abst) 207
  benefit of cyclophosphamide therapy in (abst) 192
  childhood, an approach to management 1077
Membranous glomerulopathy
  glomerular sieving defect in rat (abst) 390
  pathophysiology of (abst) 323
Membranous nephropathy
  C6 depletion dimishes proteinuria (abst) 287
Mercuric chloride
  autoimmune glomerulonephritis (abst) 608
  lipid alterations in LLC-PK1 cells 530
  phospholipids 496
Mercury
  basolateral membrane (abst) 416
  renal injury (abst) 199
Mesangial
  cell behavior control (abst) 275
  cell damage, complement (abst) 296
  expansion, glomerular filtration surface in diabetes 889
  expansion, polyamine (abst) 267
  in vitro, cell culture and characterization (abst) 944
  prostanoid, Il-1 (abst) 282
  secrete growth factor-like molecule (abst) 263
Mesangium, renal, IgA nephropathy 1229
Metabolic alkalemia, acidification(abst) 363
Metabolic function
  and transport in cultured renal tubule cell 46
Metabolism
  adaptations of the nephron in renal disease 80
  deformylase activity, renal, in drugs and xenobiotics (abst) 361
  glucose in renal tubular function 54
  glutamine, lactate, alanine, oxygen; fluorocitrate (abst) . 353
  iron, interference by alunimum S-45
  lactic acidosis 752
  metabolic fuels along the nephron 41
  mitochondrial volumes and hepatic GLN homeostasis (abst) 370
  nitrogen, energy intake in nondialyzed patients CRF ... 734
  oxidative in hypertensive rats (abst) 242
  phospholipid, biology of renal hypertrophy 619
  protein loading and pH (abst) 361
  protein loading on renal (abst) 361
  regulation of glutamine in dog kidney 68
  renal calcitonin (abst) 359
  sites of action of vitamin D in the kidney 98
  2-amino-4-(5-nitro-2-furyl) thiazole in cancer (abst) 360
Metabolites, prostaglandins 108
Metals, heavy, phospholipids 496
Methionine oxidation and PTH (abst) 169
Methotrexate overdose (abst) 216
MHC product expression (abst) 276
Microcytic anemia, non-aluminum in S-120
Microprobe techniques, x-ray 682
Mineral acid feeding, systemic pH 667
Mineralization
  abnormalities, bone aluminum intoxication S-70
  aluminum inhibits S-32
  bone development, Al 1038
Mineralocorticoid
  adrenoceptors (abst) 1258
  escape, ANP (abst) 329
Mitochondrial
  electron transport (abst) 305
  function, HgCl2 496
  store site, non- in rat 695
Model, isolated perfused kidney (abst) 351
Molecule, class I, T lymphocytes (abst) 270
Monoclonal antibodies
  BB5 on PTH (abst) 156
  bovine H+ ATPase (abst) 369
  culture of pure population of proximal tubules (abst) ... 360
  in diagnosis 142
  production for distal tubule cell types (abst) 360
  used for reaioimmunoassay to bradykinin (abst) 342
  in diagnosis 142
Monocytosis, eosinophilia (abst) 231
Mononuclear cell
  markers, rejection 708
  reduced IGA-secreting, after tonsillectomy (abst) 290
  subsets 1043
Morbidity in renal failure (abst) 202
Mortality risk on maintenance HD (abst) 228
mRNA, regulation by 1,25(OH)2D3 (abst) 172
Multiple myeloma, plasmapheresis (abst) 199
Murine
  autoimmunity, Ia (abst) 289
  monoclonal antibodies, tumor derived (abst) 284

polycystic kidney disease (abst) . . . 314
Muscle, skeletal, protein synthesis . . . 1136
Musculoskeletal, Al in bone disease . . . S-80
Muzlimine, loop diuretic (abst) . . . 1255
Myeloperoxidase H2O2 halide system(abst) . . . 271
Myocardial
funtion, hemodialysis (abst) . . . 212
infarction in ESRD (abst) . . . 185
Myoglobinuric acute renal failure
theophylline-induced protection in (abst) . . . 299

N-acetyl-beta-glucosaminidase
decrease after antihypertensive therapy (abst) . . . 258
Nagogastric tube and CPD, infants (abst) . . . 230
Naloxone, water immersion (abst) . . . 1259
Natriuresis
albumin infusion not induce (abst) . . . 392
anti-diuretic induced (abst) . . . 422
atrial extracts in rats (abst) . . . 248
atrial natriuretic peptide on hydraulic pressures (abst) . . 382
atrial peptide, mechanisms (abst) . . . 383
hormone marker (abst) . . . 240
indomethacin on, by atriopeptin III (abst) . . . 336
medullary washout (abst) . . . 407
prostaglandins not mediate pressure (abst) . . . 347
proteinuria, aldose reductase inhibition (abst) . . . 391
sodium diclofenac inhibits effect (abst) . . . 328
verapamil induced in CVAL dogs (abst) . . . 382
Neonate, chloride deficiency (abst) . . . 186
Nephrectomy
biology of renal hypertrophy . . . 619
low protein, phosphate diet inhibit proteinuria (abst) . . . 326
potassium depletion mediates extrarenal adaptation (abst) . . . 408
unilateral, CyA (abst) . . . 426
long-term renal response to high protein in dogs . . . 511
5/6, clofibric acid (abst) . . . 324
Nephritis
auto-immune, anti-GBM antibodies (abst) . . . 266
Henoch-schonlein IgG, IgA antibodies common (abst) . . 282
HgCl2 induced, methylprednisolone, byclophosphamide (abst) . . . 775
interstitial, B cell in aTBM (abst) . . . 270
interstitial T cell factor on development (abst) . . . 286
lupus, renal histology with outcome in children . . . 1066
nephrotoxic, PAF (abst) . . . 282
nephrotoxic serum, antiotensin 2 receptors (abst) . . . 293
nephrotoxic serum, stress (abst) . . . 266
primary experimental interstitial, cyclophosphamide . . . 635
spontaneous interstitial, suppression T cells (abst) . . . 280
streptococcus mutans infusion (abst) . . . 264
transitions in renal histology (abst) . . . 293
1-J+ suppressor T cells (abst) . . . 284
Nephrocalcinosis, hypokalemia (abst) . . . 183
Nephrolithiasis
idiopathic calcium, membrane defect a factor in (abst) . 609
tubulopathy . . . 563
Nephrologist urinalysis survey (abst) . . . 184
Nephron
juxtamedullary ANP on whole kidney and (abst) . . . 405
kallikrein-kinin system . . . 120
metabolic adaptations of in renal disease . . . 80
metabolism and sites of action of vitamin D in the kidney . . . 98
prostaglandins and other arachidonic acid metabolites . . 108
remnant circulation, autoregulation (abst) . . . 384
Nephropathy
adriamycin-induced, progressive glomerular disease . . . 502
alcohol-associated, complex tubular dysfunction (abst) . 609
early, immunological features in diabetes and (abst) . . . 611
experimental membranous, antigen and urinary protein (abst) . . . 292
gold, detection of autoantibodies to renal tubular antigens . . . 539
hepatic, pathogenesis of (abst) . . . 285
idiopathic IGA after tonsillectomy (abst) . . . 290
IgA, C3 deposition (abst) . . . 274
IgA, individual prognosis . . . 549
light chain, transplantation (abst) . . . 943
lithium induced interstitial . . . 875
membranous, prognosis and treatment . . . 927
Nephrosis
aminonucleoside . . . 478
aminonucleoside heparan-sulfate proteoglycans in (abst) . . . 281
dietary protein intake . . . 572
lymphokine, SIRS (abst) . . . 290
relapse (abst) . . . 193
Nephrotic syndrome
adult-onset, long-term follow-up . . . 1215
aldosterone in Na retention (abst) . . . 203
antiotensin converting enzyme activity increased (abst) . 302
children, cyclosporine A remission (abst) . . . 206
colloid volume expansion on glomerular barrier . . . 916
CyA inhibits trypanosomiasis-induced (abst) . . . 1256
focal segmental hyalinosis and sclerosis lesions (abst) . . 945
focal, segmental glomerular sclerosis, AIDS (abst) . . . 288
idiopathic, food allergy (abst) . . . 776
idiopathic, molecular basis for in children (abst) . . . 189
immunosuppressive therapy, retrospective of 55 adults (abst) . . . 1258
lowered tissue-fluid oncotic pressure (abst) . . . 194
membranous nephropathy, prognosis and treatment . . . 927
membranous nephropathy, prognosis and treatment . . . 927
remission induced by ultrafiltration . . . 776
severe hypertension in (abst) . . . 188
transferrin rectptors on lymphocytes in children (abst) . 294
Nephrotoxic serum nephritis (abst) . . . 266
Nephrotoxicity
cyclosporine enhances endotoxin (abst) . . . 431
cyclosporine, by ischemia (abst) . . . 436
cyclosporine, immunohistologic labeling of biopsy (abst) . . . 432
gentamicin (abst) . . . 297
gentamicin, glomerular prostaglandin production in (abst) . . . 298
gentamicin, PTH in PTX rats (abst) . . . 301
lithium lesions . . . 875
renal cortical subcellurlar membrane phospholipids, HgCl2 . . . 496
vasoconstriction in CyA transplant recipients (abst) . . . 428
cyclosporine A (abst) . . . 1216
stimulation, gluconeogenesis (abst) . . . 349
Nerves
renal in hypertensive (abst) . . . 256
renal response to Na (abst) . . . 253
stimulation, gluconeogenesis (abst) . . . 349
Neurogenic mechanism, hypertensive(abst) . . . 256
Neurological disorder in dialysis . . . S-104
Neutropenia, minimal, C102 (abst) . . . 221

Neutrophils
PMA-stimulated (abst) 291
stimulated, cAMP content in glomeruli (abst) 349
Newborn
ARF, continuous arterio-venous hemofiltration 908
pseudohypoaldosteronism (abst) 943
Newcastle bone disease
aluminum-induced dialysis osteodystrophy S-58
Nicotinamide inhibits K transport (abst) 161
Nifedipine
effect on carbohydrate metabolism (abst) 1257
therapy, renal failure (abst) 778
Nipride in SHR (abst) 243
Nitrogen
glutamine, in kidney (abst) 350
NMR spectroscopy
of proximal tubule suspensions 747
Nonglomerular renal diseases (abst) 180
Noninvasive study of the kidney
P NMR spectroscopy 137
Nordihydroguaiaretic acid, cysts in rat 1116
Norepinephrine
ARF (abst) 306
pressor response (abst) 261
oxygen consumption, Na-K ATPase activity (abst) 391
volume absorption in PCT (abst) 394
Nuclear magnetic resonance, biochemistry 131
Nucleosides, transport (abst) 1253
Nucleotide
adenine, after anoxia (abst) 357
exogenous, ATP (abst) 356
Nural regulation alkali excretion (abst) 365
Nutrition
low protein-essential amino acid-keto acid diet 995
Nypernephroma, ESRD (abst) 433

O-(beta-hydroxyethyl) rutoside (abst) 300
Obstruction, ureteral, acidification 1167
Occluded arteriovenous access
thrombolysis using i.v. urokinase (abst) 223
Oncotic pressure
lowered tissue-fluid, protects blood volume in NS (abst) 194
Optical measurement membrane (abst) 393
Ornithine decarboxylase activity (abst) 357
Osmotic gradient, H20 in PCT (abst) 412
Osteitis fibrosa, dialysis osteomalacia S-74
Osteodystrophy
aluminum and genesis of (abst) 169
aluminum-induced dialysis, Newcastle bone disease S-58
changes in bone histology after desferrioxamine treatment S-108
disability and bone Al in hemodialysis patients (abst) 168
encephalopathy in renal failure, desferrioxamine S-100
parathyroid hormone and aluminum levels S-41
phosphate binding gels balance Al toxicity 1131
renal in CAPD (abst) 237
unresponsiveness of bone to PTH in aluminum-related S-49
99mTc-methylene diphosphonate bone scan 1058
renal in CAPD (abst) 237
Osteomalacia
aluminum effect on bone and cell localization S-37
Al-induced (abst) 218
aluminum-induced, inhibition of apatiate formation S-17
diagnosis of aluminum bone disease S-96
PTH not prevent Al induced (abst) 168
Ouabain, vanadate (abst) 330
Oxalate
assay by GC/MS isotope (abst) 202
in CRF (abst) 321
mechanism of transport by rat ileum (abst) 161
Oxidant stress, ischemia (abst) 307
Oxidative stress, PTS (abst) 307
Oxygen
consumption of ouabain, amphotericin B, nystatin (abst) 611
consumption, sodium transport & ATP 3
deprivation, ATP levels (abst) 296
free radical in aminonucleoside nephrosis 478
glutathione depletors, effect on proximal tubules 858

PAF-acether, renal actions (abst) 342
PAH reabsorption, transport (abst) 371
Pan-electrolyte depletion (abst) 187
Pancreatitis absence in ESRD (abst) 217
Papilla
and glomeruli, sulfidopeptide leukotriene (abst) 346
Papillary cells, sorbitol (abst) 412
Papillary collecting duct, x-ray 675
Paraaminohippurate transport (abst) 424
Paraproteinemia (abst) 174
Parathyroid glands, transplant (abst) 170
Parathyroid hormone
activated calcium conductive pathway in brush border (abst) 166
age and (abst) 175
aluminum bone disease S-87
aluminum induced bone disease S-32
and 1,25(OH)2D3 maintain activity of bone cells (abst) 165
assay, amino-terminal vs. carboxy-terminal 239
bicarbonate absorption in urinary acidification (abst) 363
Ca2+ transport by ATPase of endoplasmic reticulum (abst) 421
clinical evidence on interactions with 1,25(OH)2D3 202
compensatory renal growth by Ca, 1,25(OH)2D3 1124
cytosolic calcium effect of (abst) 175
dependent phosphorylation of proteins in tubules (abst) 167
dialysis osteomalacia S-74
effect of aluminum on secretion S-41
effect of aluminum on tissue incubation medium 924
effect of monoclonal antibody BB5 on (abst) 156
effects on water flow in toad bladder 170
enhances stimulatory effect of Ca+ on aldosterone (abst) 168
gentamicin nephrotoxicity, PTH in PTX (abst) 301
glucagon, effect on juxtamedullary nephrons 807
high dialysate Ca and 1,25(OH)2D3 effect (abst) 231
induced dephosphorylation of protein (abst) 171
modulates Vmax, pH of na/h antiporter (abst) 372
Na+-Ca+ exchange (abst) 171
oxidation of specific methionine residues of (abst) 169
response of plasma 1,25(OH)2D on (abst) 158
role in hypercalcemia and hypertension (abst) 248
secretion and UcAMP during sequential changes of Ca (abst) 172
skeletal resistance to, in uremia (abst) 319
stimulates cellular calcium absorption (abst) 159
suppression by WR-2721 174
unresponsiveness of bone to, in Al-related osteodystrophy S-49

Parathyroidectomy
effects on renal PO4 handling (abst) ... 161
fall in 1,25(OH)2D3 and bone GLA (abst) ... 186
Parathyroidectomy, PTH, Ca (abst) ... 322
Parenchymatous kidney disease (abst) ... 1259
Pars recta, rabbit
arachidonate acid epoxygenase activity (abst) ... 356
Pathologic scoring system, IGAN (abst) ... 205
Pentose pathway, role (abst) ... 161
Peptide
and amine hormones, Ca and cyclic AMP ... 90
atriopeptin II effect on arterioles (abst) ... 333
cellular physiology of glandular kallikrein ... 953
Perenteral solution (abst) ... 369
Peripheral blood mononuclear cells, IgA ... 718
Peritoneal
dialysis schedule (abst) ... 233
mass transfer, effect of dialysate volume (abst) ... 235
transport, model (abst) ... 234
Peritoneovenous shunt in HRS (abst) ... 196
Peritoneum, dextran transfer (abst) ... 232
Peritonitis
increased fibronectin concentration during, CAPD (abst) ... 232
reduction of CAPD, by UV-XD system (abst) ... 240
risk of intermittent dialysis in hospital (abst) ... 238
sclerosing encapsulating induced by chlorhexidine (abst) ... 234
treatment with vancomycin in CAPD (abst) ... 229
Permeability
brush border membrane, age related changes (abst) ... 414
cholera toxin increases water permeability (abst) ... 417
inner medullary collecting duct, surfact epithelium (abst) ... 418
regulation of water in ADH and cAMP treated bladder (abst) ... 417
tubular water, adrenal steroids affect (abst) ... 417
Peroral administration indocin (abst) ... 345
Pertussis toxin
AII, PGE2 (abst) ... 344
in renin (abst) ... 342
PGE2, hydrogen peroxide (abst) ... 291
pH
acetazolamide increases (abst) ... 366
chronic mineral acid feeding, systemic ... 667
in MDCK cells, kinetics of Na-H antiporter (abst) ... 376
luminal, peritubular, on citrate reabsorption (abst) ... 413
mitochondria-rich cells, turtle bladder regulate (abst) ... 378
radial gradient in cortical collecting duct lumen (abst) ... 377
Pharmacokinetics in CAPD (abst) ... 236
Phlebotomies, effect (abst) ... 776
Phorbol ester
alkalinization (abst) ... 372
fluid and phosphate fluxes in tubules (abst) ... 411
hyperosmolarity, cation fluxes in mTALH (abst) ... 395
stimulate Na+/H+ exchange in renal brush border (abst) ... 408
Phorbol myristate acetate
(abst) ... 338
InsPL (abst) ... 348
Phosphate
alkalosis on transport by renal proximal tubule (abst) ... 163
binding compound, non-aluminum ... S-120
binding gels, balance K adsorption and Al toxicity ... 1131
cytosolic, metabolism in familial hypophosphatemia (abst) ... 157
depletion arrests progression of CRF independent of protein ... 658
depletion, proteinuria of diabetes (abst) ... 313
diet, response of senescent rats to (abst) ... 162
dietary intake on serum vitamin D metabolites (abst) ... 609
epithelial inorganic transport (abst) ... 172
groups and anionic sites in glomerulus (abst) ... 285
impairment of reabsorption by chronic hypercalcemia (abst) ... 163
Mg(OH)2 binder (abst) ... 168
Na-dependent in LLC-PK1 cells (abst) ... 167
NMR spectroscopy ... 131
phosphonocarboxylic acids inhibit transport (abst) ... 172
prevention of secondary hyperparathyroisim by (abst) ... 164
regulation of intestinal absorption, vitamin D (abst) ... 163
transport, effects of Pi (abst) ... 171
transport inhibition (abst) ... 164
uptake by luminal membrane (abst) ... 155
Phosphatidylcholine transfer
(abst) ... 162
stimulation by 1,25(OH)2D3 involves brush border (abst) ... 174
Phosphatidylinositol, gentamicin (abst) ... 308
Phosphinositide metabolism (abst) ... 353
Phospholipase A2 in uremia (abst) ... 316
Phospholipase D, urokinase (abst) ... 344
Phospholipase, exogenous, PTS (abst) ... 307
Phospholipid, BBM, BLM in SHR (abst) ... 252
Phospholipidosis, gentamicin (abst) ... 311
Phosphonoformic Acid on Pi (abst) ... 174
Phosphoramidon, effect in renal (abst) ... 348
Phosphorus
compensatory renal growth, modulation ... 1124
synthesis of 1,25(OH)2D3 in proximal tubules (abst) ... 162
Phosphorylation
IGF I stimulated, renal basolateral membranes (abst) ... 354
Pituitary-renotropin, renal growth(abst) ... 341
Plasma
chronic sodium homeostasis and ANF ... 1004
therapeutic levels of sulindac sulfide during hemorrage ... 484
during hemodialysis (abst) ... 203
Plasma arginine vasopressin
(abst) ... 346
hospital-associated hyponatremia ... 1237
modulation by cardiac function ... 1188
Plasma chromagranin A in RF (abst) ... 198
Plasma kallikrein ... 120
Plasma polypeptides, hypertension (abst) ... 260
Plasma renin
dietary NaCl (abst) ... 349
Plasma transferrin after DFO (abst) ... 225
Plasma vasopressin
humoral control of water and electrolyte excretion ... 1152
Plasmapheresis
multiple myeloma (abst) ... 199
treatment of renal graft rejection (abst) ... 613
Plasminogen activator
polyunsaturated fatty acids decrease EC production (abst) ... 279
Plasmodium Yoelii, malarial GLN (abst) ... 280
Plasticizer Dl-2-(ethyhexyl) (abst) ... 214
Platelet activating factor, NTN (abst) ... 282, 469
Platelet derived growth factor (abst) ... 263

Pneumonia
Goodpasture's syndroms as post-mycoplasma (abst) .. 1256
podocyte plasma membrane (abst) 1248
Pokeweed mitogen, IgA synthesis..... 718
Polarized cells
regulation of growth and function 46
Polyamine, mesangial expansion (abst)..... 267
Polyanion, glomerular in PAN (abst) 276
Polyarteritis Nodosa, lesions (abst)..... 272
Polyclonal immune response (abst)..... 268
Polycystic kidney disease
tubular changes during development (abst)..... 320
adult (abst) 181
autosomal dominant, epithelial hyperplastic (abst)..... 276
changes in tubular basement membrane (abst) 268
reduce (abst)..... 179
steroid metabolism (abst)..... 271
transplantation (abst) 437
trimethoprim sulfamethoxazole in cyst fluid (abst)..... 185
ultrastructure of cyst derived epithelium (abst)..... 323
Polyelectrolyte, gelifundol (abst)..... 230
Polyethylene glycol assay, IgA (abst)..... 278
Polymorphonuclear neutrophils
dialysis membranes, electrical charge (abst)..... 609
Polypeptide, 60kDa duplet (abst)..... 279
Porphyrin matabolism and Al (abst) 211
Positive end expiratory pressure (abst) 415
Poststreptococcal
glomerulonephritis in children (abst)..... 178
Potassium
acidosis (abst)..... 363
ATPase, distribution and function of classes of 21
bicarbonate on Na-K-ATPase in CCD (abst) 395
chronic loading in man (abst)..... 1251
conductance of cells, early distal vonvoluted (abst)..... 409
depletion during chronic metabolic acidosis (abst)..... 374
depletion effect on brain buffering (abst)..... 362
depletion mediates extrarenal adaptation (abst) 408
depletion on HCO3 transport (abst)..... 368
depletion, antihypertensive effect (abst) 255
depletion, lysine (abst)..... 421
diet on transport of CCD of adrenalectomized rabbit (abst)..... 403
diet reduces brain infarcts (abst)..... 250
efflux, furosemide-sensitive (abst)..... 396
electrolyte concentrations of renal cortex (abst)..... 1251
ESRD (abst)..... 324
K-pump, reabsorptive in K depleted rat (abst)..... 400
lactate stimulates (abst)..... 350
regulation of, conductance in MDCK cells (abst)..... 1251
test of in hypertension (abst)..... 259
transport in apical membrane vesicles (abst)..... 405
Precipitation, Ca and K, Al effect..... S-20
Prediction of outcome in ARF (abst) 184
Preeclampsia, antibodies to laminin 1050
Pregnancy
antibodies to laminin in preeclampsia 1050
Pressor response, glucocorticoids (abst)..... 246
Primary nephrotic syndrome
biopsy in 65 teenagers (abst) 284
Prioxicam, diabetics..... 611
Procoagulant activity
in urine 591
rabbits (abst)..... 295
Prognostic factors in cirrhosis (abst)..... 184
Progressive renal disease
anti-hypertensive drugs (abst) 314
Prolactin
excess causes hypercalcuria (abst) 156
levels in CRF (abst)..... 322
Prostacyclin synthesis (abst) 260
Prostaglandin
ADH, sodium excretion in IEPK (abst) 401
alpha 2 adrenoceptors, cAMP (abst)..... 346
and other arachidonic acid metabolites in the kidney... 108
and thromboxane production, protein (abst)..... 336
AII, AVP, bradykinin, meclofenamate on, cAMP systems (abst)..... 341
AII, AVP, bradykinin, meclofenamate on, cAMP systems (abst)..... 341
dependent, R2 chemoreceptor activiation (abst)..... 329
E2, furosemide (abst)..... 337
glomerular, gentamicin nephrotoxicity (abst) 298
glomerular vasodilatory, diet induced hyperfiltration (abst)..... 343
hexose monophosphate shunt activity (abst)..... 338
histidine (abst) 331
hyperfiltration of early diabetes (abst)..... 332
in cirrhotic rats (abst)..... 343
in nephrectomy (abst)..... 329
increased urinary excretion of, during antidiuresis, DDAVP..... 1110
isolated renal afferent arteriole, production (abst) 385
mediated loss of proteins during peritonitis in CAPD... 584
nerve-induced glomerular dynamics (abst) 334
not mediate pressure natriuresis (abst) 347
pregnancy, urinary excretion during hypertension (abst)..... 777
regulation of renal cellular cAMP levels by 703
regulatory in remnant glomerulus (abst) 341
renal blood flow in ARF (abst) 342
renal cortical mitochondrial ammoniagenesis (abst) 355
renin release in uninephrectomy (abst) 381
renovascular resistance determinant of response (abst) . 337
synthesis on renal sodium handling (abst)..... 405
synthesis in renal papillae (abst) 345
Prostanoid production GEC (abst) 277
Prostate and pituitary, kallikrein..... 953
Protease
cytotoxic factor (abst) 283
free renin preparation (abst)..... 343
NGN (abst)..... 275
Protein
aldosterone, short circuit current and conductance (abst)..... 408
aluminum sites in S-12
angiotensin II, BP and vascular reactivity (abst) 383
atrial natriuretic factor during change in (abst)..... 384
band 3 anion exchange in rabbit (abst) 376
biology of renal hypertrophy 619
binding,indoxyl sulfate secretion (abst)..... 317
binding of cefamandole (abst) 239
bolus, effect on GFR (abst) 339
chronic renal insufficiency (abst)..... 318
dietary intake on albumin homeostasis in nephrotics ... 572
dietary, gentamicin nephrotoxicity (abst) 297
dietary, long-term response in dogs with..... 75
nephrectomy 511
effect of loading in remnant rat kidney (abst)..... 324
effect on normal kidney (abst)..... 297

experimental diabetes mellitus (abst) . . . 289
fenoldopam (abst) . . . 313
filtration fraction among superficial nephrons . . . 814
GFR, albumin, renal growth after increased (abst) . . . 321
glomerular function in human renal disease (abst) . . . 325
glomerular injury in antihypertensive therapy (abst) . . . 319
guanine nucleotide regulatory in TAL (abst) . . . 333
influence of charge, cathepsin activity (abst) . . . 293
inhibitory nucleotide regulatory mediates ADH (abst) . . 423
interactions of aluminum with cofactors, enzymes and. S-12
load on lysosomal enzymes in proximal tubule (abst) . . . 357
loading, glucose control (abst) . . . 196
loading, on renal metabolism (abst) . . . 361
low, essential amino acid diet, risk and benefit . . . 995
low molecular weight in isolated perfused kidney (abst) . . 354
phosphate depletion arrests progression of CRF without . . . 658
phosphorylation, angiotensin II (abst) . . . 329
prostaglandin-mediated loss during peritonitis . . . 584
renal amyloid lambda 2 light chain subgroup (abst) . . . 288
synthesis and degradation in skeletal muscle, uremic rats . . . 1136
Tamm-Horsfall, antibodies for . . . 971
tubuloglomerular feedback, glomerular morphology . . . 520
uninephrectomy and, volume reabsorption (abst) . . . 320
urinary, antigen in expermental membranous nephropathy(abst) . . . 292

Proteinuria
adriamycin-induced, cyclosporine exacerbates (abst) . . . 434
adult onset, minimal change nephrotic syndrome . . . 1215
angiotensin II induced (abst) . . . 270
childhood membranoproliferative glomerulonephritis . . 1077
colloid volume expansion on glomerular barrier . . . 916
converting enzyme inhibition prevents (abst) . . . 265
C6 depletion diminishes in membranous nephropathy (abst) . . . 287
glomerular epithelial cell,protein overload (abst) . . . 290
glomerular, effect of dietary protein on albumin homeostasis . . . 572
in diabetic influenced by metabolic control and BP (abst) . . . 189
induced by aminonucleoside of puromycin . . . 478
low protein, phosphate inhibit (abst) . . . 326
membranous glomerulopathy (abst) . . . 323
natriuresis, aldose reductase inhibition (abst) . . . 391
nephrotic plasma increases (abst) . . . 295
prognosis and treatment of membranous nephropathy . . 927
protein restriction in diabetic nephropathy (abst) . . . 209
serum and urinary high density lopoproteins . . . 1224
thromboxane synthesis inhibition (abst) . . . 347
transition from proliferative to membranous GN . . . 841
urine samples . . . 182
urinary histamine excretion (abst) . . . 206

Proton magnetic resonance
differentiates ARF (abst) . . . 302

Proton pumps
clathrin-coated vesicles, ATPase (abst) . . . 378

Proton, mutant, ATPase (abst) . . . 377

Proximal convoluted tubules
brushborder membrane vesicles (abst) . . . 352

Proximal phosphate reabsorption (abst) . . . 155

Proximal straight tubule transport
cisplatinum (abst) . . . 306

Proximal straight tubules
ammonia production by isolated perfused (abst) . . . 373
protein, uninephrectomy affect volume readsorption (abst) . . . 320

Proximal tubular cell
growth occurs at periphery of a colony (abst) . . . 402
Ca2- mobilizing hormones on brush border topography (abst) . . . 160
CyA (abst) . . . 307

Proximal tubular cyst formation (abst) . . . 314

Proximal tubular injury
monoclonal antibodies in diagnosing renal disease . . . 142

Proximal tubule
calcium transport across cortical segment two (abst) . . . 155
enriched, post ischemic injury (abst) . . . 353
metabolism and sites of action of vitamin D in kidney . . . 98
Na+ reabsorption energy requirements . . . 32
response, immunological injury (abst) . . . 267
segments, oxidative stress . . . 307
segments, PL (abst) . . . 307

Pseudohypoaldosteronism, infant (abst) . . . 943

Psychiatric patients
lithium effect on kidney function, serumproteinuria (abst) . . . 1255

PTH
effects of on renal gluconeogenesis . . . 90
suppression of, by iron (abst) . . . 173

Pulmonary diseases, IgA deposition . . . 557

Pulmonary edema, acid-base (abst) . . . 197

Pulse methylprednisolone therapy (abst) . . . 180

Pulse, BP, house officers on call (abst) . . . 253

Pump
Na, K-ATPase, structure, function and regulation . . . 10
reabsorptive K (abst) . . . 400

Puromycin aminonucleoside (abst) . . . 276

PVC tubing in HD, leaching (abst) . . . 217

Quin 2 flourescence, bradykinin (abst) . . . 344

Race, allograft survival (abst) . . . 428

Radiocontrast agent
diatrizoate precipitates renal tubules, membranes (abst) . . 312
diatrizoate (abst) . . . 302

Radiocontrast agents
GFR decrease (abst) . . . 300
influence on kidney (abst) . . . 309

Raffinose, NaCl coefficients (abst) . . . 410

Ramipril, pharmacokinetics of (abst) . . . 241

Raw foods, sodium, chloride (abst) . . . 262

Reabsorption
H2O, HCO3 (abst) . . . 372
renal Na energy requirements . . . 32

Receptor, renorenal injury in SHR (abst) . . . 249

Red cell morphology in hematuria (abst) . . . 201

Rejection
cytomegalovirus glomerulopathy, controversial lesion . . 725
interleukin 2 therapy spares T cell (abst) . . . 432
renal graft, plasmapheresis in treatment (abst) . . . 613

Rejection, allograft
aminoaciduria in (abst) . . . 436
characterization of mononuclear cell subsets . . . 1043
CyA nephrotoxicity, immunohistologic labeling (abst) . . 432
cytodiagnostic urinalysis (abst) . . . 429
HLA-DR antigens (abst) . . . 944
immunopathology, monoclonal antibodies to mononuclear cell . . . 708
leukotriene C4 increase in (abst) . . . 332

magnetic resonance imaging, detects (abst) 434
MHC unrestricted cytotoxic T lymphocytes (abst) 281
T4 and T8 cytotoxic lymphocytes in (abst) 432
urinary thromboxane B2 in diagnosis (abst) 1260
Relapse, nephrosis (abst) 193
Relapsing polychondritis (abst) 182
Remnant glomerulus, PG2 (abst) 340
Remnant kidney, hypertensive (abst) 314
Renal
involvement in relapsing polychondritis (abst) 182
kallikrein-kinin system 120
regulation of function 1
artery occlusion, surgery (abst) 191
Renal artery stenosis
cerebrovascular disease 262
Renal biopsy in elderly (abst) 204
Renal cortex
brush border membrane vesicle fraction (abst) 352
Renal cystic disease
accelerated cyst development in deconditioned germ-free rats 1116
Renal diluting ability (abst) 190
Renal disease
biopsy findings in adolescents (abst) 207
urinary flow rate influence on protein excretion 941
Renal failure
AIDS-associated (abst) 201
biliary excretion of conjugated small molecular wt (abst) 317
biogenesis of hyperparathyroidism (abst) 166
increase Ca, decrease P in PTX (abst) 322
morbidity in indigent patients (abst) 202
plasma chromogranin A in patients with (abst) 198
transcapillary colloid osmotic gradient, body fluid vol. . 895
Renal function
altered, mechanism of progressive hepatic congestion (abst) 385
Renal infection
prediction of outcome by chromogenic endotoxin assay (abst) 207
Renal injury from mercury (abst) 199
Renal insufficiency
ablation, eicosapentaenoic acid (abst) 325
Renal mass reduction, Ca (abst) 321
Renal medulla
glycerophosphorylcholine (abst) 1252
Renal papilla
comparison of two techniques for x-ray analysis 675
Renal plasma flow, arginine (abst) 190
estimated (abst) 261
response to aldosterone (abst) 208
Renal scanning by water loading (abst) 189
Renal sympathetic nerve activity (abst) 249
Renal tissue
platet activating factor in 469
Renal vein thrombosis, MRI (abst) 206
Renaovascular resistance, PGE2 (abst) 336
Renin
antihypertensive treatment in hypertensive rats 1011
cells transplanted into anterior eye chamber 1234
endocytosis (abst) 255
in glomeruli (abst) 331
kallikrein, immunocytochemical localization in cortex . . 965
rapid preparation of protease-free (abst) 343
release, prostaglandin-stimulated in uninephctomy (abst) 381
secretion, pertussis toxin in (abst) 342
Renin-aldosterone system
hypertension following coronary artery bypass (abst) . . 263
Renin-angiotensin-aldosterone system
altered during captopril therapy (abst) 257
Renorenal reflexes impaired, SHR (abst) 249
Renotropic effects, indomethacin (abst) 339
Renovascular resistance, PGE2 (abst) 337
Respiration
ANF, nephron segments (abst) 340
liganded platinum (abst) 309
sodium transport, oxygen consumption and ATP 3
Restless legs syndrome (abst) 195
Rheumatoid arthritis
Cya, Aza in treatment of 1180
gold nephropathy, detection of autoantibodies to antigens 539
Ribonuclease II isozyme, ARF (abst) 305
Richard Bright's disease 779
Rubidum uptake in nephron (abst) 391

Salt DOCA hypertension, receptor (abst) 252
Salt, chronic renal injury (abst) 244
Sarcolemmal vesicles, Na-H (abst) 248
Scanning electron microscopy GN (abst) 282
Sclerosis
glomerular, interstitial nephropathy, lithium 875
long-term blood pressure and renal function in donors. 1072
Secondary hyperparathyroidism (abst) 317
Seiving, glomerular in MGN (abst) 390
Sepsis, vasoactive hormones (abst) 300
Serotonin
synthesis by renal proximal tubules 689
Shunting
arteriovenous (abst) 195
arteriovenous, PAVP (abst) 346
Shwartzman phenomenon, PCA (abst) 295
Silastic tenckhoff catheter (abst) 239
Sodiaum diclofenac, natriuretic (abst) 328
Sodium
acidification activates Na-H exchange, Na-K pump (abst) 397
aldosterone induced, glucocorticoids (abst) 330
ATPases, classes, distribution and function of 21
calcium exchange system of basolateral membranes (abst) 425
channel, modification in frog skin epithelium (abst) 400
chronic loading, angiotensin II, adenosine (abst) 385
cotransport with glucose 54
cyclosporine treatment (abst) 304
dependent aldosterone stimulation of CCD (abst) 397
effect of acid medium pH on (abst) 164
energy requirements for reabsorption 32
epithelial, solubilization of channel (abst) 400
excretion during volume expansion, ANP (abst) 407
excretion in IEPK, ADH and PGE2 (abst) 401
excretion, dietary potassium as determinant (abst) 182
furosemide sensitive, uremic plasma (abst) 316
H+ antiport inhibition by sulfated bile acid (abst) 1257
high, plasma levels of ANF and ouabain factor (abst) . . 404
homeostasis, atrial natriuretic facter determinations and 1004
hyperglycemia induces retention (abst) 417
hypernatremia inhibits NaHCO3 reabsorption 820

inhibits H-driven Na-H exchange (abst) 397
K-ATPase in the kidney 10
MNR measures in proximal tubules, diabetic (abst) 356
Na-H antiport activity of exchanger (abst) 396
Na-H exchange is pathway for influx (abst) 401
Na/H antiporter, ammonium on (abst) 402
not visable in proximal tubules Tal (abst) 392
PGE2 synthesis of (abst) 405
plasma concentrations, hospital-associated hyponatremia 1237
pump in salt gland, gut tubes of brine shrimp (abst) 394
regulation of renal acid secretion in distal nephron segment 1099
restriction moderates hypertension (abst) 254
restriction, ACE-inhibition and hypertension (abst) 945
restriction, role of renal nerves in adaptation (abst) 253
retention in nephrotic syndrome, aldosterone (abst) 203
retention, role of aldosterone-independent tubular (abst) 260
reversible modification of channel (abst) 1255
saline volume expansion, ANP levels during (abst) 406
single channel events in apical membrane of CCD (abst) 397
single channels in apical membrane of CCT (abst) 404
transition from proliferative to membranous GLN 841
transport in papillary collecting tubule (abst) 401
transport in red blood cells from dialyzed uremic 1197
transport, apical, entry into ambystoma (abst) 403
transport, CGMP and atriopeptin effect on (abst) 331
transport, oxygen consumption and ATP 3
uptake by papillary collecting duct cells (abst) 399
washout, angiotensin II from VSMCs (abst) 338
x-ray microprobe technique in finding 682
23Na NMR spectroscopy of proximal tubule suspensions 747
Sodium-calcium exchange, PTH (abst) 171
Solubility of aluminum S-3
Somatostatin 14, 28 (abst) 358
Somatostatin, AVP cAMP in MDCK (abst) 416
Sorbitol, renal papillary cells (abst) 412
Spatial reconstructor, blood flow (abst) 380
Spectroscopy, NMR in renal biochemistry 131
Sphingolipids, dexamethasone (abst) 334
Steady-state
IP3 on rat kidney cortex 695
Stenosis, renal artery, ERPF scan (abst) 261
Steriod metabolism in PKD (abst) 271
Steroid pulse therapy, MGN 927
Steroid, hypertensinogenic 19-NOR (abst) 253
Steroids
SECO, Ca-dependent K channels inactivated by (abst) . 158
Stone formers
nephrolithiasis 563
nonstruvite (abst) 194
Stones, renal
isolation of glycoprotein crystal growth inhibitor (abst) . 167
Streptococcus mutans perfusion (abst) 264
Streptozotocin diabetic, indomethacin 490
Streptozotocin, ARF (abst) 301
Stress management for ESRD (abst) 201
Strip test, specific gravity (abst) 177
Struvite stone disease (abst) 170, 194
Submitochondrial particles
glutamine transport in (abst) 359
Substrate
metabolic fuels along the nephron 41
Suckling, effects blood pressure (abst) 241
Sulfidopeptide leukotriene (abst) 346
Sulfur
mediation in bone and PTH inhibitory action of WR2721 (abst) 159
Sulindac sulfide during hemmorage 484
Superoxide stimulation (abst) 268
Suppressor cell
activity factor (abst) 289
in transfusions (abst) 427
induction, T cell (abst) 428
Suppressor factor, lymphocyte (abst) 432
Survival, allograft, by race (abst) 428
Symptomatic hyponatremia (abst) 205
Synovial amyloid deposits (abst) 229
Systemic edema, SCLS (abst) 181
Systemic illness, hypernatremia (abst) 204
Systemic lupus erythematosus
(abst) 273, 276
children 1066
CyA (abst) 294
glomerulonephritis in ANF negative (abst) 1256
study (abst) 287
Systems, PGE2, BP, AII (abst) 346

T cell
interleukin-2 mitogenic to peripheral blood (abst) 286
interstitial nephritis (abst) 286
mononuclear cell marker, renal allograft rejection 708
new model (abst) 436
suppressor cell activity maintenance factor (abst) 289
interleukin 2 receptor therapy spares (abst) 432
performation of suppressor (abst) 433
splenic (abst) 428
suppressor, contrasuppressor in SIN (abst) 280
1-J+ suppressor, interstitial nephritis (abst) 284
T lymphocytes in hybrid molecule (abst) 270
Tamm-Horsfall
biochemistry of protein in diabetes mellitus (abst) 1257
characterization of monoclonal antibodies specific for .. 971
crystal growth inhibitor, albumin (abst) 295
urinary calcium oxalate crystal growth inhibitor 829
Terminal complement components
hypertensive glomerular injury (abst) 274
Theophylline in ARF (abst) 308
Theophylline-induced protect ARF (abst) 299
Thrombotic microangiopathy (abst) 280
Thromboxane
A2 in glycerol-induced ARF (abst) 1257
A2, glucose reabsorption increased (abst) 330
B2, in diagnosis of allograft rejection (abst) 1260
B2 formation in GN (abst) 1250
endoperoxide, mesangial cells (abst) 340
in hypertension (abst) 227
in nephrectomy (abst) 329
prostaglandin production, protein (abst) 336
synthetase inhibition (abst) 777
synthesis inhibition of proteinuria, GFR (abst) 347
Thromboxytosis, progressive
chronic peritoneal dialysis associated with (abst) 240
Thyroid
ablation, glomerular (abst) 318
hormone, uremia (abst) 322

parathyroidectomy in rabbits (abst) 161
Thyrotoxicosis, ADH, Type B Syn (abst) 421
Thyroxine, fluid balance in DOCA (abst) 243
Tobramycin, toxicity (abst) 313
Torasemide (abst) 1254
Total body irradiation
prior to bone marrow transplantation (abst) 206
Toxicity
aluminum in CHD (abst) 211
aluminum-induced bone disease S-32
aluminum, with experimental renal failure (abst) 175
Bence Jones protein (abst) 309
calcium to renal medulla (abst) 298
cyclosporine A, intraluminal obstruction (abst) 312
gentamicin, bacteremia (abst) 313
gold nephropathy, detection of autoantibodies to antigens 539
phosphate binding gels balance adsorption, Al 1131
role of plasma aluminum in detection, prevention of . . S-91
tobramycin dosing (abst) 313
WR-2721 protects against cisplatinum (abst) 311
2-bromohydroquinone, glutathione (abst) 310
Toxin
aluminum-related bone disease S-80
Transdermal clonidine in RI (abst) 251
Transfusion
donor specific, suppressor cells (abst) 427
Transluminal angioplasty in renal (abst) 191
Transplantation
anencephalic neonate donor (abst) 430
blood pressure in donor, recipient (abst) 436
blood transfusions and cyclosporine (abst) 435
cadaveric renal without dialysis, in ESRD (abst) 942
cardiovascular rehabilitation after renal (abst) 1263
CMV-prophylaxis (abst) 1262
convert from CyA to azathioprine improves function (abst) 433
coronary revascularization, valvular procedure (abst) . . 427
corpulence-index in CyA dosage (abst) 1262
cryoprotective dimethyl sulfoxide perfusion (abst) 431
Cya, Aza in allografts with severly impaired function (abst) 1261
cyclosporin in cadaveric renal (abst) 612
cyclosporine conversion in stable (abst) 437
cyclosporine therapy convert to azathioprine (abst) 435
exercise, cardiovascular responses to (abst) 434
expression of HLA-DR, DP, DQ antigens (abst) 1261
familial glomerulopathy, giant fibrillar deposits (abst) . . 1262
fine needle biopsy in kidney (abst) 430
GFR in CyA treated (abst) 428
hematopoiesis following (abst) 427
hepatic veno-occlusive disease (abst) 435
HLA-A, B compatible blood transfusion (abst) 612
influenza vaccination in hemodialysis and renal (abst) . . 942
instrumented conscious dogs, CyA (abst) 1262
light chain nephropathy (abst) 943
living nonrelated donor (abst) 430
kidney cells into anterior eye chamber 1234
magnetic resonance imaging, loss of demarcation (abst) . . 429
membranoproliferative glomerulonephritis in (abst) 429
mononuclear subsets monitor CMV infection in renal (abst) 944
polycystic kidney disease (abst) 437
primary renal (abst) 430
rejecting, cyclosporine rescues (abst) 426
renal biopsy and fine-needle biopsy in (abst) 612
serum urate levels and cyclosporine (abst) 426
survival, risk factors in 600 grafts (abst) 434
T cell activation, new model (abst) 436
Transport
adenosine, theophylline and papaverine effect (abst) . . . 332
aldosterone induces chloride (abst) 1229
alkalosis on phosphate, in renal proximal tubule (abst) . 163
amiloride on renal MG handling in distal tubule (abst) . . 163
ammonia in medullary collecting tubule (abst) 367
and metabolic functions in cultured renal tubule cell 46
apical membrane, Na entry in ambystoma tubule (abst) . . 403
ATP, Na-K-ATPase activity, luminal active (abst) 611
ATPase in tubular electrolyte 21
calcium, across cortical segment two proximal tubules (abst) 155
calcium, PTH in uremia effect on (abst) 158
Ca2+, PTH stimulates (abst) 421
cephalosporin (cefodizim) (abst) 1256
chloride, pathways in CCT (abst) 409
co- electrogenic Na/HCO3 in necturus proximal tubules (abst) 371
co-, NaHCO3 in BLMV (abst) 362
contol of cell pH in BLM (abst) 362
cystine, change in characteristics (abst) 350
dependent cell injury in S3 segment 1033
effects of phosphate (Pi) on (abst) 171
epithelial inorganic phosphate (abst) 172
glutamine in renal submitochondrial particles (abst) 359
H+/OH-, renal brush border (abst) 378
high K diet on CCD of adrenalectomized rabbit (abst) . . 403
inhibition of phosphate by phosphonocarboxylic acids (abst) 164
inhibitor, produced by mTAL (abst) 351
inorganic sulfate (abst) 1254
inositol triphosphate-sensitive calcium pool (abst) 157
insulin, luminal uptake and intracellular 983
ion, fusion of renal epithelial cells (abst) 404
K and ammonia in turtle bladder (abst) 377
K depletion effect on HCO3 (abst) 368
luminal uptake and intracellular, of insulin 983
luminal, basolater lactate, pH in tubules (abst) 376
metabolism of dipeptides (abst) 1252
Na or membrane lipid events, dietary amino acid (abst) . . 413
Na-dependent acetate on pH (abst) 373
Na-HCO3in BLMV (abst) 367
Na+ channel modification in frog skin epithelium (abst) 400
Na+ reabsorption, energy requirements 32
Na,K-ATPase structure, function and regulation in the kidney 10
NaCl, formate stimulates active (abst) 407
nucleosides in brush border vesicles (abst) 1253
N1-methylnicotinamide in proximal renal tubules (abst) . . 414
osmotic water in tubule cells in suspension (abst) 421
oxalate, method of (abst) 161
PAH reabsorption (abst) 371
paraaminohippurate kinetics (abst) 424
parallel antiporters, NaCl in PCT (abst) 390
peritoneal by captopril (abst) 233
peritoneal in CAPD patients (abst) 941
peritoneal, dual barrier model of (abst) 234
phosphate, heterogeneity of sodium-dependent (abst) . . 169
phosphate, nicotinamide inhibits (abst) 161
phosphate, phosphonocarboxylic acids inhibit (abst) . . . 172

phosphonocarboxylic acids inhibit Na+ dependent (abst) ... 172
physiological characteristics, symposium ... 1
regulation of Na, K by adrenal cortiocosteroids (abst) ... 407
renal glucocorticoid metabolites on membrane (abst) ... 358
renal tubular support by glucose ... 54
role of loop segment in hypercalcemia ... 977
sodium, cGMP and atriopeptin II effect on (abst) ... 331
sodium, in red blood cells from dialyzed uremic patients ... 1197
sodium, in renal papillary collecting tubule (abst) ... 401
sodium, potassium activity (abst) ... 392
sodium, relationship of renal ATP to (abst) ... 359
sugar co-, in LLC-PK1 (abst) ... 419
tetraethylammonium and morphine (abst) ... 423
TPA stimulates Na-dependent phosphate in (abst) ... 167
transepithelial ammonia in proximal straight tubule (abst) ... 366
two sodium-dependent glucose, in small intestine (abst) ... 423
urate, uricase as carrier (abst) ... 422
vitamin D stimulates phosphatidylcholine transfer (abst) ... 162
Travenol, reduction peritonitis (abst) ... 240
Treatment of ESDR by state (abst) ... 201
Tripeptide
glutathione depletors, proximal tubules ... 858
Tripletherapy
effects of antihypertensive treatment in hypertensive rats ... 1011
Tubular
basement membrane component change in PKD (abst) ... 268
changes during PKD (abst) ... 320
dysfunction, alcohol-associated nephropathy (abst) ... 609
reabsorption, aldosterone-independent (abst) ... 260
transport function ... 1
Tubule
acidification in medullary collecting duct ... 1167
ambystoma proximal, transport on cell pH (abst) ... 376
ammonia production, isolated perfused proximal (abst) ... 373
ammonia transport in medullary collecting (abst) ... 367
amphiuma, K and CL+ channels in membrane (abst) ... 399
atrial extract, atriopeptin III (abst) ... 401
atrial natriuretic factor, intrarenal effects (abst) ... 408
Ca, nephron segment as determinants of anoxic cell death ... 11
cell pH in, luminal HCO3- (abst) ... 374
cortical collecting, Na channels in apical membrane (abst) ... 404
cortical collecting, Cl secretion on diet (abst) ... 410
cortical collecting, basolateral amiloride (abst) ... 371
cortical collecting, immunodissection and culture (abst) ... 424
cortical suspensions, norepinephrine, Na-K ATPase (abst) ... 391
distal cell types, monoclonal antibodies (abst) ... 360
distal, bicarbonate reabsorption is load-dependant (abst) ... 365
early distal convoluted, basolateral K conductance (abst) ... 409
electrophysiological characteristics of (abst) ... 391
functions during hypotonic volume expansion (abst) ... 420
glucagon in man, effects of (abst) ... 413
glutathione depletors on proximal ... 858
hypotonicity, K, Na, Cl in renal proximal (abst) ... 406
hypoxic injury in proximal ... 1021
indomethacin secretion by PST (abst) ... 414
inhibitory effect of atrial natriuretic peptide (abst) ... 425
isolated cortical collecting, vasopressin (abst) ... 419
isolated perfused PST, phorbol ester (abst) ... 411
isolated renal, glomerular preparation (abst) ... 352
lithium renal lesions ... 875
luminal uptake and intracellular transport of insulin ... 983
method to get a suspension enriched in proximal (abst) ... 611
mid-cortical collecting, intercalated cell difference (abst) ... 375
osmotic water transport (abst) ... 421
paired responses to osmolar raffinose and NaCl (abst) ... 410
proximal BBM, ATPase activity (abst) ... 368
proximal cells, x-ray analysis ... 682
proximal convoluted, dopamine on NaKATPase activity (abst) ... 390
proximal convoluted, H2O permeability on gradient (abst) ... 412
proximal convoluted, luminal and peritubular pH (abst) ... 413
proximal convoluted, norepinephrine mechanism (abst) ... 394
proximal, acid-base disturbance, HCO3- (abst) ... 375
proximal, CO2 stimulates growth (abst) ... 363
proximal, hypernatremia inhibits NaHCO3 reabsorption ... 820
proximal snake, N1-methylnicotinamide in (abst) ... 414
PTH dependent phosphorylation of proteins in (abst) ... 167
regulation of renal acid secretion ... 1099
renal proximal, pathway for serotonin ... 689
systemic acidosis (abst) ... 368
S2, anisotonic media regulation (abst) ... 419
thick ascending limb, sodium, NMR (abst) ... 392
transport of K and Na in PCT (abst) ... 392
transport-dependent cell injury in S3 segment ... 1033
tubulopathy in nephrolithiasis ... 563
23Na NMR spectroscopy of proximal, suspensions ... 747
Tubuloglomerular feedback
acute volume expansion (abst) ... 388
control of GFR (abst) ... 388
increase in GFR during volume expansion (abst) ... 1253
Tubulopathy in nephrolithiasis ... 563

Ultrafiltration
maximum on peritoneal dialysis (abst) ... 235
remission induced by, NS and FGS (abst) ... 776
transcapillary colloid osmotic gradient, body fluid volumes ... 895
Uninephrectomy
response of plasma 1,25(OH)2D to PTH (abst) ... 158
Urea formation, acid-base (abst) ... 367
Uremia
aluminum metabolism ... S-8
associated hyporesponsiveness to thyroid hormone (abst) ... 322
calcium carbonate, Al-free agent for control ... S-114
diminishes 1,25(OH)2D3 receptors (abst) ... 170
effect of aluminum on PTH secretion ... S-41
effect of 1,25(OH)2D3 on zinc absorption (abst) ... 154
epitrochlearis muscle, insulin (abst) ... 316
hematopoietic inhibitors in chronic renal failure ... 641
low protein-essential amino acid diet, risk and benefits ... 995
mouse model (abst) ... 318
phosphate restriction and CRF ... 658
plasma phospholipase A2 activity (abst) ... 316
PTH effects on calcium transport in brain (abst) ... 158
skeletal resistance to PTH in (abst) ... 319
zinc balances of (abst) ... 321

99mTc-methylene diphosphonate bone scan in osteodystrophy 1058
Uremic
adrenalectomy, protein in (abst) 309
alpha-ketoisocaproate for protein synthesis (abst) 326
calcium transport (abst) 315
dialysis encephalopathy S-53
enhanced gastrointestinal adsorption of Al in (abst) ... 1260
hemolytic syndrome, oral contraceptives (abst) 777
methods for aluminum measurement S-24
nitrogen metabolism, energy intake, in CRF 734
pericarditis in diabetics (abst) 186
plasma, Na+ efflux (abst) 316
protein synthesis and degradation in skeletal muscle .. 1136
serum, calcium oxalate (abst) 315
serum and spinal fluid aluminum levels in (abst) 211
sodium transport in red blood cells from dialyzed 1197
symptoms at start of chronic hemodialysis (abst) 176
Ureteral ligation, bilateral
elimination of plasticizer DI-2-(ethylhexyl) 214
Ureteric ligation, histology (abst) 296
Ureteropelvic junction obstruction
separate renal function in children (abst) 200
Uricase
for urate transport (abst) 422
in isolated membrane (abst) 411
Urinalysis
cytodiagnostic (abst) 429
survey (abst) 184
Urinary
doubly refractile lipid bodies in NGRD (abst) 180
erythrocyte morphology, excretion, IgA nephropathy (abst) 181
protein excretion, teenagers (abst) 191
thromboxane, cyclosporin nephrotoxicity (abst) 304
tract anomalies, lasix renography for diagnostic (abst) .. 208
tract obstruction, changes in renal metabolism 80
Urine
anion gap, diagnostic tool (abst) 188
assessment of urinary chloride (abst) 186
atrial natriuretic factor inhibition of AVP (abst) 328
blood PCO2 gradiant in bicarbonate diuresis (abst) 373
calcium and calcium intake relationship during calcitriol 578
characterization of monoclonal antibodies for Tamm-Horsfall 971
concentrating ability, hypercalcemia, role of loop segment 977
diagnostic value of erythrocyte morphology in (abst) .. 1258
excretion, circadian variations in nephrotic syndrome (abst) 942
excretion, colloid volume expansion on glomerular barrier 916
flow rate influence on protein excretion (abst) 941
hypercalcemia on concentrating ability (abst) 423
osmolality, leukotrienes (abst) 335
plasma ANF levels following infusion (abst) 409
procoagulant activity associated with subcellular particles 591
proteinuria and oxygen free radicals 478
samples in assessment of proteinuria (abst) 182
sodium excretion, ANF 1004
anion gap, diagnostic tool (abst) 188
Urokinase
i.v. (abst) 223
phospholipase D (abst) 344
restores catheter (abst) 235
Urolithiasis, tubulopathy 563
Uropathy
congenital obstructive (abst) 331
obstructive, acidification 1167

Validation of method
atomic absorption spectroscopy to detect aluminum ... S-28
Valproate stimulation of ammonia (abst) 350
Vanadate
acidification (abst) 364
ouabain (abst) 330
PO4 clearance (abst) 425
Vancomycin clearances in HD (abst) 228
Vasa recta blood flow, V2 (abst) 418
Vascular
a-adrenoceptor, assess (abst) 244
abberancies of ARF (abst) 299
effects of acetate (abst) 218
diameter response to angiotensin II (abst) 381
hemodynamic effect of atrial natriuretic peptide (abst) .. 383
hemodynamics during infusion of amino acids, dopamine 870
L-platelet activating factor changes RVR (abst) 388
recirculation rate, HD (abst) 219
smooth muscle, Na-H 248
Vasoconstrictor
ANP-induced (abst) 245
serotonin synthesis by proximal tubules 689
Vasodilation, renal
arterial pressures in dog (abst) 380
therapy, hypertension (abst) 175
Vasomotor response, AII (abst) 610
Vasopressin
adenylate cyclase activity, protein kinase C (abst) 415
activation of system, a pathway for pressor agents (abst) 246
antagonist prevents hyponatremia (abst) 418
AVP-induced cAMP accumulation in MDCK (abst) 416
calcium in mobilization of (abst) 415
captopril through PGE2 production, cAMP generation (abst) 420
clinical hyponatremia (abst) 1258
hospital-associated hyponatremia 1237
increased urinary excretion of PGE2 during antidiuresis 1110
inhibition of permeability after repeated (abst) 419
modulation of plasma, platelet, by cardiac function ... 1188
phosphatidyl inositol 4,5 bisphosphate hydrolysis (abst) .. 422
renin-angiotensin system in congestive heart failure (abst) 193
stimulated cAMP formation by increased Ca (abst) 425
V2 receptor, GTP-binding proteins (abst) 424
Ventilation
acetate vs. bicarbonate dialysis in (abst) 944
positive end expiratory pressure ventilation (abst) 415
Verapamil
aminoglycoside-induced ARF (abst) 312
atriopeptin III on renal function after ischemia (abst) .. 943
chronic renal failure (abst0 319
induced natriuresis in CVAL dogs (abst) 382
modulates hormonal action 863
protective effect of on bone resorption (abst) 156

Vesicles
medullary, chloride channel in bovine kidney (abst).... 398
Veterinary, canine chronic renal disease..... 1144
Vitamin B6 deficiency (abst)..... 228
Vitamin D
abnormal in hypertensive (abst)..... 247
Al binding protein (abst)..... 154
metabolism and sites of action in the kidney..... 98
regulation of intestinal phosphate absorption (abst).... 163
Vitamin D3
inhibitory effect on growth of renal carcinoma cell line . 834
Vitamin E
gentamicin induced lipid peroxidation (abst)..... 303
Volume
inorganic sulfate transport (abst)..... 1253

Water
Australian municipal supplies, aluminum contamination . S-65
restriction, humoral control of water, electrolyte excretion..... 1152
soft vs. hard in Ca stone formers (abst)..... 778
intake, angiotensin II (abst)..... 1252
loading, renal scanning (abst)..... 189
treatment in Newcastle disease..... S-58
Wegener's granulomatosis (abst)..... 185
Western-blot technique, antigens (abst)..... 1116
WR-2721
PTH secretion suppression by (abst)..... 174
sulfur group activity mediates bone and PTH action (abst)..... 159

X-ray
comparison of two techniques for analysis, renal papilla..... 675
microprobe techniques for analysis of proximal tubule cells..... 682

Zinc
absorption in uremia (abst)..... 154
balances uremic (abst)..... 321
metabolism in CAPD (abst)..... 234

1,25(OH)2D3
and bone GLA decrease and parathyroidectomy (abst) . 186
compensatory renal growth, modulation by Ca PTH and..... 1124
evidence for an endogenous receptor activator (abst)... 156
immunomodulation (abst)..... 265
inhibitory effect on growth of renal carcinoma cell line . 834
intestinal calcium absorption in hypertensive (abst).... 159
PTH, effects of on intestinal and renal Al handling (abst)..... 173
reduced in hypertensive rat (abst)..... 165
regulation by, of pre-proparathyroid hormone mRNA (abst)..... 172
stimulates interleukin-2 production (abst)..... 160
synthesis of in proximal tubules (abst)..... 162
uremia dimishes receptors (abst)..... 170
12-hydroxyeicosatetraenoic acid (abst)..... 335
125I iothalamate clearance, GFR (abst)..... 188
31P-NMR, hypoxia (abst)..... 358
6-thiouric acid, AZA (abst)..... 437

KIDNEY INTERNATIONAL

Volume 29, Number 1, January 1986

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

SYMPOSIUM ON BIOCHEMICAL INSIGHTS INTO REGULATION OF RENAL FUNCTION

Introduction. *Kiyoshi Kurokawa* 1

Primary active sodium transport, oxygen consumption, and ATP: Coupling and regulation. *Lazaro J. Mandel* 3

Structure, function, and regulation of Na,K-ATPase in the kidney. *Peter J. Jørgensen* 10

Distribution and function of classes of ATPases along the nephron. *Adrian I. Katz* 21

Relationship between energy requirements for Na^+ reabsorption and other renal functions. *Julius J. Cohen* 32

Metabolic fuels along the nephron: Pathways and intracellular mechanisms of interaction. *Walter G. Guder, Siegfried Wagner, and Gabriel Wirthensohn* 41

Transport and metabolic functions in cultured renal tubule cells. *Michael F. Horster and Martin Stopp* 46

Glucose metabolism in renal tubular function. *Brian D. Ross, Joseph Espinale, and Patricio Silva* 54

Regulation of glutamine metabolism in dog kidney in vivo. *Patrick Vinay, Guy Lemieux, André Gougoux, and Mitchell Halperin* 68

Metabolic adaptations of the nephron in renal disease. *Saulo Klahr, Steven J. Schwab, and Thomas J. Stokes* 80

Cellular mechanism of hormone action in the kidney: Messenger function of calcium and cyclic AMP. *Howard Rasmussen, Itaru Kojima, William Apfeldorf, and Paula Barrett* 90

Metabolism and sites of action of vitamin D in the kidney. *Hiroyuki Kawashima and Kiyoshi Kurokawa* 98

Prostaglandins and other arachidonic acid metabolites in the kidney. *Detlef Schlondorff and Raymond Ardaillou* 108

Renal kallikrein-kinin system. *A. Guillermo Scicli and Oscar A. Carretero* 120

Contributions of nuclear magnetic resonance to renal biochemistry. *Brian Ross, Dominique Freeman, and Laurence Chan* 131

NEPHROLOGY FORUM

Monoclonal antibodies in the diagnosis of renal disease: A preliminary report. *Nina E. Tolkoff-Rubin* 142

ABSTRACTS

The American Society of Nephrology 153

THE INTERNATIONAL SOCIETY OF NEPHROLOGY

Announcements 462

Awards and Grants 465

KIDNEY INTERNATIONAL

Volume 29, Number 2, February 1986

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Potential role of platelet-activating factor in renal pathophysiology. *Giovanni Camussi* 469

LABORATORY INVESTIGATION

A role for oxygen free radicals in aminonucleoside nephrosis. *Jonathan R. Diamond, Joseph V. Bonventre, and Morris J. Karnovsky* 478

Renal hemodynamic effects of therapeutic plasma levels of sulindac sulfide during hemorrhage. *William L. Henrich, D. Craig Brater, and William B. Campbell* 484

Effects of indomethacin on glomerular hemodynamics in experimental diabetes. *Peter Koch Jensen, Kenneth Steven, Hanne Blæhr, Jens Sandahl Christiansen, and Hans-Henrik Parving* .. 490

Modification of renal cortical subcellular membrane phospholipids induced by mercuric chloride. *Aubrey R. Morrison and Nina Pascoe* 496

Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. *Seiya Okuda, Yukinori Oh, Hiroshi Tsuruda, Kaoru Onoyama, Satoru Fujimi, and Masatoshi Fujishima* 502

Long-term renal responses to high dietary protein in dogs with 75% nephrectomy. *John L. Robertson, Michael Goldschmidt, David S. Kronfeld, John E. Tomaszewski, Gary S. Hill, and Kenneth C. Bovee* 511

Tubuloglomerular feedback and glomerular morphology in Goldblatt hypertensive rats on a varying diet. *Jürgen Schnermann, Michael Gokel, Peter C. Weber, Gisela Schubert, and Josephine P. Briggs* 520

Lipid alterations in LLC-PK_1 cells exposed to mercuric chloride. *Dean A. Troyer, Jeffrey I. Kreisberg, and Manjeri A. Venkatachalam* 530

Experimental gold nephropathy in guinea pigs: Detection of autoantibodies to renal tubular antigens. *Shiro Ueda, Masafumi Wakashin, Yoko Wakashin, Hiromichi Yoshida, Kenji Iesato, Teruo Mori, Yoshio Mori, Bunshiro Akikusa, and Kunio Okuda* 539

CLINICAL INVESTIGATION

Toward individual prognosis of IgA nephropathy. *Johan R. Beukhof, Otto Kardaun, Willem Schaafsma, Klaas Poortema, Ab J. M. Donker, Philip J. Hoedemaeker, and Gjalt K. van der Hem* 549

Glomerular IgA deposition in pulmonary diseases. *Yuzo Endo and Mitsuru Hara* 557

Tubulopathy in nephrolithiasis: Consequence rather than cause. *Philippe Jaeger, Luc Portmann, Jean-Marie Ginalski, Anne-Francoise Jacquet, Evelyne Temler, and Peter Burckhardt* 563

Effect of dietary protein intake on albumin homeostasis in nephrotic patients. *George A. Kaysen, John Gambertoglio, Irma Jimenez, Hardin Jones, and Florence N. Hutchinson* 572

Relationship between urinary calcium and calcium intake during calcitriol administration. *Ruth L. Smothers, Barton S. Levine, Frederick R. Singer, Graeme F. Bryce, John P. Mallon, O. Neal Miller, and Jack W. Coburn* 578

Contents continued on next page

Prostaglandin-mediated loss of proteins during peritonitis in continuous ambulatory peritoneal dialysis. *Hjalmar B. Steinhauer and Peter Schollmeyer* 584

Procoagulant activity in normal human urine is associated with subcellular particles. *Roger C. Wiggins, Arthur Glatfelter, Bharati Ksirsagar and Jorge Brukman* 591

NEPHROLOGY FORUM

Renal and cardiovascular dysfunction in liver disease. *Ori S. Better* 598

ABSTRACTS

Italian Society of Nephrology 608

INTERNATIONAL SOCIETY OF NEPHROLOGY

Announcements 614

Awards and Grants 618

Editor's Note:
The Editors and Management Committee of the International Society of Nephrology have agreed that, beginning with this issue, French translations of Abstracts of original articles will not appear in *Kidney International*. This was instituted to accelerate publication of papers at a time when the number of submitted manuscripts has increased appreciably.

KIDNEY INTERNATIONAL

Volume 29, Supplement 18

Proceedings of the Conference on Aluminum-related Disease:
Pathogenesis, Recognition, Treatment, and Prevention
June 18–20, 1984, Newport Beach, California, USA

Table of contents

Introduction. *Jack W. Coburn and Allen C. Alfrey* S-1
Geochemistry and aqueous chemistry of aluminum. *John D. Hem* S-3
Aluminum metabolism. *Allen C. Alfrey* S-8
Interactions of aluminum with cofactors, enzymes, and other proteins. *George A. Trapp* S-12
Model of aluminum-induced osteomalacia: Inhibition of apatite formation and growth. *Aaron S. Posner, Norman C. Blumenthal, and Adele L. Boskey* S-17
Aluminum and aluminum complex. Effect of calcium phosphate precipitation. *John L. Meyer and William C. Thomas, Jr.* S-20
Analytical methods for aluminum measurement. *John Savory and Michael R. Wills* S-24
Electrothermal determination of aluminum in biologic samples by atomic absorption spectroscopy. *Hillel J. Gitelman and Frances R. Alderman* S-28
Experimental aluminum-induced bone disease: Studies in vivo. *William G. Goodman* S-32
Effect of aluminum on bone and cell localization. *Giulia Cournot-Witmer, Jean-Jacques Placot, Agnès Bourdeau, Michèle Lieberherr, Vanda Jorgetti, Vulmario Mendes, Sylvain Halpern, Joseph Hemmerle, Tilmann Drüeke, and Sonia Balsan* S-37
Effect of aluminum on parathyroid hormone secretion. *Jeremiah Morrissey and Eduardo Slatopolsky* S-41
Effect of aluminum on hematopoiesis. *Tilmann B. Drüeke, Bernard Lacour, Malik Touam, Jean-Pierre Jucquel, Jean-Jacques Placot, Giulia Cournot-Witmer, and Pierre Galle* S-45
Unresponsiveness of bone to parathyroid hormone in aluminum-related renal osteodystrophy. *Yoshindo Kawaguchi, Yoshitaka Oda, Noritugu Imamura, Takashi Shigematu, Yasuo Kimura, Sumio Aizawa, Hiroshi Fujimaki, Ryo Shoji, Itsupei Tsukui, Yosuke Ogura, and Tadashi Miyahara* S-49
Dialysis encephalopathy. *Allen C. Alfrey* S-53
Aluminum-induced dialysis osteodystrophy: The demise of "Newcastle bone disease"? *David N. S. Kerr, Michael K. Ward, Ricardo S. Arze, J. Mauricio Ramos, Dimitrios Grekas, Ian S. Parkinson, Hewett A. Ellis, J. Phillip Owen, William Simpson, James Dewar, Anthony M. Martin, and Mary F. McHugh* S-58
Aluminum and renal bone disease in Australia. *Colin R. Dunstan and Richard A. Evans* S-65
Aluminum intoxication of bone in renal failure—Fact or fiction? *Hartmut H. Malluche, Marie-Claude Faugere, Albert J. Smith, Jr., and Robert M. Friedler* S-70
The natural course of dialysis osteomalacia. *Francisco Llach, Arnold J. Felsenfeld, Michael D. Coleman, John J. Keveney, Jr., James A. Pederson, and T. Richard Medlock* S-74
Clinical and biochemical features of aluminum-related bone disease. *Benno B. Ihle, Gavin J. Becker, and Priscilla S. Kincaid-Smith* S-80
Parathyroid hormone in aluminum bone disease: A comparison of parathyroid hormone assays. *Dennis L. Andress, David B. Endres, Susan M. Ott, and Donald J. Sherrard* S-87
Role of plasma aluminum in the detection and prevention of aluminum toxicity. *Robin J. Winney, John F. Cowie, and James S. Robson* S-91

Contents continued on next page

Contents continued

Indirect methods for diagnosis of aluminum bone disease: Plasma aluminum, the desferrioxamine infusion test, and serum iPTH. *Henry G. Nebeker, Dennis L. Andress, Dawn S. Milliner, Susan M. Ott, Allen C. Alfrey, Eduardo Slatopolsky, Donald J. Sherrard, and Jack W. Coburn* S-96

Clearance of aluminum by hemodialysis: Effect of desferrioxamine. *Dawn S. Milliner, Gavril Hercz, Joseph H. Miller, James H. Shinaberger, Allen R. Nissenson, and Jack W. Coburn* S-100

Role of desferrioxamine in the treatment of dialysis encephalopathy. *Peter Ackrill, Anthony J. Ralston, and J. Phillip Day* S-104

Changes in bone histology after treatment with desferrioxamine. *Susan M. Ott, Dennis L. Andress, Henry G. Nebeker, Dawn S. Milliner, Norma A. Maloney, Jack W. Coburn, and Donald J. Sherrard* S-108

Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia. *Albert Fournier, Phillipe Moriniere, Jean Luc Sebert, Hocine Dkhissi, Atik Ahssene, Paul Leflon, Henri Renaud, Jean Gueris, Isabelle Gregoire, Abderahim Idrissi and Michele Garabedian* S-114

In vitro and in vivo studies with a non-aluminum phosphate-binding compound. *Hans W. Schneider, Klaus D. Kulbe, Hans Weber, and Erich Streicher* S-120

KIDNEY INTERNATIONAL

Volume 29, Number 3, March 1986

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

The biology of renal hypertrophy. *Leon G. Fine* 619

LABORATORY INVESTIGATION

The effects of daily cyclophosphamide administration on the development and extent of primary experimental interstitial nephritis in rats. *David Agus, Richard Mann, Michael Clayman, Carolyn Kelly, Lauren Michaud, Debra Cohn, and Eric G. Neilson* 635

Hematopoietic inhibitors in chronic renal failure: Lack of in vitro specificity. *Francis Delwiche, Gerald M. Segal, Joseph W. Eschbach, and John W. Adamson* 641

Antibody, antigen, and glomerular capillary wall charge interactions: Influence of antigen location on in situ immune complex formation. *Irwin D. Feintzeig, John E. Dittmer, Andrey V. Cybulsky, and David J. Salant* 649

Phosphate depletion arrests progression of chronic renal failure independent of protein intake. *Dusit Lumlertgul, Thomas J. Burke, David M. Gillum, Allen C. Alfrey, David C. Harris, William S. Hammond, and Robert W. Schrier* 658

The renal response to chronic mineral acid feeding: A re-examination of the role of systemic pH. *Nicolaos E. Madias and Steven J. Zelman* 667

Rat renal papilla: Comparison of two techniques for x-ray analysis. *Albert J. Saubermann, Dennis C. Dobyan, Vicky L. Scheid, and Ruth Ellen Bulger* 675

Simultaneous comparison of techniques for x-ray analysis of proximal tubule cells. *Albert J. Saubermann, Vicky L. Scheid, Dennis C. Dobyan, and Ruth Ellen Bulger* 682

An active pathway for serotonin synthesis by renal proximal tubules. *Michael J. Sole, Annie Madapallimattam, and Andrew D. Baines* 689

Inositol 1,4,5-trisphosphate releases Ca^{2+} from a nonmitochondrial store site in permeabilized rat cortical kidney cells. *F. Thévenod, H. Streb, K. J. Ullrich and I. Schulz* 695

Regulation of renal cellular cAMP levels by prostaglandins and α_2-adrenoceptors: Microdissection studies. *Satoshi Umemura, Donald D. Smyth, and William A. Pettinger* 703

CLINICAL INVESTIGATION

Immunopathology of renal allograft rejection analyzed with monoclonal antibodies to mononuclear cell markers. *G. Alex Bishop, Bruce M. Hall, Geoffrey G. Duggin, John S. Horvath, A. G. Ross Sheil, and David J. Tiller* 708

Evidence for IgA-specific B cell hyperactivity in patients with IgA nephropathy. *Gerard M. Hale, Sonia L. McIntosh, Yoshiyuki Hiki, Anthony R. Clarkson, and Andrew J. Woodroffe* 718

Cytomegalovirus glomerulopathy: A controversial lesion. *Guillermo A. Herrera, Ronald W. Alexander, Caroline F. Cooley, Robert G. Luke, David R. Kelly, John J. Curtis, and Jon P. Gockerman* 725

Effect of energy intake on nitrogen metabolism in nondialyzed patients with chronic renal failure. *Joel D. Kopple, Francisco J. Monteon, and John K. Shaib* 734

The importance of renal net acid excretion as a determinant of fasting urinary calcium excretion. *Jacob Lemann, Jr., Richard W. Gray, William J. Maierhofer, and Herman S. Cheung* 743

Contents continued on next page

Contents continued

TECHNICAL NOTE

^{23}Na NMR spectroscopy of proximal tubule suspensions. *Adarsh M. Kumar, Adrian Spitzer, and Raj K. Gupta* 747

NEPHROLOGY FORUM

Lactic acidosis. *Nicolaos E. Madias* 752

ABSTRACTS

Sociètè de Néphrologie. *Bordeaux, France* 775

HISTORICAL ARCHIVES

Pathological specimens of the kidney examined by Richard Bright. *Leon G. Fine* 779

INTERNATIONAL SOCIETY OF NEPHROLOGY

Announcements 784

Awards and Grants 788

KIDNEY INTERNATIONAL

Volume 29, Number 4, April 1986

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Genetic factors in focal segmental glomerulosclerosis. *Jan J. Weening, Joke J.B. Beukers, Joris Grond, and Job D. Elema* 789

LABORATORY INVESTIGATION

Cardiopulmonary effects of cuprophane–activated plasma in the swine. *Alfred K. Cheung, Martin LeWinter, Dennis E. Chenoweth, Wilbur Y.W. Lew, and Lee W. Henderson* 799

Effects of glucagon and PTH on the loop of Henle of rat juxtamedullary nephrons. *Jean-Marc Elalouf, Nicole Roinel, and Christian de Rouffignac, with the technical assistance of P. Malorey, P. Philippe, N. Soyeux, and A. Zimmerman* 807

Interglomerular heterogeneity of filtration fraction among superficial nephrons. *M. Laurette Hughes and Iekuni Ichikawa* 814

Hypernatremia inhibits $NaHCO_3$ reabsorption and associated NaCl reabsorption in dogs. *Harald Langberg, Anders Hartmann, Jonny Østensen, Øystein Mathisen, and Fredrik Kiil* 820

Immunochemistry of urinary calcium oxalate crystal growth inhibitor (CGI). *Michelle Lopez, Yasushi Nakagawa, Frederic L. Coe, Cheng Tsai, Alfred F. Michael, and Jon I. Scheinman* ... 829

Inhibitory effect of 1α,25-dihydroxyvitamin D_3 on the growth of the renal carcinoma cell line. *Kazuhiko Nagakura, Etsuko Abe, Tatsuo Suda, Masamichi Hayakawa, Hiroshi Nakamura, and Hiroshi Tazaki* 834

A transition from proliferative to membranous glomerulonephritis in chronic serum sickness. *Bernice Noble, Judith B. Van Liew, and Jan R. Brentjens* 841

Relation of glomerular injury to preglomerular resistance in experimental hypertension. *Jean L. Olson, Stephen K. Wilson, and Robert H. Heptinstall* 849

Multiple effects of presumed glutathione depletors on rabbit proximal tubules. *Rick G. Schnellmann and Lazaro J. Mandel* 858

Modulation by verapamil of hormonal action on the Henle's loop of mice. *Katsuji Takeda, Shozo Torikai, Yasushi Asano, and Masashi Imai* 863

Renal hemodynamics during separate and combined infusion of amino acids and dopamine. *Piet M. ter Wee, Johan B. Rosman, Siebe van der Geest, Wim J. Sluiter, and Ab J.M. Donker* 870

Chronic progressive renal lesions induced by lithium. *Rowan G. Walker, Margot Escott, Ian Birchall, John P.Dowling, and Priscilla Kincaid-Smith* 875

CLINICAL INVESTIGATION

Blood pressure control in normotensive members of hypertensive families. *Mario G. Bianchetti, Carlo Beretta-Piccoli, Peter Weidmann, and Claudia Ferrier* 882

Glomerular filtration surface in type I diabetes mellitus. *Eileen N. Ellis, Michael W. Steffes, Fred C. Goetz, David E. R. Sutherland, and S. Michael Mauer* 889

Transcapillary colloid osmotic gradient and body fluid volumes in renal failure. *Per Fauchald* .. 895

Heterogeneity of the cardiovascular response to hemofiltration. *Lee W. Henderson* 901

Treatment of acute renal failure in newborns by continuous arterio–venous hemofiltration. *Claudio Ronco, Alessandra Brendolan, Luisa Bragantini, Stefano Chiaramonte, Mariano Feriani, Aldo Fabris, Roberto Dell'Aquila, and Giuseppe La Greca* 908

Effect of colloid volume expansion on glomerular barrier size–selectivity in humans. *Ovadia Shemesh, William M. Deen, Barry M. Brenner, Elizabeth McNeely, and Bryan D. Myers* 916

Contents continued on next page

TECHNICAL NOTE

Effects of aluminum addition on parathyroid tissue incubation medium composition. *Agnès M. Bourdeau, Raymond Bourdon, Catherine Kindermans, and Charles Sachs* 924

NEPHROLOGY FORUM

Prognosis and treatment of membranous nephropathy. *Claudio Ponticelli* 927

ABSTRACTS

The Dutch Society of Nephrology. 941

INTERNATIONAL SOCIETY OF NEPHROLOGY

Announcements 947

Awards and Grants 950

KIDNEY INTERNATIONAL

Volume 29, Number 5, May 1986

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

The cellular physiology of glandular kallikrein. *Peter J. Fuller and John W. Funder* 953

LABORATORY INVESTIGATION

Immunocytochemical localization of renin and kallikrein in the rat renal cortex. *Luciano Barajas, Kenneth Powers, Oscar Carretero, A. Guillermo Scicli, and Tadashi Inagami* 965

Characterization of monoclonal antibodies specific for human Tamm–Horsfall protein. *M. Brunisholz, M. Geniteau-Legendre, Pierre M. Ronco, Phillippe Moullier, F. Pontillon, Gabriel Richet, and Pierre Verroust* 971

Role of the loop segment in the urinary concentrating defect of hypercalcemia. *John H. Galla, Beverly B. Booker, and Robert G. Luke* 977

Luminal uptake and intracellular transport of insulin in renal proximal tubules. *Michel Hellfritzsch, Erik Ilsø Christensen, and Ole Sonne* 983

Renal acid–base metabolism after ischemia. *J.C. Holloway, T. Phifer, R. Henderson, and T.C. Welbourne* 989

The risks and benefits of a low protein–essential amino acid–keto acid diet. *Philip A. Lucas, Judyth H. Meadows, David E. Roberts, and Gerald A. Coles* 995

Atrial natriuretic factor determinations and chronic sodium homeostasis. *Friedrich C. Luft, R. Bernd Sterzel, Rudolf E. Lang, Eva Maria Trabold, Roland Veelken, Heikki Ruskoaho, Yi Gao, Detlev Ganten, and Thomas Unger* 1004

Effects of antihypertensive treatment in one–clip, two kidney hypertension in rats. *Jean–Baptiste Michel, Jean–Claud Dussaule, Laurence Choudat, Colette Auzan, Dominique Nochy, Pierre Corvol, and Joel Menard* 1011

Hypoxic injury in the proximal tubule of the isolated perfused rat kidney. *Paul F. Shanley, Mayer Brezis, Katherine Spokes, Patricio Silva, Franklin H. Epstein, and Seymour Rosen* 1021

Transport–dependent cell injury in the S_3 segment of the proximal tubule. *Paul F. Shanley, Mayer Brezis, Katherine Spokes, Patricio Silva, Franklin H. Epstein, and Seymour Rosen* 1033

Influence of aluminum on mineralization during matrix-induced bone development. *Harvinder S. Talwar, A. Hari Reddi, Jacob Menczel, William C. Thomas Jr., and John L. Meyer* 1038

CLINICAL INVESTIGATION

Characterization of mononuclear cell subsets in renal cellular interstitial infiltrates. *Anne Boucher, Dominique Droz, Elda Adafer, and Laure–Hélène Nöel* 1043

Antibodies to laminin in preeclampsia. *Jean-Michael Foidart, John Hunt, Charles-Marie Lapiere, Betty Nusgens, Cecile De Rycker, Michele Bruwier, Rene Lambotte, Alfred Bernard, and Philippe Mahiel* 1050

Value of the 99mTc-methylene diphosphonate bone scan in renal osteodystrophy. *Gerard Karsenty, Nadine Vigneron, Vanda Jorgetti, Michel Fauchet, Johanna Zingraff, Tilman Drüeke, and Giulia Cournot–Witmer* 1058

Correlation of renal histology with outcome in children with lupus nephritis. *Perry J. Rush, Reuben Baumal, Abraham Shore, J. Williamson Balfe, and Martin Schreiber* 1066

Long–term blood pressure and renal function in kidney donors. *Tore Talseth, Per Fauchald, Sverre Skrede, Ole Djøseland, Knut J. Berg, Jean Stenstrøm, Arne Heilo, Erling K. Brodwall, and Audun Flatmark* 1072

Contents continued on next page

Contents continued

NEPHROLOGY FORUM

Childhood membranoproliferative glomerulonephritis: An approach to management. *Clark D. West* 1077

INTERNATIONAL SOCIETY OF NEPHROLOGY

Announcements 1094

Awards and Grants 1097

KIDNEY INTERNATIONAL

Volume 29, Number 6, June 1986

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

The regulation of renal acid secretion: New observations from studies of distal nephron segments. *David Z. Levine and Harry R. Jacobson* 1099

LABORATORY INVESTIGATION

Increased urinary excretion of PGE_2 during inappropriate antidiuresis induced by DDAVP. *Patricia A. Craven, Joseph G. Verbalis, and Frederick R. DeRubertis* 1110

Accelerated renal cyst development in deconditioned germ-free rats. *Kenneth D. Gardner, Jr., Andrew P. Evan, and William P. Reed* 1116

Compensatory renal growth: Modulation by calcium PTH and 1,25-$(OH)_2D_3$. *Jacques R. Jobin and J. P. Bonjour* 1124

Phosphate binding gels: Balancing phosphate adsorption and aluminum toxicity. *Elizabeth A. Larson, Stephen R. Ash, Joe L. White, and Stanley L. Hem* 1131

Protein synthesis and degradation in skeletal muscle of chronically uremic rats. *Jeanne B. Li and Steven J. Wassner* 1136

Canine chronic renal disease: Prevalence and types of glomerulonephritis in the dog. *Dugald F. Macdougal, Terence Cook, Adrian P. Steward, and Victoria Cattell* 1144

Humoral control of water and electrolyte excretion during water restriction. *David C. Merrill, Meredith M. Skelton, and Allen W. Cowley Jr.* 1152

Hypothyroidism protects against free radical damage in ischemic acute renal failure. *Mark S. Paller with the technical assistance of Joseph J. Sikora* 1162

Acidification in the medullary collecting duct following ureteral obstruction. *Carla Ribeiro and Wadi N. Suki* 1167

Nephron segment and calcium as determinants of anoxic cell death in renal cultures. *Patricia D. Wilson and Robert W. Schrier* 1172

CLINICAL INVESTIGATION

Side effects of cyclosporin A treatment in patients with rheumatoid arthritis. *Knut Joachim Berg, Øystein Førre, Frithjof Bjerkhoel, Egil Amundsen, Ole Djøseland, Hans Erik Rugstad, and Bjørn Westre* 1180

Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. *Daniel G. Bichet, Claude Kortas, Bertrand Mettauer, Christiane Manzini, Julien Marc-Aurele, Jean-Lucien Rouleau, and Robert W. Schrier* 1188

Sodium transport in red blood cells from dialyzed uremic patients. *Dalila B. Corry, Michael L. Tuck, Arnold S. Brickman, Norimoto Yanagawa, and David B. N. Lee* 1197

Guanabenz: A centrally acting, natriuretic antihypertensive drug. *Marc Gehr, E. Paul MacCarthy, and Martin Goldberg* 1203

Impaired cellular immune responses in chronic renal failure: Evidence for a T cell defect. *Peter Kurz, Hans Köhler, Stephan Meuer, Thomas Hütteroth, and Karl-Hermann Meyer zum Büschenfelde* 1209

Adult-onset minimal change nephrotic syndrome: A long-term follow-up. *Fernando Nolasco, J. Stewart Cameron, E.F. Heywood, Jackie Hicks, Chisholm Ogg, and D. Gwyn Williams* ... 1215

Contents continued on next page

Serum and urinary high density lipoproteins in glomerular disease with proteinuria. *Colin D. Short, Paul N. Durrington, Netar P. Mallick, Linda P. Hunt, Lesley Tetlow, and Monica Ishola* .. 1224

IgA synthesis by lymphocytes from patients with IgA nephropathy and their relatives. *F. Bryson Waldo, Linda Beischel, and Clark D. West* 1229

TECHNICAL NOTE

Renin–containing cells in kidney transplants into the anterior eye chamber. *Marco R. Celio* 1234

NEPHROLOGY FORUM

Hospital–associated hyponatremia. *Robert J. Anderson*..... 1237

ABSTRACT

17. Kongress der Gesellschaft für Nephrologie 1248

INTERNATIONAL SOCIETY OF NEPHROLOGY

Announcements 1265

Awards and Grants 1268

REFEREES 1270

INDEXES TO VOLUME 29